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Abstract 
Mobile genetic elements (MGEs, e.g. transposons, plasmids and phage) are an 
important driver of genetic diversity in microorganisms, and have diverse effects on 
microbe populations. Adaptation of Bacteria and Archaea to overcome negative 
effects of phage infection is sometimes referred to as an “arms race” that provokes 
the development of systems to protect against phage attack. One such defence is 
CRISPR-Cas, the topic of this research thesis. CRISPR (Clustered Regular Interspersed 
Short Palindromic Repeat) loci and Cas (CRISPR-associated) proteins are the 
molecular basis of this resistance mechanism. CRISPR-Cas can protect against phage 
and other foreign MGEs by incorporating a fragment of novel DNA into CRISPR 
(spacer acquisition) and using this as a template to generate a small RNA molecule, 
CRISPR RNA (crRNA), which targets the degradation of complementary sequences 
(interference). Effective interference requires formation of R-loop nucleic acid 
structure of crRNA base-pairing to homologous DNA, at positions flanked by PAM 
(Protospacer Adjacent Motif) sequence within the invader. 
This thesis investigates actions of CRISPR-Cas interference proteins, with focus on 
archaeal species Methanothermobacter thermautotrophicus (Mth) and Haloferax 
volcanii (Hvo). Mth and Hvo catalyse interference by utilizing a Cascade (CRISPR-
associated Complex for Antiviral DEfence) protein-crRNA complex. Cas8, the large 
subunit protein in Cascade, was investigated to explain it’s essential role in 
interference. It is a PAM sensing protein that stabilizes R-loop formation to bring 
about interference. In addition, this analysis identified a surprising RNase activity of 
Cas8 that remains of unknown function. The thesis also details recent work on 
adaptation by Cas1 and Cas2 in Escherichia coli. Cas1 nuclease and transesterification 
activities upon replication fork intermediates are presented alongside a new model 
for spacer acquisition. 
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1 
1 Introduction 
1.1 General overview of genome dynamics and stability 
The dynamic nature of prokaryotic genomes is readily detectable as genetic variation 
from numerous (6814) genome-sequencing projects, as of September 2015 available 
from a "Genome Database Search" on the National Centre for Biotechnology 
Information, (search for details on specific genomes by organism name and strain). 
Examples include acquisition of mobile genetic elements (e.g. horizontal transfer of 
transposons, plasmids) and variation of conserved gene neighbourhoods. Yet 
prokaryotes also have numerous systems to maintain genome integrity by 
eliminating invasive genetic elements or repressing expression (e.g. histone-like 
nucleoid-structuring protein [H-NS]) (1, 2). In addition, there are various prokaryotic 
DNA repair systems that control mutagenesis arising from endogenous and 
exogenous genotoxic agents (1, 2). Many genome rearrangements result in the 
appearance of new sequences that have the potential to alter protein expression or 
function, either by introducing promoters or interrupting regulatory regions of the 
host chromosome (3). The innate restriction-modification (RM) systems and adaptive 
CRISPR-Cas systems (comprising clustered regularly interspaced short palindromic 
repeats [CRISPR] and CRISPR-associated [Cas] proteins) constitute prokaryotic 
defences against invading genetic elements. Genome instability can be random or 
programmed causing phase (general protein expression) and antigenic variation (cell 
surface protein alterations) within a population (4-7).  
1.1.1 Mechanisms of Horizontal Gene Transfer 
New sequences often derive from horizontal gene transfer (HGT), the movement of 
non-parental genetic information between cells (8). HGT can become fixed into the 
new recipient cell if it proves advantageous during selection pressure, but is likely to 
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be lost if its effects are metabolically negative or neutral (9). Genetic advantages of 
HGT can include attenuation of gene expression, alteration of chromosomes by 
rearrangements, insertions or deletions (10) or generation of novel responses to 
cellular stress to drive niche adaptation (11). Below is a brief overview of the types of 
HGT observed in prokaryotes. 
 
Figure 1-1. Flow of genetic information in prokaryotes. The fitness of prokaryotic populations is 
determined by the balance of genetic instability, DNA repair and selection pressure. Endogenous and 
exogenous stresses cause mutations and DNA damage, generating genetic variation that is often 
harmful. Diversity is directed by recombination and horizontal gene transfer (HGT). Phase variation and 
antigenic variation are important for cell surface alterations affecting virulence factors and host 
immunity avoidance. A delicate balance of genetic variation is maintained by DNA-repair pathways. 
Selective pressures such as environmental factors and antibiotics, influence fitness and survival. BER, 
base excision repair; MMR, mismatch repair; NER, nucleotide excision repair; TLS, translesion synthesis. 
Adapted from (12). 
1.1.1.1 Transformation 
Transformation is the direct uptake of free DNA from the environment (13). 
Transformation can be triggered by cellular stress that allows the uptake of 
extracellular DNA which has adhered to specific cell surface regions (Bayer junctions) 
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(14), and its recombination into the host genome.  Analysis of the Escherichia coli 
(E.coli) genome determined 17% of genes were acquired by HGT, as calculated by 
comparing the GC content and codon bias from deep sequencing data (15).  
Transformation was first reported by Frederick Griffith in Streptococcus pneumoniae 
where addition of heat-killed virulent strains of S. pneumoniae made harmless strains 
virulent (1928). Avery, MacLeod and McCarty (1944) identified that this acquired 
virulence stemmed from transfer of DNA between the two strains. Transformation is 
now a routine tool for molecular biology employed to introduce a desired genetic 
element into a cell for further study (16, 17).  
1.1.1.2 Transduction 
Prokaryotic transduction is the process of DNA (viral or prokaryotic) packaging into a 
viral envelope, release of viral particles from a lysed cell and transfer (by infection) to 
another cell (18, 19). DNA has three fates upon insertion into another cell: absorption 
and degradation, plasmid recirculation or recombination with a homologous region 
of the recipient’s genome. Imprecise excision of viral DNA from a host genome 
(prophage) might result in packaging of host genes adjacent to the prophage into 
new virus particles, thereby potentiating HGT into a new host via transduction. This 
specialised transduction occurs in lambdoid (λ) phage infection of E.coli. Viral 
particles act indirectly as gene transfer agents (GTA) (20, 21). Gene flow from virus to 
host is overwhelmingly unidirectional; viral genomes rarely incorporate prokaryotic 
genes. Up to 15-20% of prokaryotic genomes consist of viral or plasmid DNA (22-24) 
and at least 50% of eukaryotic genomes are derived from mobile elements and 
endogenous viruses (25, 26). Mobile elements are usually subject to strong 
repression although novel genes can be advantageous by exaptation, the utilisation 
of a gene that once served one function but was subsequently adapted to serve 
another (27-29). 
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1.1.1.3 Conjugation 
Conjugation is the transfer of DNA through direct cell-to-cell ’bridging’ by pili (30-32). 
Conjugative replication transfers a copy of the pili encoding F-plasmid to the 
recipient that can integrate onto the genome by homologous recombination. 
Fragments of donor genetic information can be transferred by inaccurate 
disintegration of the F-plasmid.  
 
Figure 1-2. The three general mechanisms of gene transfer in prokaryotes. Transformation, 
transduction and conjugation are the mechanisms of genetic transfer. Antibiotic resistance genes and 
other selective advantages can be shared by horizontal gene transfer. (Adapted from “The limits of 
horizontal gene transfer”, Dan Rhodes 2007) 
1.1.1.4 Phase and antigenic variation effects of genome instability on 
prokaryotes 
Variation is essential for evolution. Several programmed genetic and epigenetic 
mechanisms induce specific, adaptive and reversible phenotypic alterations (4, 6). 
Phase variants are important for gene expression variation (typically on/off) (33) 
whereas antigenic variation alters protein structure and function. Phase and 
antigenic variation create differing subpopulations that can create adaptive 
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advantages (34). The mechanisms of phase and antigenic variation are either through 
DNA replication, repair and recombination dependent events or independently 
through excision and integration events (5). 
1.2 Overview of prokaryotic genome defence against HGT 
Prokaryotes have evolved several strategies to control or prevent effects of HGT on 
recipient cell metabolism. The major defence mechanisms are described in the next 
sections, with emphasis on how nucleic acids are manipulated or enzymatically 
processed to establish defence against the mobile genetic element.  However, 
phages have also developed methods to avoid prokaryotic immune systems (Table 1). 
Table 1. The adaptive mechanisms employed by phage to escape detection upon bacterial infection. 
Adapted from (35). 
Phage Escape strategy Phage Escape mechanism 
Inhibition of phage adsorption 
Adapting to new receptors Coliphage φX174 and T7 Mutations in the RBP-encoding gene lead 
to adsorption to a modified LPS 
Digging for receptors Coliphage K1F and K1-5 Encoded endosialidase or glycosidase 
degrades E.coli capsule 
Stochastic recognition of 
variable host receptors 
Coliphage T4 Duplication of His Box element in tail 
proteins, shuffling tail specificity to host 
receptors 
Abortive-infection (Abi) system 
Mutation in phage genes Coliphage T4 Mutation in gol prevents activation of Abi 
Lit 
Encoding antitoxin molecule Coliphage T4 Dmd neutralises RnIA and LsoA toxins 
during phage replication 
Restriction modification  (RM) systems 
Fewer restriction sites or 
unrecognisable orientation 
Coliphage T7 and T3 EcoRII sites distant on genome preventing 
REase EcoRII cleavage 
Modified restriction sites Coliphage P1 DarA and DarB co-injected and bind 
restriction sites of phage genome, 
protecting against type I RM systems. 
Mimicry of phage DNA Coliphage T7 Ocr mimics DNA backbone and sequesters 
REase 
Stimulation of modification 
enzymes 
Coliphage λ Ral enhances EcoKI methyltransferase, 
rapidly methylating phage DNA, protecting 
phage DNA from EcoKI recognition 
Degradation of an R-M 
cofactor 
Coliphage T3 S-adenosyl-L-methionine hydrolase 
removes S-adensoyl-L-methionine, 
inhibiting REase 
CRISPR-Cas systems 
Mutation in PAM or 
protospacer 
Streptococcus 
thermophilus phage 
Mutations or deletions in PAM or 
protospacer result in CRISPR avoidance. 
Antibacterial CRISPR-Cas 
system 
Vibrio cholera serogroup 
01ICP1 phage 
Phage encoded CRISPR system targets 
phage inducible bacterial CRISPR system 
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1.2.1 Abortive infections systems: Toxin-antitoxin  
Toxin-antitoxin (TA) systems are often auto regulated mobile elements that encode a 
stable toxin gene and an unstable antitoxin gene (36-38). Toxins are always small 
proteins, but antitoxins can be either protein or RNA. An antitoxin can act in two 
ways, as a transcriptional repressor or to sequester its toxin counterpart. Loss of the 
antitoxin part of TA systems by mutation, recombination or segregation is toxic to 
the host as the stable toxin protein can persistently interfere with host DNA 
replication and cell surface molecules (39-41). 
The precise role of TA systems varies. They may contribute to the maintenance of 
other mobile genetic elements (MGEs), stabilise chromosomal regions susceptible to 
deletion, become integrated into host cell regulation network, or contribute to 
pathogenicity and stress induced altruistic cell suicide (42).  TA systems have been 
reported as ‘junk’ DNA or selfish elements only promoting self-survival, but some 
play critical roles in prokaryotic cell biology. Some antitoxins can be degraded by 
stress-induced proteases allowing toxin activation to induce abortive infection (cell 
suicide) (43), biofilm formation (44), differentiation into persistors (dormant multi-
drug resistance strains) or stop infection (45). 
1.2.2 Restriction-modification systems 
Restriction-Modification systems are present in over 90% of all bacterial and archaeal 
sequenced genomes. They encode a target-specific DNA endonuclease and its 
cognate modification activity, typically a DNA methyltransferase (46-48). These two 
genes are usually located in the same neighbourhood of the host genome, virus or 
MGE. Both the nuclease and the modification activity are sequence-specific, unique 
to each R-M system. Mutations that affect the regulation of expression or targeting 
 
 
7 
of these restriction endonucleases can cause lethal unregulated degradation of host 
genomes. 
Five different function have been associated with the role of R-M systems: (a) 
defence systems (49), (b) selfish genetic elements , (c) stabilisation of genomic 
islands (50, 51), (d) roles in recombination and genome rearrangements controlling 
speciation and evolution (47) and (e) regulation of host chromosome DNA 
methylation (52). Endonucleases identify their cognate DNA modification and 
degrade elements that do not display it. Therefore inactivated R-M systems allow 
MGE integration into host as there is no specific degradation. R-M systems are often 
connected to MGE and stabilize these elements in a population by targeted 
degradation of competing DNA, acting as a selfish genetic element. Other systems 
are hypothesised to target host chromosomes to facilitate transposition. Targeting of 
host chromosomes allows genome rearrangements or methyl-DNA modifications 
that are linked to epigenetic regulation and diversity.  
1.2.3 CRISPR-Cas 
Recently identified CRISPR-Cas systems are the only adaptive immune system of 
prokaryotes. CRISPR-Cas systems are predicted to be mobile selfish genetic elements 
(defence islands) that confer resistance to invading phage and mobile genetic 
elements (53, 54). CRISPR-Cas systems are discussed in greater detail later.  
1.2.4 Transcriptional repression of horizontally acquired genes 
Small and abundant histone-like nucleoid structuring (H-NS) proteins are involved in 
chromosome organisation and gene regulation (55). H-NS binds to AT-rich DNA 
sequences with high affinity and induces sequence specific DNA curvature (56-58). 
Mutation or deletion of H-NS increases cellular transcription levels, indicating H-NS 
has a gene silencing effect. H-NS are known to silence virF (59), a horizontally 
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acquired virulence factor, and the Cas genes of the E.coli CRISPR-Cas locus. H-NS 
negatively regulates genes by binding over promoters, occluding RNA polymerase or 
trapping RNA polymerase in H-NS bridged DNA loops (60-62). 
1.3 Roles of Homologous recombination in horizontal gene 
transfer 
Homologous recombination (HR) pathways play important roles in meiosis (63), 
repair of DNA strand breaks and in overcoming blocked or broken DNA replication 
forks (64-66). A corollary to the roles of HR in underpinning DNA replication is that it 
promotes replication of mobile genetic elements such as transposons and phage, 
which rely on host cell replisome for their propagation. There is also emerging 
evidence that HR enzymes in bacteria are important for establishment of CRISPR 
immunity (67), and therefore I present a review of relevant aspects of HR in the 
following sections, and summarised in Figure 1-3. 
1.3.1 Homologous recombination 
Homologous recombination (HR) descirbes the exchange of nucleotide sequences 
between either identical (homologous) or near-identical (homeologous) sequences of 
DNA. HR is initiated by invasion of single stranded DNA into a homologous DNA 
duplex, termed ‘strand exchange’, generating a ‘D-loop’ intermediate.  This reaction 
is catalysed by RecA-family enzymes that are found in bacteria (RecA) (68), Archaea 
(RadA) (69), eukaryotes (Rad51) (70) and viruses (Cre) (71). D-loop formation can set 
in motion a number of subsequent DNA processing reactions depending on the 
context of strand exchange. For example, a D-loop can be extended into a Holliday 
junction by the actions of heliCases (RuvAB and RecG) (72-77) and so activating the 
classical double-strand break or ‘long tract’ HR pathways. However, these require 
Holliday junction resolution (RuvC, RusA, Mus81 etc.) (78-80) or dissolution (RecQ-
TopoI) (81-84) to restore duplex DNA after synthetic repair (85). 
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Holliday junctions (“chicken-feet”) are proposed to form in HR based repair of stalled 
replication forks, resulting from encountering a blocking lesion (86). RecG, RecA and 
RuvAB enzymes can catalyse Holliday junction formation. RecG recognises and 
unwinds a variety of substrates including strand invasion products generated by 
RecA. RuvAB drives Holliday junction formation at D- and R-loops to allow resolution 
by RuvC (85). Removal of D- and R-loops is important for blocked replication fork 
progression. Typically, DnaA initiates bacterial replication at a replication origin (87, 
88). However, in strains deleted for DnaA and RecG, a distinct pathway independent 
of DnaA, known as stable DNA replication (SDR), follows, whereby PriA triggers 
chromosomal replication at 3’flaps (89). RecG acts as an antagonist to PriA most 
likely to prevent pathological over-replication by controlling replication restart by 
SDR (90-92). PriA-PriB facilitates DnaB (the replicative heliCase) loading and 
replisome assembly at branched substrates; however, heliCase defective PriA300 
reduces SDR (93).  
At unstable integrated transposable elements which create gap regions and long 
flanking DNA stall replication forks. Replication stalling initiates co-ordinated repair 
at fork-dependent double strand ends by gap filling, concomitant with degradation of 
the extraneous flanking DNA leaving invading elements intact and stable (94, 95). 
This is thought to occur with other mobile genetic elements including HIV-1 DNA and 
lambda phage. Lambda phage can integrate into the host genome through lambda P 
protein recruiting the replicative heliCase DnaB to lambda O initiation site (96, 97), 
acting analogously to E.coli DnaC and as a competitive inhibitor of DnaB-DnaC 
complex formation (98, 99). DnaB-DnaC associate to DnaA bound origins, DnaC acts 
as a loading factor for DnaB.  
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Current understanding of homologous replication and replication fork restart stems 
from research carried out in yeast and bacteria. Homologs of RuvABC and RecG are 
absent from most archaeal species as archaeal DNA and RNA metabolism is more 
closely related to eukaryotic systems. However, archaea do encode some analogous 
proteins such as Holliday junction resolvase Hjc (100, 101) and branch migration 
protein Rad54 (102, 103). 
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Figure 1-3. An overview of homologous recombination (HR) and its role in DNA repair and blocked 
replication fork restart. (i) Comparative crystal structures of recombinases from archaea (RadA), 
bacteria (RecA) and eukaryotes (Rad51) demonstrates archaeal and eukaryotic recombinases are very 
similar in tertiary structure. (ii) HR-mediated DNA repair is either synthesis dependent stand annealing 
(SDSA) or double strand break repair (DSBR). DNA damage (here a double strand break [DSB]), is 
successively repaired through pre-synapsis (end resection), synapsis (strand invasion) and post-synapsis 
(D-loop or Holliday junction resolution). (iii) During replication, replication forks (RF) encounter 
blockages that either collapse or stall the fork. RFs can be restarted by the mechanisms summarised. 
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1.3.2 Recombination at repeated sequences drives genome instability 
Homologous or illegitimate recombination at repeat regions in a genome can cause 
DNA deletions or amplifications. Amplifications usually revert to their original state 
unless they pose an advantage to the organism, for example, an antibiotic resistance 
gene amplification improves viability. During recombination subtle junction 
alterations may alter gene expression or function. Stability of repeats is dependent 
upon repeat sequence (104), distance (105), and genomic context (106). Palindromic 
sequences form hairpins in genomes and stimulate strand slippage, promoting 
illegitimate recombination and repair (micro-homology mediated end joining, 
MMEJ). Hairpins that form in the lagging strand during replication can be deleted if 
situated between Okazaki fragments (107, 108). Nucleases such as SbcCD cleave 
hairpins and initiate homologous recombination mediated repair (109, 110). If 
hairpins are flanked by direct repeats incorrect recombination can stimulate genome 
instability, creating deletions as in single strand annealing. Homologous 
recombination mediated instability can also occur through rolling-circle replication 
and non-equal recombination. Non-equal recombination or unequal crossover 
deletes a sequence in one strand and replaces it with a duplication from the sister 
chromatid during mitosis or its homologous chromosome in meiosis (111, 112).  
1.4 CRISPR 
1.4.1 Background to the discovery of CRISPR-Cas defence system  
A 1987 analysis of the genomic context of the E. coli alkaline phosphatase gene (iap) 
noted a region of repetitive DNA that is now referred to as CRISPR (Clustered 
regularly interspaced short palindromic repeats) (113). There is great diversity in 
CRISPR-Cas loci across bacteria and archaea but some common principles are 
described in this section and shown in Figure 1-5, which summarises CRISPR loci 
relevant to this study (114). The wide range of sequence variations found in CRISPR 
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loci allowed their application in serotyping methodology in clinical settings. The 
sequence variability arises from the presence of distinct ‘spacer’ regions of 24-48 
base pars (bp) that alternate with the repeat sequences (113). Two key observations 
from bioinformatics have helped to advance our understanding of the biological role 
of CRISPR loci: First, the identification of spacer sequences as matched sequences 
from extant mobile genetic elements (115)and second, the recognition of a genetic 
linkage between CRISPR loci and several different open reading frames (ORFs) 
predicted to encode DNA processing enzymes (116, 117). The CRISPR associated (Cas) 
ORFs suggested a conserved biological function of CRISPR through a diverse range of 
bacteria and archaea. Further bioinformatics analyses of predicted functions of Cas 
proteins led to the suggestion that CRISPR-Cas was a DNA repair system or, later, an 
RNA processing system similar to RNA interference (RNAi) found in many eukaryotes 
(118). In 2007, Barrangou et al. demonstrated CRISPR-acquired resistance to phage 
(119). Strains of the yoghurt-producing bacteria Streptococcus thermophilus were 
inoculated with phage isolates from industrial fermenters. Some S. thermophilus 
were phage resistant and sequencing identified acquisition of new DNA matching 
phage DNA, i.e. novel spacers. Only S. thermophilus genomes containing perfectly 
matched spacers correlated to phage resistance. 
At the time of writing the CRISPR database (CRISPR finder and CRISPRI (120)) has 
analysed 2762 prokaryotic genomes identifying 4065 CRISPRs. CRISPR loci are widely 
distributed in prokaryotes and have now been discovered in 126 (out of 150) 
archaeal and 1167 (out of 2612) bacterial genomes. Given that similar CRISPR loci 
have been identified between different organisms, HGT and selective adaptation 
have most likely taken place (121). The origin of CRISPR is not known, but various 
hypotheses indicate a MGE that is by nature selfish and acts through non-self 
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targeting. Some Cas genes (Cas1 and Cas2) have been identified as transposons (122, 
123) and so could be the origin of CRISPR-Cas immune systems (124).  
1.4.1.1 CRISPR-Cas loci 
CRISPR loci share common architecture: direct repeats (24 to 48 nt) separated by 
spacers (22 to 33 nt) (124, 125). Two organisms that were the subject of this study, 
the bacterial E.coli K-12 strain MG1655 has 29bp long direct repeats and 32bp long 
spacers and the archaeal Methanothermobacter thermautotrophicus (Mth) ΔH strain 
possesses repeats of 2-60bp and spacers of 30bp. Since the spacers provide a 
historical account of an organism’s exposure to invading genetic elements, it is 
unsurprising the number of spacers varies between organisms. Indeed, E.coli has 13 
spacers, whereas Mth contains 123. Upstream of the CRISPR array is the AT-rich 
‘leader’ (20-543 bp in length) which acts as a promoter for RNA polymerase-catalysed 
transcription, generating a transcript called pre-CRISPR RNA (pre-crRNA). Leaders 
form cruciform structures that are proposed to be essential for novel spacer 
integration. Cas genes are located in close proximity to the CRISPR locus, either up or 
downstream. Cas genes are diverse in organisation and the different constituents at 
each locus give rise to different ‘Type’ definitions of each CRISPR system.  
Since 2007 discovery that CRISPR-Cas systems provide resistance to phage, a great 
deal of further research lead to uncovering the notable diversity in CRISPR systems, 
and the various subtypes encoded by different genes (126). A summary of the main 
CRISPR-Cas types (Figure 1-4) demonstrates the universal conservation of Cas1 and 
Cas2 genes and the variation of the other genes which gives rise to different protein 
complexes and activities. The core ‘chassis’ of CRISPR interference is similar between 
types, a protein and RNA complex targets invading nucleic acids for degradation 
(127). Type I systems CRISPR gene clusters encode several Cas proteins that form a 
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ribonucleoprotein complex, Cascade (128, 129). Since Type I systems were the focus 
of this study it is expanded upon in later sections. Type II CRISPR systems vary by 
encoding only a single protein Cas9, with together with guide RNA (gRNA) forms an 
analogous complex for DNA targeting (130, 131). Given the greater simplicity of the 
Cas9 Type II system it is currently being exploited as a genome-editing tool in 
mainstream research (132-136). The greatest diversity can be seen in type III 
systems. Type III-A CRISPR systems are analogous to the type I CRISPR systems, 
encoding similar proteins which assemble into a so-called Csm complex that targets 
DNA for degradation (137). Type III-B systems are unique, as the Cmr complexes 
formed can target only RNA for degradation (138). 
 
Figure 1-4. A summary of CRISPR adaptation, expression and interference proteins comparing the 
difference between the major CRISPR types. The universally conserved Cas1 and Cas2 are for spacer 
acquisition – adaptation. Expression and processing of CRISPR RNA (crRNA) is typically carried out by 
Cas6 proteins except in Type II system where host RNase III and Cas9 mature the crRNA molecules. 
Interference complexes have varied protein constituents depending on the subtype, Type I systems 
encode a Cascade complex with varied subunits, Type III-A encode a Csm complex. Whereas Type I, Type 
II and Type III-A systems target DNA for interference, the Type III-B type targets RNA. Type II systems 
differ from all the other CRISPR types in that the formed ribonucleoprotein complex involves only a 
single protein: Cas9. CRISPR systems are all mechanistically homologous in the overall three step 
process for resistance to invading genetic elements and only have nuances in the specific catalytic 
pathways and mechanisms. (Adapted from Van der Oost et al 2014) (139). 
Prokaryotic genomes can contain between 1 and 20 different CRISPR loci with rare 
duplications such as those seen in Sulfolobus solfataricus (140). Within these loci 
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more than 20 different Cas genes have been identified displaying diversity between 
organisms and CRISPR subtypes. While the different subtypes have been defined by 
bioinformatics analysis there is however a conserved overall mechanism of CRISPR-
mediated immunity. The Type I-B CRISPR-Cas system was recently sub-divided to 
include types I-G and I-B V1-2, henceforth referred to as I-H. Mth contains two 
subtypes: a Type I-H (141, 142) and a Type III-A subtype. The Type I-H system 
contains Cas3, Cas5, Cas6, Cas7, Cas8’ and Cas8’’ encoding genes. The E.coli system is 
a Type I-E subtype, encodes CasA, CasB, CasC, CasD, CasE and Cas3. The present 
study explores the two Type I subsystems of E.coli and Mth (shown in Figure 1-5), 
with further analysis via comparison with Haloferax volcanii Type I-B CRISPR system.  
 
Figure 1-5. Genomic arrangement of CRISPR array and Cas genes in E.coli and Methanothermobacter 
thermautotrophicus. (i) E.coli Type I-E CRISPR system encodes adaptation proteins (Cas1 and Cas2) and 
interference proteins (Cas3 and CasABCDE) with a CRISPR array downstream (ii). E.coli CRISPR array 
initiates with the AT leader region followed by 28 nt direct repeats (DR) and then 12 different spacers 
(Sp). (iii) CRISPR locus arrangement in Mth, a fusion of Type I-H (Cas5, Cas7, Cas8’’, Cas8’ and Cas6) and 
Type III-A (Csm genes) and including the conserved adaptation proteins (Cas1 and Cas2). The Mth 
CRISPR array is laid out as in E.coli, only with 123 spacers instead. (Adapted from (143, 144)). 
1.4.2 CRISPR-Cas immunity in three stages 
CRISPR-mediated immunity consists of three stages: Adaptation, processing and 
interference as summarised in Figure 1-6. This response is triggered by phage 
adhesion or other stress responses (145, 146). Adaptation requires Cas1 and Cas2 
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and host DNA metabolism factors (67, 147, 148). Cas1 and Cas2 proteins capture a 
small region of foreign genetic information: the process known as target capture. 
Following capture, DNA is then integrated into the host genome at the CRISPR locus 
by an as of yet unknown mechanism. Novel spacers are usually acquired proximal to 
 
Figure 1-6. Overview of the CRISPR-Cas immune system of prokaryotes. CRISPR-Cas mediated adaptive 
immunity is split into three stages: (1) Adaptation, the acquisition of a novel short sequence of DNA 
originating from the invading DNA element – known as a spacer, here represented by viral infection. (2) 
Expression, the transcription of the CRISPR locus into a long pre-CRISPR RNA (pre-crRNA) and 
subsequent processing into small mature crRNA molecules that are packaged into the interference 
complex (consisting of Cas proteins). (3) Interference; target identification by sequence homology 
between the spacer and the invading element followed by strand invasion forming R-loops and the 
recruitment of the nuclease component to degrade the invading element. 
  
the leader region (149-152). Once spacer acquisition is complete, the CRISPR locus is 
transcribed to long pre-crRNA (pre-CRISPR RNA). Cas6 or Cas9 and RNases cleave pre-
crRNA into mature crRNA (153-156). Mature crRNA is assembled into a 
ribonucleoprotein complex with Cas proteins, generally termed Cascades (CRISPR 
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associated complex for antiviral defence) or interference/effector complexes. The 
ribonucleoprotein interference complex then targets invader genetic elements in a 
sequence specific manner and upon correct identification, an R-loop is formed (157-
159). The interference complex-stabilised R-loop triggers degradation of the invading 
elements, either directly through Cas9 or through recruitment and activation of Cas3 
or Cas10 (127, 160-168). 
CRISPR and Cas gene regulation varies between organisms. In Salmonella enterica 
Serova Typhi and other bacteria the ‘master’ repressor H-NS represses CRISPR-Cas, in 
combination with the leucine-responsive regulatory protein (LRP) (1, 169). H-NS and 
LRP respond to environmental factors and affect Cas gene repression. LeuO activates 
both E.coli and Senterica typhi CRISPR-Cas systems. The two-component regulatory 
system BaeSR responds to envelope stress in E.coli to stimulate Cas gene expression 
(170, 171). BaeS senses envelope stress and modulates the phosphorylation state of 
BaeR. BaeR is a transcription factor which activates the CasA promotor, when 
overexpressed (146). CRISPR gene expression can be sensitive to metabolic change; 
in energy metabolism cyclic AMP (cAMP) and CRP (adenylate cyclase) form a complex 
that increase expression of 100 genes in E.coli, including Cas1 and Cas2-3 genes 
(172). These mechanisms of CRISPR regulation illustrate the general principle of gene 
expression regulation.  
1.4.2.1 Adaptation / Spacer acquisition 
The assembly of invader DNA fragments as spacers into CRISPR loci underpins CRISPR 
immunity, by providing interfering crRNA that can target the invader in a sequence 
specific manner. Cas1 and Cas2 proteins fulfil an essential role in this process as they 
catalyse spacer acquisition into CRISPR via an ‘adaptation reaction’ (148, 149, 173). 
The current model for this integration event is summarised in Figure 1-7. However, 
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evidence is emerging that additional non-Cas host proteins are also required for this 
reaction. Indeed, in E.coli RecBCD processing of double strand breaks at replication 
forks has been suggested to generate DNA fragments used by Cas1 and Cas2 for 
spacer integration (67). E.coli Cas1 and Cas2 overexpression in BL21AI – an E.coli 
strain lacking Cas genes but including a CRISPR loci, induced spacer acquisition of 
sequences derived from the inducible plasmid or host genome (147). Part of the 
adaptation reactions involves Cas1 and Cas2 searching for short target sequences 
know as PAMs (protospacer adjacent motifs) in the invading nucleic acids (150, 174). 
Subsequently, PAMs direct Cas1 and Cas2 to initiate spacer integration. However, 
PAMs are required in both adaptation and interference and are thus classified into 
two sub-sets: SAMs (spacer acquisition motifs) and TIMs (target interference motifs) 
(175, 176). Whereas SAMs constitute the 5’ sequences flanking the novel spacers, 
TIMs are the 5’ or 3’ sequences proximal to the R-loop formed in the interference 
step (157, 163, 177-179). SAMs are important in the selection of spacer sequences 
and constitutes the final nucleotides of the repeat elements found at CRISPR loci. On 
the other hand, TIMs prevent interference complexes targeting self CRISPR loci (179).  
Adaptation can be stimulated by inefficient interference (‘primed’) (180, 181), or can 
act independently (‘naïve’) (182, 183). ‘Primed’ adaptation is more efficient and 
requires invading elements evading interference through mutation in either PAM or 
protospacer sequences. This allows interference complexes to bind to but not 
degrade the invader. Therefore novel spacer acquisition is required to re-establish 
immunity against the invader.  Primed adaptation requires Cas1, Cas2, Cas3, Cascade 
and a spacer that was originally complementary to the protospacer sequence flanked 
by PAM, as shown genetically. Cas1 and Cas2 mediate naïve adaptation 
independently of Cascade both in vivo and in vitro.  
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Figure 1-7. The current model of Cas1 mediated spacer acquisition in CRISPR adaptation. Cas1 and 
Cas2 are involved in the capture of a short DNA molecule from the invading element by a mechanism 
unknown creating a mature protospacer. The protospacer is then targeted to the CRISPR array by 
cruciform structures formed by the repeat sections. A series of transesterification reactions at either 
end of repeat 1 integrates a novel spacer at position 0. DNA repair enzymes then repair the resulting 
gaps. (Taken from (184). 
Several hypotheses exist for the action of Cas1 and Cas2 proteins and the mechanism 
of adaptation. Models require isolation of a short piece of duplex DNA and then an 
integration event into the host genome at the 0 position of the CRISPR loci (Figure 
1-7). The leader and the repeats of the CRISPR loci form cruciform structures, which 
function either as target recognition sites for the adaptation machinery or as road 
blocks that stall replication forks (148, 184). Through a series of transesterification 
reactions repeat 1 is split and the new spacer inserted into this region, a process 
known as spacer integration (SpIN). During preparation of this report the catalytic 
activity of Cas1 has been reported as transesterification (150) hence facilitating 
disintegration of a short (ds)DNA fragment at replication fork structures. This reflects 
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the difficulties in separating the two process of adaptation, protospacer capture and 
spacer integration. Finally, DNA duplex gaps are filled, most likely by gap-filling 
polymerases.   
1.4.2.1.1 Cas1 
Further analysis identified some Cas1 genes independent of CRISPR arrays. 
Specifically, two distinct groups of ‘Cas1-solo’ were described (123). The first group 
was found exclusively in the Methanomicrobiales and the second group was shown in 
Euryarchaeota and Thaumarchaeota clades. The latter has a patchy distribution, 
suggestive of horizontal gene transfer (as with transposases). The gene 
neighbourhood of Cas1-solos in Thaumarcheota contains PolBs, specific DNA 
polymerases that are protein-primed and are encoded by viruses and self-
synthesising transposons in eukaryotes. Cas1-solo elements act in a manner akin to 
DNA transposons, genomic islands containing TIRs (tandem inverted repeats). No 
known transposases or recombinases are encoded within this island suggesting Cas1-
solo genes are novel transposases, that have been designated Casposons (122).  
Despite substantial amino acid sequence diversity in bacterial and archaeal Cas1 
proteins, the available crystal structures all conform to the same core dimeric overall 
shape, adorned with additional N-terminal domain (NTD) or C-terminal domain (CTD) 
regions. In each Case, the NTD of the two monomers constitute the dimer interface. 
There is a conserved hinge like region between these domains, as shown in 
Pseudomonas aeruginosa PA14 Cas1, a DNA specific endonuclease (185). Analysis of 
Cas1 catalytic activity shows nuclease and transesterase activities upon forked 
structures. E.coli Cas1 (YgbT gene) has been characterised with cleavage activity on 
Holliday junction, flapped substrate, ssRNA and dsDNA in a divalent metal cation 
dependent manner (118, 185). This DNA and RNA nuclease activity is also observed in 
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Archaeoglobus fulgidus Cas1 (186). Despite disputed catalytic activities, in vivo spacer 
acquisition is dependent on catalytically active Cas1 protein. There is no published 
information of the Mth Cas1 protein function. 
1.4.2.1.2 Cas1 homology to Integrase enzymes 
Strikingly, Cas1 genes (YgbT in E.coli) have sequence homology to HIV-1 integrase 
(184). Integrases (IN) have two biochemical activities: 3’ DNA end processing and 
strand transfer (187). The two reactions have been separated by in vitro analysis 
(188). Synthetic 3’ end pre-processed DNA molecules were provided as target DNA 
and integration was observed. Recently, analysis of the IN enzyme of Prototype 
Foamy Virus (PFV) has revealed mechanistic detail of 3’ end processing and strand 
transfer reactions (189). 3’ ends are joined with host DNA by two proposed 
mechanisms. A host phosphodiester bond is broken and the resulting energy is 
stored in an intermediate between DNA and the integrase with the strand transfer 
reaction actually requiring only little energy. Alternatively, an isoenergetic 
transesterification reaction concomitantly directs the new bond formation in a single 
step. The remaining 5’ flaps from this integration reaction are removed by host DNA 
repair enzymes and the ensuing gap ligated.  From the hypothetical models 
presented, it appears the activities of IN are likely to be very similar to the CRISPR 
spacer acquisition reaction (190). 
1.4.2.1.3 Cas2 
The crystallisation of Cas2 proteins gave important insights into their role during 
spacer integration. Identical structures of Streptococcus pyogenes Cas2 were 
deduced at different pHs (5.6-7.5) demonstrating pH dependent DNA duplex 
nuclease activity (191). DNA duplex nuclease activity is also observed in Bacillus 
halodurans Cas2 (192), in contradiction to previous findings that Sulfolobus 
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solfataricus (Sso) Cas2 is an endoribonuclease with preference for single-stranded 
(ss) RNA (116). Nonetheless, catalytically inactive mutants of E.coli Cas2 in E.coli 
show no loss of function in in vivo spacer acquisition which suggests Cas2 has a 
structural rather than a catalytic role in the process (148, 184). 
1.4.2.1.4 Cas1 and Cas2 
E.coli Cas1 and Cas2 have been shown to interact in vivo and can be seen to co-purify 
in pull-down assays and carry out spacer acquisition. ITC and AUC results from E.coli 
proposed it was dimers of Cas1 and Cas2 which interact to form a heterotetramer. 
However, in vitro reconstitution and crystallisation established Cas1 and Cas2 in fact 
organise into a hexameric arrangement, where a Cas2 dimer is sandwiched between 
two Cas1 dimers (Figure 1-8) (148). Interference with these interaction surfaces 
exhibits a loss of in vivo spacer acquisition. Therefore, interaction between Cas1 and 
Cas2 is essential for adaptation in E.coli. Sequence comparison revealed conserved 
catalytic residues of Cas1 proteins in bacteria: E141, H208, D218, D221 and K224. 
Mutation of any of these residues abolishes spacer acquisition in vivo (148). 
Whereas, in Cas2 only mutations that disrupt the Cas1:Cas2 interaction surfaces have 
a significant effect on acquisition. 
Complex formation of Cas1 and Cas2 dictates DNA binding specificity. Co-expression 
of Cas2 with Cas1 indicates preferential binding to DNA containing the leader and the 
first repeat of the E.coli CRISPR locus rather than random DNA sequences. This 
corresponds with Cas1 and Cas2 targeting the cruciform structure of the leader and 
repeat sequences. 
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Figure 1-8. Co-crystal structure of Cas1 and Cas2 heterohexamer. (i) Overall structure of the adaptation 
machinery of the CRISPR immune system, consisting of a Cas1-Cas2 complex where a Cas2 dimer (yellow 
and orange) forms a linking bridge between two Cas1 dimers (blue and teal).  (ii) Detailed views of both 
the Cas1 and Cas2 active sites with the conserved residues highlighted. (Adapted (148)). 
1.4.2.1.5 Other factors involved in spacer acquisition 
Analysis of the Cas4 gene from Sso revealed 5’ to 3’ exonuclease activity (193, 194).  
Cas4 end resects DNA creating 3’ flaps suggestive of a recombinogenic precursor 
important for spacer integration, similar to IN proteins. This activity was observed on 
single strands of duplex DNA as well as single stranded DNA. However, the Cas4 gene 
is not well conserved between CRISPR systems and can be found only in bacterial 
strains lacking recB. For instance, it is reported Cas4 forms functional complexes with 
Cas1 and Cas2 in the archaeon Thermoproteus tenax (195). In Enterococcus faecalis 
and Streptococcus agalactiae Csn2 proteins have been linked to CRISPR adaptation, 
carrying out a similar role to Cas4 (196).  
 
 
25 
1.4.2.2 Expression and processing of crRNA 
1.4.2.2.1 Cas6 and Cas9/RNase III 
Transcription of CRISPR generates a single mRNA of varied lengths called pre-crRNA. 
Repeat-spacer units within pre-crRNA generate RNA secondary structure that may be 
identified by nucleolytic processing enzymes. In type I and III CRISPR systems Cas6 
carries out the maturation of pre-crRNA to crRNA (153, 154, 197-201). Cas6 proteins 
of Sso have been characterised. In Sso there are 6 CRISPR loci and 4 Cas6 genes, two 
of which have been studied and characterized at the protein level: Sso1437 and 
Sso2004 (197). Both of these enzymes form dimeric structures that cleave pre-crRNA 
hairpin structures into the mature crRNA product 8 nucleotides from the end of a 
repeat section (Figure 1-9). However, other Cas6 proteins display an alternate 
mechanism. PfuCas6 (Pyrococcus furiosus) has two RAMP domains that wrap the RNA 
molecule around the Cas6 protein itself, Which in this manner acts as a molecular 
ruler to generate the mature crRNA (198), schematically shown in Figure 1-9. Cas6 
proteins have significantly higher affinities for their cleaved RNA products, indicative 
of a single turnover event ensuring correct crRNA processing. The three possible 
fates of Cas6 after completing crRNA maturation are: (i) the release of crRNA, or 
shifting either (ii) up or (iii) downstream of the cleavage point creating an anchor for 
effector complex assembly.  In the Type I-E systems of E.coli and Thermus 
thermophilus (Tt) Cas6 (Cas6e/CasE) remains bound to the mature crRNA and forms 
part of the Cascade complex. On the other hand, Cas6 family proteins of archaeal 
Csm and Cmr complexes release the mature crRNA for interference complex 
assembly without these Cas6 proteins (202-204). 
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Figure 1-9. Cas6 proteins mature CRISPR-RNA (crRNA) in two different ways. Some Cas6 proteins 
identify the RNA stem loop structure in pre-crRNA long transcripts (i). This allows targeted cleavage, 
which has been mapped in Sulfolobus solfataricus (ii) and also shown in crystallised Cas6 to map the 
active site (iii). Other Cas6 proteins perform a molecular ruler type mechanism to cleave pre-crRNA in 
mature crRNA. (iv). Each Cas6 can then follow several fates depending on the subtype and on the 
interference complex that follows (i) either by disassociating from the crRNA, or sliding up or down the 
crRNA molecule and forming part of the CRIPSR interference complex. (Adapted from (199) and (154)). 
The catalytic site of Cas6 proteins shows variability. There is no conserved active site 
and the mechanism of cleavage site identification also varies. Interestingly, Cas6 
generates crRNA molecules with a 3’ –OH and 5’ cyclic phosphate (205). This specific 
processing may be important for interference complex assembly or identification of 
crRNAs for complex integration. RNA that was extracted and sequenced from the 
active Methanopyrus kandleri CRISPR system demonstrated crRNA sequences 
proximal to the leader where the highest transcribed (206). A second leader-like AT 
rich region was found distal from the CRISPR locus that showed a second spike in 
transcription levels. This suggests there is little regulation in completing transcription 
of the entire CRISPR array. 
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Figure 1-10. Type II CRISPR type maturation of CRISPR-RNA (crRNA) by Csn1 and host RNase factors. 
Type II systems differ from other CRISPR types as the recruit host RNase III for maturation of crRNA. 
Type II systems involve two RNA molecules for structural assembly: trans activating crRNA (tracrRNA) 
and guide RNA (gRNA), similar to crRNA. TracrRNA allows the first processing event to target the pre-
crRNA transcript at repeat regions. (Taken from (207)). 
Type II systems without Cas6 proteins utilise host RNases to prepare crRNA (155). In 
Streptococcus pyogenes an extra RNA molecule is required for the processing of 
crRNA (Figure 1-10). Differential RNA sequencing (dRNA-seq) detected an RNA 
species that is transcribed 210 nt upstream on the anti-sense strand of the coding 
sequence for the Cas genes. Transcripts were termed tracrRNA (trans-activating 
CRISPR RNA). Within tracrRNA a 25nt stretch has almost complete (one mismatch) 
complementation to the CRISPR repeats of S. pyogenes. Deletion of tracrRNA inhibits 
the generation of mature crRNA; tracrRNA is therefore essential in Type II crRNA 
maturation. 
The importance of host RNases was identified through RNA analysis of Cas9 CRISPR 
(Type II) systems revealing the presence of 3’ overhangs reminiscent of products of 
RNase III cleavage (155, 168, 208). In some systems, RNaseIII or Csn1 deletions 
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impeded mature crRNA formation (207). Csn1 is proposed to act as a molecular 
anchor protecting pre-crRNA and tracrRNA and carrying out a second cleavage event 
through a RuvC-like fold (RNase H)(209). Host RNase III and anti-CRISPR transcripts 
are conserved between CRISPR Type II systems. Evolutionarily, CRISPR Cas9 systems 
may be a precursor to eukaryotic Dicer and Drosha nucleases and the production of 
small interfering RNAs (siRNA) and micro RNAs (miRNAs) important for gene 
regulation (210-212). 
1.4.2.3 Interference - degradation of invading genetic elements 
Mature crRNA is incorporated into interference complexes that target invader 
genetic elements. Atomic resolution structures have shed light on the existence of 
four interference pathways.  
1.4.2.3.1 Cascades and multi-protein interference complexes 
The structure of the E.coli Cascade complex was determined both with crRNA alone 
and with crRNA/protospacer RNA duplex. The core of the interference complex is a 
backbone constructed of six Cas7 proteins (213, 214). These Cas7 monomers form a 
hexameric helical structure with a binding groove that crRNA resides in. In the 
archaeal type I system from Sso homologs of Cas5 and Cas7 show a similar helical 
arrangement (213). Interestingly, Sso helix length was dependent on the RNA 
molecule length and other Cascade proteins present. Other variants of Cascades 
include Pseudomonas aeruginosa in which six Csy3 organise with a similar helical 
pitch and RNA topology (215). Structural similarities suggest that Csy3 and other 
proteins in the type I systems such as Csc2 in fact all belonging to a Cas7 superfamily 
(216). Therefore, it is Cas7 family proteins which invariably form the core of Cascade 
complexes across different organisms. Moreover, Cas7 proteins are proposed to 
perform the same structural role in both the Mth I-H and Hvo I-B systems as well.  
 
 
29 
As previously discussed in Expression and processing of crRNA, Cas6 and Cas9 
coupled to tracrRNA and RNase III execute crRNA maturation in Types I and III and 
Type II, respectively. Variants of Cas6 (and some Cas5s) contain a typical RNase 
ferredoxin-like fold. Whereas, Cas5c of Bacillus halodurans is thought to process pre-
crRNA, thus presenting with catalytic activity, it is not the Case for other Cas5 
proteins (217, 218). Generally Cas5 has a structural crRNA capping role. In E.coli Cas5 
(CasD) interacts stably with Cas7 and Cse1 (CasA) but additionally interacts with the 
Cas7 superfamily protein Cse2 (CasB) (214). This series of interactions combined with 
PAM/TIM interactions are important for R-loop stabilisation. CRISPR systems that 
lack a Cas6 contain a catalytically active Cas5 (Cas5c) instead, combined with ‘regular’ 
Cas5 for its structural role.  There are only a few examples where no Cas5 gene can 
be found, specifically CRISPR subtypes I-D and I-F (125). However it is predicted that 
Csc1 and Csy2 from the respective subtypes belong to the Cas5 protien family. 
Nonetheless, as shown by SAXS analysis, these proteins don’t interact with Cas7 (214, 
219).  
The ‘small’ subunits of some interference complexes and are predicted to belong to 
the Cas11 superfamily. Csa5 (I-A), Cse2 (I-E), Csm2 (III-A) and Cmr5 (III-B) are all 
homologous in their N-terminal domains but diverge in their C-terminal domains 
(216). The E.coli Cse2 (CasB) protein dimer is an integral part of the E.coli Cascade 
(220, 221), stabilising the formed R-loop and increasing overall affinity of Cascade for 
dsDNA by an order of magnitude. The ‘small’ subunit of the Cmr complex Cmr5, is 
not essential for interference in the Type III-B system (222), unlike its counterparts 
CasB and Cas5 from other CRISPR systems. These results indicate that the ‘small’ 
subunits of interference complexes maintain structural similarities but lack close 
functional links.  
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1.4.2.3.2 ‘Large’ subunits of interference complexes (Cascades) 
Interference complexes of Type I and III systems contain a ‘large’ subunit: Cas8 (I-A, I-
B, I-C), Cse1 (I-E), Csy1 (I-F) and Cas10 (I-D, III-A and III-B).  Originally, Cas10 proteins 
were believed to be novel polymerases based on sequence homology to other 
polymerases and cyclase palm domains. No homology is observed between Cas10 
proteins and those of other Type I ‘large’ subunits (e.g. Cas8) (223). Cas10 proteins 
contain a phosphohydrolase domain, similar to that found in Cas3 proteins described 
later. Some ‘large’ subunit proteins interact with crRNA. Cas10 of Cmr complexes 
interact with Cmr3 (the Cas7 family protein) (224, 225), indicating an interaction with 
crRNA at the protein: protein interface. Cas8 family protein CasA (Cse1) interacts 
with the 5’ handle of crRNA and is discussed in greater detail a later section (226, 
227): Biochemical analysis of archaeal Cas8 in CRISPR interference. The importance of 
CasA in crRNA binding and PAM recognition is explained, along with the role of the 
‘large’ subunit in CRISPR mediated immunity. The ‘large’ subunits of these 
interference complexes have important roles in identifying PAM/TIM sequences 
(228), exemplified by the E.coli CasA (162). By analogy, Cas8 and Csy1 proteins are 
suggested to localise to similar regions of the ribonucleoprotein complex (214, 229). 
The association of the ‘large’ subunit with the rest of the complex seems to be 
transient and may well indicate that proteins like CasA scan invading genetic 
elements and when a target sequence is identified acts as a trigger to recruit the 
Cascade complex to test for crRNA homology.  
Through a combination of crystal structure analysis and Cryo-EM, E.coli CasA has 
been shown to interact with the PAM region of target DNA identifying it as non-self 
DNA, and helping to prevent host DNA targeting (162, 227). CasA interaction with the 
CasBCDE-crRNA complex doesn’t alter DNA binding affinity, as KDs determined for 
CasBCDE and CasABCDE binding to dsDNA are indistinguishable (5 ± 1nM and 8 ± 
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4nM, respectively)(128). CasA protein did not interact with DNA. When modelled into 
the electron density map the L1 region (residues 130-143) interacted with the 5’ 
handle of the crRNA. The suggestion is that CasA scans for PAM, triggering duplex 
destabilisation and crRNA/Cascade binding. Target binding by Cascade triggers a 
conformational change of CasA, CasB1-2 and CasE around the axis of CasC helical 
bundle. CasA and Cas3 have been shown to co-localise in vivo, supported by some 
CRISPR systems encoding Cas3-CasA fusions (167). Cas3 and the interaction with the 
‘large’ subunit of Cascade complexes are essential for transfer of information and 
interference. The interaction of CasA with PAM and CasD (Cas5 family) facilitates 
seeding of the crRNA. It is also believed that L1 loop of CasA is responsible for the 
transfer of information from CasA and the Cascade complex to Cas3 (227). Mutations 
made in the L1 region, specifically N131A, perturbed Cas3 nuclease activity.  
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Figure 1-11. Comparison of the structures of different interference complexes from Type I and Type III 
CRISPR systems. The third stage of CRISPR-Cas immunity is orchestrated by interference complexes. In 
Type I systems these are called Cascades, the best studied example is that of E.coli (i). This Cascade has 
been co-crystallised with CRISPR-RNA (crRNA) and is said to structurally represent a ‘sea-horse’. Type III 
systems have two general interference complexes: Csm and Cmr. The Cmr complex of P. furiosus (ii) has 
been well studied and also co-crystallised with crRNA. The Csm complex is less well understood and is 
typical of archaeal CRISPR immune systems. Atomic force microscopy (AFM) structures of the Csm 
complex have been determined to a much lower resolution (iii). Overall conservation of key architecture 
of various interference complexes presented here can be seen: Helical stacking of the crRNA and 
capping at the 3’ and 5’ ends of the RNA molecule. (Adapted from (214), (230) and (137)). 
The diversity of ribonucleoprotein complexes explained above and structurally 
represented in Figure 1-11 does not alter the targeted identification of foreign 
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genetic elements. Type III-B system Cmr interference complexes are the only CRISPR 
defence mechanism against foreign RNA elements (224, 231). In Type I CRISPR 
systems Cas3 is recruited to the R-loop formed by Cascade complexes (167). Transfer 
of correct R-loop and PAM information triggers heliCase/nuclease activity of Cas3 to 
degrade the invader DNA. In Type II systems, the interference complex consists of the 
Cas9 protein and one or two RNA molecules, tracrRNA and crRNA (guide RNA) or a 
chimeric RNA molecule. Cas9 protein has two nuclease catalytic domains: RuvC-like 
and HNH, and transloCase domains to degrade the invading DNA duplex (209, 232). 
Type III systems utilise Cas10 family proteins to carry out the degradation function 
(233).  
1.4.2.3.3 Cas9 
Recently, Cas9 has been exploited for its genome editing potential (132-136, 234-
236). As a commercial successor to TALEN’s (transcription activator-like effector 
nuclease) and transposases co-expression of Cas9 with synthetic crRNA’s (or guide 
RNA [gRNA]) can attenuate gene expression (134, 237-241). TALEs were first 
discovered in the plant pathogen Xanthomonas sp. bound to DNA RVDs (repeat 
variable di-residues) altering gene expression in a sequence specific manner (242). 
Fusion of a TALE with Fok I nuclease (TALEN) bought about the first genome editing 
tool (243), which, through generation of targeted double-strand DNA breaks (DSBs) 
subsequently repaired by non-homologous end joining (NHEJ), could induce insertion 
or deletion mutations (244). These mutations cause frame shifts and subsequent 
gene expression attenuation. However repair by homologous recombination reduces 
mutation frequency. While TALENs were cost effective, mutation rates were low 
leaving the stage open to the development of more efficient new tools for genetic 
engineering such as Cas9.   
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Atomic resolution of Cas9 proteins has identified two nuclease domains: a RuvC-like 
RNase H fold and an HNH fold (similar to that found in T4 Endo VII) (130, 168, 245), 
shown in Figure 1-12. These folds are essential for nuclease degradation, shown by 
mutational analysis. Type II Cas9 has been harnessed for site-specific DSB generation. 
Through the use of programmable gRNAs, the efficiency of genome editing in human 
and mouse cell lines and zebrafish embryos has improved from 2-4% to 20% (246). 
Nuclease-deficient mutants (dCas9) have been developed for regulating transcription 
without DSB induction (247). Cas9 mediated genome engineering requires PAM 
sequences for stable target binding (157, 177). Cloning and transfection of multiple 
gRNAs can generate simultaneous targeting and expression regulation. Cas9 is an 
attractive mammalian editing tool with approximately 40.5% of human exons being 
suitable unique targets.  
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Figure 1-12. Crystal Structure of Cas9 in complex with Guide RNA and Target DNA. (i) Electrostatic 
surface potential of Cas9 protein in complex with guide RNA (gRNA – cyan), target DNA (yellow) and 
trans-activating CRISPR RNA (tracrRNA - red). HNH domain omitted for clarity. (ii) Cas9 forms R-loops 
through CRISPR-RNA (crRNA) or guide-RNA (gRNA) that is structurally arranged within the Cas9 by trans-
activating crRNA (TracrRNA). Cas9 cleaves at R-loops through its RuvC-like domain and HNH fold. Pam 
sequence is essential for HNH activated cleavage. (Adapted from (131) and (248)). 
PAM and gRNA are essential for complete double strand cleavage (two nicking 
reactions). Without PAM in a double strand context, only the HNH domain nicks the 
strand bound by the gRNA, the displaced strand remains intact. A single strand can 
be repaired by ligases without following DSBR, decreasing the likelihood of a 
phenotypically deleterious mutation. Mutant Cas9s (dCas9) are now used in gene 
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regulation across a host of organisms by transfection and gene knockdown 
experiments. 
1.4.2.3.4 CRISPR interference via R-loops 
DNA/RNA hybrids and R-loops are important for regulating genome stability (153, 
249), with their roles in various processes summarised in Table 2.  An RNA strand 
invades a DNA duplex (typically supercoiled) and base pairs with one DNA strand, 
forming an R-loop. R-loops were first identified in bacteria, priming ColE1 plasmid 
replication (250). The importance of R-loops has also been recognised in 
mitochondrial and viral DNA replication priming. Persistent R-loops affect genome 
stability by blocking replication forks and initiating additional DNA replication, 
provoking illegitimate HR (251). Regulation and reversal of R-loops is carried out by 
host proteins, summarised in  
 
 
 
 
Table 3.  
Table 2. RNA molecules involved in genome dynamics. (Adapted from (159)) 
Process RNA–DNA hybrid/R-loop 
Transcription Nascent RNA synthesis from DNA templates “Thread-back” and “extended hybrid” models 
of R-loop persistence during transcription (251) 
Epigenetics: 
methylation 
Protection of CpG promoter islands from methylation (252) 
DNA replication Priming of lagging strand synthesis. Priming of plasmid (ColE1), viral and mitochondrial 
replication (253) 
Genome instability R-loops provoking illegitimate recombination 
CSR R-loops at G‐rich sequence provoke immunoglobulin diversity (254) 
Telomere 
processing 
“t-loop” of RNA and G‐rich DNA (255) 
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CRISPR targeting R-loop of crRNA targeting invasive DNA 
 
 
 
 
 
Table 3. Proteins involved in the regulation and reversal of R-loops. (Adapted from (159)) 
Protein Activity 
RNaseHI Ribonuclease on RNA strands base paired to DNA (256) 
Topoisomerase I Relaxation of negatively supercoiled DNA (257) 
RecG HeliCase unwinding R-loops (258) 
Pif1 HeliCase unwinding RNA–DNA hybrids (259) 
Senataxin/Sen1 HeliCases unwinding RNA–DNA hybrids (260) 
Various transcription termination and 
mRNA processing factors 
Bind to nascent RNA to prevent thread-back R-loops (251) 
Cas3 HeliCase unwinding R-loops (143) 
 
R-loops are essential to the successful targeted degradation of invading genetic 
elements. The action of the type I CRISPR interference system is summarised in a 
schematic overview from E.coli, shown in Figure 1-13. This summary suggests the 
process of interference: (a) assembly of the interference complex, (b) scanning of the 
invader by CasA, (c) R-loop formation and (d) Cas3 recruitment and degradation. Cas 
proteins from the same families have been highlighted in the figure legend to 
compare the proposed similarities with the Mth Type I-H system. 
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Figure 1-13. Comparing the E.coli Type I-E Cascade complex assembly and interference to the possible 
Mth Type I-H. This is an overview of the proposed role of Cascade proteins from E.coli: CasE (Cas6) 
processes pre-CRISPR-RNA (pre-crRNA) into mature crRNA, CasB (Cas8’’), CasC (Cas7) and CasD (Cas5) 
assemble into the Cascade complex with CasE and crRNA. Each bracketed protein is the equivalent in 
Mth. CasA (Cas8’) surveys DNA for Protospacer adjacent motif (PAM) and recruits the Cascade complex 
to initiate strand invasion and R-loop stabilisation. The stable R-loop recruits Cas3 to trigger degradation 
on the invading element and recycling of Cascade. 
1.4.2.3.5 Cas3 
Cas3 proteins are dual function enzymes consisting of an N-terminal HD 
phosphohydrolase domain and a C-terminal SFII (super family II) DExD/H-box 
heliCase domain (261). In some systems these two domains are expressed as 
separate ORFs but interact and act similarly. Other Cas3 variants exist for example, 
Cas3–Cas2 in I-F subtype (181) and Cas3–Cse1 (CasA) in some I-E systems (167). Cas3, 
unlike Cas9, is recruited to the R-loop generated by interference complexes and then 
degrades the invading genetic element. The nuclease activity of Cas3 requires 
conserved divalent metal cation coordination, typically magnesium (165). 
Superimposed HD domains of Cas3s demonstrate characteristic HD super family 
motifs in their amino acid sequence: H-HD-H-H-HD, and core 5 alpha-helical bundles 
 
 
39 
as shown in TtCas3HD (Thermus thermophilus) (164) and MjaCas3″ 
(Methanocaldococcus jannaschii) (161).   
Cas3 carries out interference via its two distinct nuclease activities: endonuclease 
cleavage of the R-loop and the 3’-5’ exonuclease activity (164, 165, 167). Cas3 crystal 
structures (Figure 1-14) aid understanding of how the exonuclease activity is coupled 
to the heliCase/transloCase activity of Cas3. Whereby two RecA-like domains 
coordinate ATP and so provide the chemical energy required for translocation 
through a ssDNA binding channel within the protein. The C-terminal heliCase domain 
of T. terrenum contains structural homology to the archaeal DNA heliCase Hel308 
(262) and flavivirus RNA heliCase N53 (263).  Cas3 recruited to the stabilised R-loop 
interacts with the ‘large’ subunit of the Cascade complexes (162). In E.coli, CasA 
(Cse1) directly interacts with Cas3 and transfers correct R-loop and PAM information 
triggering endonuclease cleavage of the R-loop, followed by transloCase/nuclease 
degradation of the invading genetic element (162, 227, 264).  
 
Figure 1-14. Crystal structure of Cas3 from Thermobaculum terrenum. (i) N-terminal HD nuclease 
domain (blue), unknown function CTD (red), and two RecA like motor domains (Cyan and green) are 
distinguished. (ii) HD nuclease domain active site, interaction lengths and distance are presented as 
dotted lines. Each metal ion label is associated with a water molecule. (Adapted from (265)) 
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1.4.3 Outstanding questions about CRISPR-Cas 
CRISPR-Cas research is still a young field and as such several important questions 
remain unanswered about the function and activity of these ‘immune’ systems: 
 CRISPRs are similar to selfish MGE as some organisms repress CRISPR gene 
expression with H-NS. Whereas some archaea encode constitutively active 
CRISPR arrays, which are then further induced by cell stress responses (SOS). 
Through silencing of this immune system implies no selective advantage 
during cellular evolution (169). It is rare for such strains to lose CRISPR 
arrays. Therefore, are CRISPR elements selfish or evolutionary beneficial? 
  The majority of spacers originate from MGE and phage, but others 
correspond to host chromosome sequences. Cas9 and synthetic CRISPR 
systems have been shown to effectively regulate gene expression in a host 
but how profound is this host regulation effect?  
  Spacer acquisition can either be primed or naïve. Naïve spacer acquisition 
has a very low efficiency; the efficacy of CRISPR-Cas immunity to lytic phage 
may therefore require an additional stage of CRISPR immunity – Facilitation 
(266), a mechanism that prevents viral replication while a novel spacer can 
be integrated to target the invader. Primed acquisition, while improved from 
naïve is still less effective than would be expected from an efficient immune 
response. Why are these processes so inefficient? What is the mechanism 
controlling CRISPR spacer library expansion (267)? 
 The mechanism of spacer integration is unknown; delineation of this process 
may lead to understanding the key details of this pathway. Cas1 proteins 
which act as transposons may improve our understanding on the function of 
CRISPR-Cas systems. Transposable DNA elements are important for driving 
diversity and evolution in a cell population, and often provide a selective 
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advantage. Do Cas proteins have additional roles distinct from simply 
producing an immune response (118)? 
1.5 Aims 
This body of work had three main objectives; as little is known about archaeal 
Cascade complexes, (i) analysis of archaeal Type I CASCADEs from 
Methanothermobacter thermautotrophicus and Haloferax volcanii, specifically the 
role of the essential Cas8 proteins in both of these similar systems, and 
understanding the mysterious heliCase/nuclease activity of Cas3. Cas proteins are 
speculated to interact with host DNA metabolism proteins with some existing 
evidence. Here, the aim was to (ii) identify interactions of E.coli Cas1, Cas2 and Cas3 
with other E.coli proteins. At the outset of this study nothing was known about the 
mechanism of spacer acquisition, therefore (iii) the biochemical activities of E.coli 
Cas1 and Cas2 were tested in vitro to create a testable model of target capture and 
spacer integration. 
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2 Materials and Methods 
2.1 Materials 
2.1.1 E.coli Strains 
Table 4. A list of bacterial strains used throughout this study. Each strain genotype is detailed and 
descriptions for use listed. 
 
2.1.2 Chemicals and enzymes 
In this study all chemicals and solutions were purchased from either Sigma, Fisher or 
VWR and were used as detailed in the methods later in this section. All commercial 
enzymes used were from New England Biolabs (NEB). 
2.1.3 Media 
2.1.3.1 E.coli media 
Mu Broth: 1% (w/v) tryptone (Bacto), 0.5% (w/v) yeast extract, 340 mM NaCl, 2 mM 
NaOH, pH 8.0. 
Mu Agar: 300ml Mu Broth, 0.5% Agar (w/v). 
Strain Genotype Details and source 
DH5α F- 80dlacZ M15 (lacZYA-argF) U169 
recA1 endA1hsdR17(rk-, mk+) 
phoAsupE44 -thi-1 gyrA96 relA1 
Most suitable as a cloning stain, used for some protein 
overexpression. High quality plasmid DNA. Restriction, 
endonuclease and recombination deficient. Dam+. From 
NEB. 
BL21Ai F- ompT hsdSB(rB
- 
mB
-
) gal dcm 
araB::T7RNAP-tetA 
Protein overexpression strain. Tightly controlled araBAD 
promoted T7RNAP. Protease deficient. Tetracyclin 
resistant. From Stratagene. 
BL21 
Codonplus 
 F– ompT hsdS(rB
– 
mB
–
) dcm+ Tetr 
gal endA Hte [argU ileY leuW Cam
r
 
Protein overexpression strain. Rare tRNA gene 
expression. Protease deficient. pLysS encoded T7RNAP. 
Chloramphenicol resistant. From Stratagene. 
T7Express fhuA2 lacZ::T7 gene1 [lon] ompT 
gal sulA11 R(mcr-73::miniTn10--
Tet
S
)2 [dcm] R(zgb-210::Tn10--
Tet
S
) endA1 Δ(mcrC-mrr)114::IS10 
Protein overexpression strain. Protease deficient. 
T7RNAP within lac operon. Enhanced BL21 derivative. 
From NEB. 
SoluBL21 F- ompT hsdSB (rB
-
 mB
-
 ) gal dcm 
(DE3) 
Protein overexpression strain. T7RNAP compatible. 
Protease deficient. Uncharacterised mutations obtained 
through special selection criteria for soluble intact 
expression. From Genlantis 
IIB924 F
-
, DE(araD-araB)567, 
lacZ4787(del)::rrnB-3, LAM
-
, rph-1, 
DE(rhaD-rhaB)568, hsdR514 
araB::T7RNAP-tetA 
Protein overexpression and genetic test strain. Inducible 
T7RNAP. Tetracycline resistant. From Ivana Ivancic-Bace 
XL10-Gold F´ proAB lacIqZDM15 Tn10 
(Tet
r
) Amy Cam
r
 
Cloning strain. High efficiency plasmid transformation. 
Tetracycline and Chloramphenicol resistant. Restriction, 
endonuclease and recombination deficient. From 
Stratagene. 
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All solutions were prepared and sterilised by autoclave. Broth was stored in the dark 
at room temperature until needed. Mu agar plates were stored in sealed bags to 
prevent desiccation at 4°C. 
2.1.3.2 E.coli media supplements 
Each supplement was dissolved in Sterile Distilled Water (SDW), with the exception 
of chloramphenicol which was dissolved in 100% ethanol. 
Table 5. Summary of media supplements used and their final working concentrations. 
Supplement Abbreviation Final Concentration 
Ampicillin Amp 50 μg/ml 
Chloramphenicol Cm 10 μg/ml 
Kanamycin Km 40 μg/ml 
Tetracycline Tet 10 μg/ml 
Streptomycin Str 100 μg/ml 
Apramycin Appr 40 μg/ml 
Isopropyl β-D-1-thiogalactopyranoside IPTG 0.5 mM 
D-Arabinose Ara 0.2 % 
2.2 Methods 
2.2.1 General microbiology 
2.2.1.1 Growth and Storage of Escherichia coli 
Cultures on solid media were grown overnight at 37°C in a static incubator (LEEC). 
Liquid cultures were grown at either small scale (5-10 ml) or large scale (200-2000ml) 
in a shaking water bath or orbital shaker at 150-180rpm and were grown overnight or 
until desired OD600. Typically large-scale cultures were for over-expression of 
proteins; growth and induction temperatures varied from 22°C to 37°C. Plates, when 
stored, were refrigerated. For long-term storage, glycerol stocks were prepared. A 
final concentration of 20% (v/v) glycerol was added to an overnight culture, flash 
frozen and stored at -80°C. 
2.2.1.2 Preparation of chemically competent Escherichia coli 
E.coli strains were initially streaked out on Mu agar plates containing appropriate 
antibiotic for strain selection and grown overnight at stated above. 8ml of Mu broth 
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containing the selective antibiotic was inoculated with a single colony from the streak 
plate and grown overnight in a shaking water bath. 1:100 inocula of the overnight 
were inoculated into 50ml Mu broth, again with antibiotic selection where 
appropriate. Cultures were incubated with shaking until they reached an OD600 
between 0.4-0.8. Typically at OD600 = 0.6 the culture was centrifuged at 4 krpm for 10 
minutes. Supernatant was discarded and cell pellet was resuspended in 5ml ice cold 
0.1M Calcium chloride (CaCl) and kept on ice for a minimum of an hour. Cells were 
centrifuged and resuspended as before with fresh CaCl for a further 15 minutes. For 
storage, 2ml of ice cold 80% glycerol was added and mixed. Cells were then aliquoted 
and frozen at -80°C until required. 
2.2.1.3 Transformation of chemically competent Escherichia coli 
For all transformations the Heat shock procedure was used, summarised briefly. 
500ng of plasmid DNA was added to 100μl of chemically competent E.coli cells and 
incubated on ice for 30 minutes. Then the DNA/cell mix was subjected to heat shock 
at 42°C for 1 minute. After 1 minute rest on ice, 750μl of Mu broth was added and 
the cells were then incubated at 37°C in a shaking water bath for 30-60 minutes. Cells 
were then centrifuged at 13.2 krpm for 1 minute and 750μl of supernatant removed. 
The resuspended cell pellet was then plated on Mu agar that contained the 
appropriate antibiotic to select for strain and plasmid. Plates once dried were 
incubated overnight at 37°C. 
2.2.2 Molecular cloning and mutagenesis 
2.2.2.1 PCR gene amplification and Quick change (QuCh) mutagenesis 
Amplification of either genomic or plasmid DNA was carried out using either Vent or 
Q5 polymerases. These enzymes are both high fidelity enzymes that ‘proof-read’ to 
ensure accurate gene amplification by checking correct base pairing. Reaction 
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conditions for both enzymes are shown below and either Biometra thermocycler 
basic or gradient were used. Typical PCR reaction is as follows: 
Vent DNA Polymerase: 
1 x Thermopol Buffer 
10mM dNTPs 
10μM forward and reverse Primers 
10-100ng template DNA 
0.5μl Vent polymerase 
(Additional MgSO4 if required) 
Final reaction volume of 50μl 
 
Q5 High Fidelity DNA Polymerase: 
1 x Q5 Reaction Buffer 
10mM dNTPs 
10μM forward and reverse Primers 
10-100ng template DNA 
0.5μl Q5 polymerase 
1x GC enhancer 
Final reaction volume of 50μl 
 
For annealing temperatures NEB Tm Calculator was used, which follows Howley et al’s 
equation, taking into account GC content, primer length and sequence homology. If 
this annealing temperature generated no product however, a gradient PCR was set 
up over the annealing temperatures to cover 7.5°C above and below the suggested 
Tm. 
Table 6. Typical thermocycling programme for Polymerase Chain Reaction. Steps of primer based 
extension include denaturing template, annealing primers and polymerase extension, repeated 30 
times. 
Cycle Vent Q5  
Denaturation 5min 95°C 5min 95°C 
Denaturation 45sec 95°C 45sec 95°C 
Annealing 1min 45-65°C 1min 45-65°C 
Extension 1min+1min per kb 
at 72°C 
30sec+30sec per kb 
at 72°C 
Final extension 5min at 72°C 5min at 72°C 
For QuCh PCR’s the same principle was followed. In each of these specific mono or 
dinucleotide mismatched primers were used for the forward and the reverse primer. 
x 30 
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The template was always that of a sequenced plasmid encoding the gene of interest. 
A total of 13 cycles of the ‘PCR’ were used; thermocycling is the more accurate 
description here. 
2.2.2.2 Restriction Endonuclease Digestion of oligonucleotides 
All restriction digests were carried out as per the manufacturer’s instructions (NEB). 
Where required digests were supplemented with the addition of 200 ng/μl BSA 
(NEB). When double digests were performed, NEB buffers were selected where both 
enzymes had 100% activity, otherwise a sequential digest was carried out. DNA was 
digested for between 30 minutes and 16 hours, when appropriate for cutting near 
the ends of PCR products. Longer digests were carried out in a sealed 37°C incubator, 
to prevent evaporation and star activity from increased enzyme concentration. 
2.2.2.3 Dephosphorylation of digested vector DNA during cloning 
 Antarctic phosphatase was used to remove 5′phosphate groups of the linearized 
plasmids. Removal of the 5’ phosphate prevents self ligation of the linear vector, thus 
reducing the chance of colonies containing only vector DNA. Vectors were incubated 
with 1 unit of Antarctic phosphatase/μg of DNA with the addition of Antarctic 
phosphatase buffer to a final 1X concentration for 30 minutes at 37°C. Antarctic 
phosphatase could be heat inactivated at 65°C for 5 minutes afterwards, often 
though this step was omitted because the enzyme did not affect subsequent 
modification of the DNA 
2.2.2.4 Ligation of DNA 
Ligations of gene insert and vector were performed using T4 DNA ligase. 5 units of 
DNA ligase were used plus T4 ligase buffer at a final 1X concentration for each 
reaction. Ligations contained a molar ratio of ~3:1 (insert:vector) DNA. Ligations were 
carried out at 4°C overnight. 
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2.2.2.5 Ethanol Precipitation of DNA 
Ethanol precipitation was used to either concentrate DNA samples, exchange buffer 
or remove unwanted protein contaminants. 1 volume of 4M ammonium acetate and 
4 volumes of 100% ethanol (stored at -20°C) were added to DNA samples and 
incubated at -20°C overnight. Samples were centrifuged at 4°C, 20,000 ×g for 30 
minutes and the supernatant removed. Pellets were immediately washed in 100μl of 
70% ethanol followed by centrifugation as before. The supernatant was removed and 
pellets allowed to air dry before resuspension in buffer (usually Sterile distilled water, 
SDW). 
2.2.2.6 Nucleic acid Purification 
DNA was purified by two main methods. Plasmid DNA was purified by Qiagen mini 
and maxi prep protocols. PCRs and restriction digests were purified using the Qiagen 
Gel Extraction kit. Plasmid extractions are based on the alkaline lysis method 
followed by adsorption of DNA onto a silica gel in high salt. Maxi preps include an 
ethanol precipitation step for higher quality DNA. Plasmid extractions were from 
E.coli overnight cultures. 8ml cultures in the miniprep method and 500ml for 
maxiprep. These cultures were always grown in the DH5α strain at 37°C in Mu broth 
with appropriate antibiotic supplement. The protocols were followed exactly as is the 
manufacturer’s instructions directed, except DNA was eluted from mini preps and 
finally resuspended from maxi preps with SDW. This was the Case with gel 
extractions also, elution into SDW. Plasmid stocks generated were stored at -20°C. 
2.2.2.7 DNA Sequencing 
The Biopolymer Synthesis and Analysis Unit, University of Nottingham, or Source 
Biosciences (Cambridge UK) carried out all sequencing reactions and analysis. 
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Sequencing was carried out using the dideoxy chain termination method (Sanger et 
al., 1977). 
2.2.2.8 Oligonucleotide Synthesis 
Oligonucleotides were synthesised either by the Eurofins MWG (Germany), or Sigma-
Aldrich (UK). Primer oligonucleotides were synthesis at 0.01µM scale and desalted. 
Substrate oligonucleotides were synthesised at 0.2µM scale and HPLC purified. All 
sequences were verified by MALDI-ToF. 
2.2.2.9 Nucleic Acid Quantification 
Plasmid preparation concentration was determined using the 260/280 nm 
absorbance ratio from spectrophotometer measurements (NanoDrop) (Beckman 
Coulter DU 530). 
2.2.3 Gel electrophoresis 
2.2.3.1 Agarose Gel Electrophoresis 
Buffers and Solutions: 
TBE (Tris Borate EDTA): 89 mM Tris.HCl, 89 mM boric acid, 2 mM EDTA. 
Gel Loading Dye (5×): 50 mM Tris・HCl, 100 mM EDTA, 15% Ficoll (w/v), 0.25% 
Bromophenol Blue (w/v), 0.25% Xylene Cyanol FF (w/v). 
Agarose gels were Cast using agarose powder (between 0.5-3%) and 1x TBE. Ethidium 
bromide was either added to a final concentration of 0.5 μg/ml or gels were washed 
after electrophoresis in TBE containing 0.5 μg/ml ethidium bromide to allow for 
visualisation of DNA. Samples were mixed with gel loading dye to a 1x final 
concentration and loaded alongside either a 1Kb or a 100bp (NEB) size markers. 
Standard TBE gels (10cm) were run at 100 V for 1 hour, other gels varied as detailed 
in later sections. 
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2.2.3.2  Agarose Gel Extraction and Purification of DNA 
Purification of DNA from agarose gels was carried out by UV exposure using a UV 
transilluminator (UVP inc.). Desired DNA was extracted dependant on size and 
purified using the Qiagen Gel extraction kit, detailed earlier. 
2.2.3.3 SDS-Polyacrylamide Gel Electrophoresis 
Buffers and solutions 
7.5, 10, 12 or 15% SDS-PAGE gel (resolving): 7.5, 10, 12 or 15% 
acrylamide/bisacrylamide, 0.37 M Tris (pH 8.8), 0.1% (w/v) SDS, 0.05% (w/v) APS 
(ammonium persulfate), 0.05% (v/v) TEMED (tetramethyleethylenediamine). 
3.0% SDS-PAGE gel (stacking): 3% acrylamide/bisacrylamide, 0.25 M Tris (pH 6.8), 
0.2% (w/v) SDS, 0.125% APS, (w/v) 0.125% (v/v) TEMED. 
SDS-PAGE running buffer: 0.25 M Tris, 1.92 M glycine, 1% (w/v) SDS. 
Laemmli buffer (4×): 50mM Tris pH 6.8, 100 mM DTT, 2% (w/v) SDS, 0.1% (w/v) 
bromophenol blue, 10% (v/v) glycerol. 
Staining solution: 40% (v/v) methanol, 10% (v/v) glacial acetic acid, 0.85mM 
Coomassie Brilliant Blue G-250 
Destaining solution: 20% (v/v) methanol, 7% (v/v) glacial acetic acid.  
Protein samples were analysed using SDS-PAGE (sodium dodecyl sulphate 
polyacrylamide gel electrophoresis). Gels were made in self-assembly Cassettes 
(BioRad). A 7.5, 10, 12 or 15% resolving gel was poured with a layer of butanol 
saturated water on top, leaving a level surface. Once set, the butanol was removed 
and a 3% stacking gel poured and a comb inserted. Protein samples were mixed with 
Laemmli buffer to a final concentration of 1x. Samples were denatured by boiling at 
95°C for 10 minutes and run alongside a PageRuler size ladder (Fermentas) or 
Colourplus marker (NEB). Gels were run for ~1 hour 10 minutes at 220V SDS-PAGE 
running buffer and then stained with Coomassie Brilliant blue staining solution for 
10-30 minutes, followed by gel destaining to visualise proteins. 
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2.2.3.4 Western blot 
Buffers and Solutions 
Transfer Buffer: 25mM Tris, 190mM Glycine, 0.1% (w/v) SDS. 
TBST (Tris Buffered Saline Tween): 20mM Tris-HCl pH7.5, 150mM NaCl, 0.1% (v/v) 
Tween 20. 
WBB (Western Blocking Buffer): 20mM Tris-HCl pH7.5, 150mM NaCl, 0.1% (v/v) 
Tween 20, 5% (w/v) milk powder. 
After SDS-PAGE, gels that were to be probed with antibodies rather than Coomassie 
stained were electroblotted onto PVDF (Polyvinylidene Fluoride) membrane. Gels 
were equilibrated in Transfer buffer for 10 minutes. During this time, PVDF was 
activated by exposure to 100% methanol for about 10 seconds and then also 
equilibrated in transfer buffer. For a wet blot, the Xcell SureLock (Thermo Fisher 
Scientific) was set up in the typical electroblotting ‘sandwich’, ensuring membrane 
was closer to the positive electrode than the gel and no air bubbles were present 
between any of the individual layers. Electroblot was then carried out at 100V for 1 
hour or 15V for between 4 hours and overnight.  
After blotting, membranes were blocked overnight at 4°C using the WBB with 
constant agitation to prevent nonspecific antibody binding. Primary antibodies, 
either anti-His (Sigma Aldrich), anti-MBP (NEB) or anti-strep (NEB) were washed to 
probe the membrane in WBB with a usual dilution 1:5000 of antibodies. This was 
incubated for 1 hour at room temperature with agitation. Unbound primary antibody 
was then removed by 3 wash steps. Washes were 5 minutes with fresh TBST buffer, 
and then discarded. Secondary antibodies were then used to detect the primary 
antibody depending on how the primary antibody was raised. Regularly primary 
antibodies are raised in mouse and rabbit. So secondary antibodies are anti-mouse or 
anti-rabbit and are HRP (Horse Radish Peroxidase) conjugated. Secondary was 
washed over membranes for 1 hour at room temperature at a dilution of between 
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1:1000 and 1:2500. Membranes were washed as before and the ready for 
development. Western blots were developed by ECL (Thermo Scientific) and 
visualised via FujiFilm Las-3000 chemoluminescence photography. Exposure times 
between 1 – 30 minutes. 
2.2.4 Phenotyping of Haloferax volcanii by DNA-Damage Assays 
In order to determine the extent of sensitivity to DNA damaging agents, assays were 
performed using a number of mutagens: 
2.2.4.1 UV-Irradiation 
Ultraviolet light is electromagnetic radation outside of the visible spectrum. UV light 
is the most common cause of DNA radiation damage, creating thymidine dimers. 
100µl of each H.volcanii strain was sequentially diluted in 5 ml of HV-YPC broth (+Thy 
if required) and grown at 45°C rotating at 20rpm, to an OD 650 ≈ 0.35-0.4. 1 ml of 
culture was pelleted and resuspended in 18% salt water and serial diluted x10-1 to 
x10-6. Spot tests were then carried out; 20μl spots were spotted out in duplicate onto 
Hv-YPC agar (+Thy if required) and allowed to dry at room temperature. Plates were 
exposed to UV light (254 nm, 1 J/m2/sec) and shielded from visible light to prevent 
photo-reactivation. Plates were incubated at 45°C for 4-7 days until no detectable 
growth was observed and colonies counted. Survival fractions were then calculated 
with an unirradiated control. 
2.2.4.2 Mitomycin C 
Mitomycin C (MMC), a DNA crosslinking agent often used in chemotherapies, 
sensitivity was analysed as a chronic exposure, with MMC in the agar plates. Cultures 
were grown as before and then cells were spotted directly onto Hv-YPC agar (+Thy if 
required) containing 0-0.03 μg/ml of MMC. The half-life of MMC is 4-6 days so plates 
were made fresh and only used within 5 days. 
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2.2.5 Methanothermobacter thermautotrophicus protein overexpression 
and purification 
Buffers and Solutions 
Buffer A: 20mM Tris-HCl pH 8.0, 150mM NaCl, 1mM DTT, 0.1mM PMSF.  
Buffer B: 20mM Tris-HCl pH 8.0, 150mM NaCl, 1mM DTT, 0.1mM PMSF, 3mM 
Maltose. 
His Binding Buffer: 20mM Tris-HCl pH8.0, 500mM NaCl. 
His Charge Buffer: 20mM NiCl2 
His Wash Buffer: 20mM Tris-HCl pH8.0, 500mM NaCl, 10mM Imidazole. 
His Elute Buffer: 20mM Tris-HCl pH8.0, 500mM NaCl, 500mM Imidazole. 
His Strip Buffer: 20mM Tris-HCl pH8.0, 500mM NaCl, 50mM EDTA. 
Buffer C: 20mM Tris-HCl pH 8.0, 1500mM NaCl, 1mM DTT, 0.1mM PMSF. 
Dialysis Buffer 1: Same as Buffer A 
Dialysis Buffer 2: 20mM Tris-HCl pH 8.0, 150mM NaCl, 1mM DTT, 0.1mM PMSF, 40% 
(v/v) Glycerol. 
Dialysis Buffer 3: 20mM Tris-HCl pH 8.0, 500mM KoAc, 1mM DTT, 0.1mM PMSF, 40% 
(v/v) Glycerol 
2.2.5.1 Protein induction and overexpression 
Some of the proteins used in this study already had established purification 
procedures that could be followed; these are detailed later. An initial screen on the 
remaining Mth Cas proteins was carried out by overexpression and solubility 
profiling.  
In these expression tests the plasmid constructs were transformed into BL21AI and 
BL21C+ strains. After overnight growth fresh 8ml of Mu was inoculated 1:50 with 
overnight culture and grown to an OD600= 0.6 and 37°C. Samples were taken before 
induction and then protein expression was induced with 0.5mM IPTG and 0.2% 
arabinose for BL21AI. Cultures were sampled at time points of between 2-4 hours 
and overnight. 1ml samples were centrifuged at 13.2 krpm for 1 minute, supernatant 
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removed and pellet resuspended in 300μl SDW and 100μl Laemmli buffer. These 
were then analysed via SDS-PAGE for protein expression.  
If expression was observed, a solubility screen followed. For each strain fresh 8ml of 
Mu was inoculated with overnight cultures as before and then grown at 37°C to 
OD600=0.6. Expression was then induced at temperatures between 22°C and 37°C. 
Time point samples were taken as before. Once samples were resuspended they 
were lysed via sonication, 30 seconds at 50% amplitude (intensity). Lysate was then 
clarified by centrifugation at 13.2 krpm for 10 minutes. A sample of both the pellet 
and supernatant were then taken for SDS-PAGE.  
For some Mth Cas proteins expression was also attempted in SoluBL21 and 
T7express. E.coli Cas 1 and Cas2 were found to express in either T7Express or IIB994. 
The screening tests outlined above were followed by the lab until expression 
conditions were found that were appropriate for expression. 
In each of the Cases below, upscaling of the protein expression for protein 
purification followed different procedures and they are outlined at the beginning of 
each subsequent section. All purification was carried out using the Amersham 
Pharmacia AKTA FPLC system unless stated. All pre-packed columns were from GE 
healthcare. 
2.2.5.2 Purification of Mth Cas3 
The plasmid pEB359 encoding the Mth Cas3 gene (with no affinity tag) was 
transformed into BL21C+. 4 litre expression cultures were set up containing ampicillin 
and chloramphenicol and grown to OD600=0.6 at 37°C. Once induced with IPTG at 
0.5mM the cells were incubated at 30°C for a further 2-4 hours. Biomass was 
harvested and frozen as before. 
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Purification of untagged proteins can be difficult, but this 4 step chromatographic 
method worked well (as developed by Jamieson Howard). The first step was passing 
the clarified sonicated supernatant through 5ml Heparin FF; Cas3 did not bind but 
many contaminants were removed. The flowthrough from the heparin column was 
then used as the input for a 5ml Q Sepharose FF column (cation exchange). Mth Cas3 
was eluted over a NaCl Gradient (150-1500mM) between 400-600mM NaCl. Pooled 
fractions were then loaded onto a 5ml Phenyl Sepharose FF (Hydrophobic interaction 
column, HIC) column, which was pre-equilibrated at 600mM NaCl. A gradient of NaCl 
(600-0mM) was used; Cas3 eluted at 0mM NaCl. Cas3 fractions were then loaded 
onto 7ml manually prepared DEAE (diethyl-aminoethyl) column, a second, weaker 
cation exchange column. Elution was over NaCl gradient (150-1500mM). Pooled 
fractions were dialysed into Dialysis Buffer 3 and stored at -80°C.  
2.2.5.3 Purification of Mth His6Cas8’ 
The original clone of Cas8’ (pEB389) was used to provide N-terminally tagged His6-
Cas8’; this construct was used for site directed mutagenesis of Cas8’, based on the 
Quick-change protocol. These mutations, after verification by DNA sequencing, were 
expressed and purified as with the wild-type protein (144).  
Each His6Cas8’ gene was transformed into BL21C+, overnight culture used to 
inoculate cultures and grown to O.D600=0.6, and expression induced for 2-4 hours at 
30°C with IPTG. Harvested cells were resuspended in His Binding Buffer containing 
phenyl methyl sulfonyl fluoride (PMSF, 0.1 mM), and freeze-thawed prior to lysis by 
sonication, followed by centrifugation at 39,000 g for 20 min. Soluble proteins were 
loaded onto a 5ml HiTrap Chelating FF column charged with nickel chloride and 
equilibrated in His Binding Buffer. His6Cas8’ eluted into fractions within a gradient of 
10-500mM imidazole and were pooled and loaded onto a HI Load Superdex 200 
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26/60 column equilibrated in Buffer B followed by elution in the same buffer in one 
column volume. His6Cas8’ fractions were pooled and loaded onto 5ml Heparin HP 
column equilibrated in buffer B. His6Cas8’ proteins eluted in a gradient of 150-
1500mM NaCl, and fractions containing His6Cas8’ were pooled and dialysed into 
Dialysis Buffer 2 for storage in aliquots at -80°C.  
2.2.5.4 Purification of Mth His6Cas7 
Cas7 was available as a clone that was known to overexpress and produce a soluble 
protein. pEB388 (His6Cas7 in pET14b) was transformed into BL21C+, and expressed in 
the exact same manner as His6Cas8’ proteins. Soluble proteins were then loaded 
onto 5ml HiTrap Chelating HP Column and eluted within 10-500mM imidazole 
gradient. Fractions containing His6Cas7 were pooled and loading onto 1ml Heparin 
HP equilibrated in Buffer B. Elution gradient of NaCl (150-1500mM) was used and 
fractions containing Cas7 were pooled and dialysed into Dialysis Buffer 3. Aliquots 
were stored at -80°C. 
2.2.5.5 Co-purification of Mth MBPCas5 and Cas7 
This method is summarised in Cass et al. and in the appendix (144); a full explanation 
of the method used is here. Cas5 protein could be overexpressed but not purified in 
isolation, the protein was insoluble; however, using MBP (maltose binding protein) 
and a strongly predicted interaction partner Cas7, co-expression of these 2 proteins 
generated soluble MBPCas5 and Cas7 proteins. MBPCas5 (pSDC25, Cas5 in pMal-C2x) 
and non-tagged Cas7 (pSDC38, Cas7 in pCDF-1b) were sequentially transformed into 
BL21C+ because co-transformation would not yield any colonies under any 
conditions. Plates and media contained ampicillin (for pSDC25) and streptomycin (for 
pSDC38) and cultures for overexpression were supplemented with 0.2% (w/v) 
glucose to reduce amylase production. Overexpression was carried out in the exact 
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conditions as Cas8’ and Cas7. Cultures were grown from overnight cultures at 37°C, 
expression induced with 0.5mM IPTG at 30°C for 2-4 hours and then cells harvested 
and frozen. 
Soluble proteins after sonication were loaded onto 7ml Amylose resin selfpour 
column. MBPCas5 and Cas7 co-eluted within the maltose gradient (0-3mM). 
Fractions containing MBPCas5 and Cas7 were pooled and then loaded onto 1ml 
Heparin HP and eluted within an NaCl gradient (150-1500mM). Fractions containing 
MBPCas5 and Cas7 were dialysed in Dialysis buffer 3, aliquoted and stored at -80°C. 
2.2.5.6 Purification of Mth Cas5 and Cas6 
Cas5, like Cas6, only expressed as insoluble proteins in E.coli, so after various 
expression conditions were tested, purification was attempted via refolding dialysis. 
Cas6 proteins were expressed in the same manner as previous Mth proteins. 
Inclusion bodies were then prepared. After sonication in a lysis buffer (50mM Tris-
HCl pH 8.0, 100mM NaCl, 5mM EDTA, 0.1%NaN3, 0.5% Triton X-100, 1mM DTT and 
0.1mM PMSF) the insoluble fraction was retained. 10mM MgSO4 was then added to 
chelate the EDTA, followed by DNaseI (0.01mg/ml) and lysozyme (0.1mg/ml) 
treatment for 20 minutes at room temperature. The mix was then centrifuged at 6 
krpm for 15 minutes. The pellet was crushed with a spatula before resuspending in 
lysis buffer by sonication. DNaseI and lysozyme treatment was carried out again. This 
process was repeated three more times; the final resuspension step was in lysis 
buffer minus Triton X-100 followed by centrifugation, pelleting inclusion bodies. 
Inclusion bodies were diluted in 100mM Tris-HCl pH 8.0, 50mM Glycine and 
dispersed using sonication. To dissolve the suspension, it was added dropwise to 
vigorously mixing solubilisation buffer (100mM Tris-HCl pH 8.0, 50mM Glycine, 8.5M 
Urea). Dissolved inclusion bodies were then ready for refolding. Refolding was a 
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week-long process of sequential dialysis steps in a refolding buffer (0.1M Tris, 0.4M L-
Arginine) supplemented with decreasing urea (4M, 2M, 1M, 0M), adjusted to pH 8.0 
and then 1mM EDTA and 0.1mM PMSF added immediately before use. Each dialysis 
step was for 24 hours. At different stages of this purification Cas5 and Cas6 
precipitated and formed stubborn aggregates that were only soluble in reducing 
agents. So a similar method was approached with Cas6, for soluble expression in 
E.coli. 
2.2.5.7 Purification of Mth MBPCas6 
MBPCas6 (pSDC28, Cas6 in pMal-C2x) was transformed into BL21C+ and was 
expressed and purified in the exact same manner as MBPCas5 and Cas7. Expression 
at 30°C, purification by amylose affinity column and then heparin affinity/cation 
exchange and storage in Dialysis buffer 3 at -80°C. 
2.2.6 E.coli Protein overexpression and purification 
Buffers and Solutions 
Buffer A: 20mM Tris-HCl pH 8.0, 150mM NaCl, 1mM DTT, 0.1mM PMSF.  
Buffer B: 20mM Tris-HCl pH 8.0, 150mM NaCl, 1mM DTT, 0.1mM PMSF, 3mM 
Maltose. 
His Binding Buffer: 20mM Tris-HCl pH8.0, 500mM NaCl. 
His Charge Buffer: 20mM NiCl2 
His Wash Buffer: 20mM Tris-HCl pH8.0, 500mM NaCl, 10mM Imidazole. 
His Elute Buffer: 20mM Tris-HCl pH8.0, 500mM NaCl, 500mM Imidazole. 
His Strip Buffer: 20mM Tris-HCl pH8.0, 500mM NaCl, 50mM EDTA. 
Buffer C: 20mM Tris-HCl pH 8.0, 1500mM NaCl, 1mM DTT, 0.1mM PMSF. 
Dialysis Buffer 1: Same as Buffer A 
Dialysis Buffer 2: 20mM Tris-HCl pH 8.0, 150mM NaCl, 1mM DTT, 0.1mM PMSF, 40% 
(v/v)  Glycerol. 
 
 
58 
Dialysis Buffer 3: 20mM Tris-HCl pH 8.0, 500mM KoAc, 1mM DTT, 0.1mM PMSF, 40% 
(v/v) Glycerol 
2.2.6.1 Purification of E.coli MBPCas3 
E.coli MBPCas was overexpressed following the established protocol described in 
Howard et al. 2011 (143). DH5α was transformed with pAH1 (Cas3 in pMal-C2x). A 
fresh overnight culture was used to inoculate 4 litres of Mu broth containing 
ampicillin and 0.2% Glucose, to inhibit amylase production. 10 x 400ml of cultures 
were incubated at 37°C until OD600=0.6. Protein expression was induced with 0.5mM 
IPTG for 30 minutes. Culture was then immediately transferred to chilled centrifuge 
bottles and centrifuged at 4 krpm for 20 minutes at 4°C in a pre-chilled centrifuge 
Avanti-G50. Supernatants were discarded and pellets resuspended in a minimum 
volume of Buffer A, 5-20ml, and flash frozen and stored at -80°C. 
Biomass was thawed on ice and sonicated at 50% intensity for a total of 1 minute, (10 
seconds on, 10 seconds off) to allow cooling. The lysate was clarified by 
centrifugation at 20 krpm for 20 minutes. The soluble fraction was then loaded 
directly onto a self-pour 7ml Amylose resin column, pre-equilibrated in Buffer A. An 
amylose gradient was then used to elute bound proteins (0-3mM maltose). Elution 
peaks were analysed and fractions containing MBPCas3 were pooled. These fractions 
were then loaded onto 5ml Heparin HP column. Bound proteins were eluted over a 
NaCl gradient (150-1500mM). One broad peak was observed on the UV trace, 
fractions were analysed as before and highest concentration fractions were pooled. A 
repeat of the previous Amylose column was carried out here. This is because of the 
contaminating MBP degradation products (previously shown by western blotting by 
Jamieson Howard). This column removed some of the degradation products and 
resulted in a higher purity of full length MBPCas3. After elution from this column 
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pooled fractions were dialysed overnight into Dialysis buffer 2, aliquoted and stored 
at -80°C. 
2.2.6.2 Purification of E.coli His6-Topoisomerase I 
pEB350 (TopoI in pET14b) was transformed into BL21AI. TopoI was expressed in a 
similar way as MBPCas3. 4 litres of Mu broth with ampicillin was inoculated with 
overnight culture and grown to OD600=0.6. Expression was then induced with 0.2% 
arabinose and 0.5mM IPTG for 2-4 hours at 37°C. Cells were pelleted and 
resuspended in His Binding Buffer and frozen. 
Biomass was thawed, sonicated and clarified as before. 5ml HiTrap Chelating column 
was prepared by charging with His Charge Buffer and the equilibrated in His Binding 
Buffer. Supernantant from clarification was loaded and after a wash step in His Wash 
Buffer an elution of imidazole (10-500mM) was used to elute bound proteins. Peak 
fractions were pooled and then dialysed for 3 hours or overnight into Dialysis Buffer 
1. After this the sample was loaded onto a 1ml Heparin FF column. A NaCl gradient 
(150-1500mM) was used for elution, again peak fractions were analysed, pooled and 
the dialysed into Dialysis Buffer 2. Concentrated protein was then aliquoted and 
stored at -80°C. 
2.2.6.3 Purification of E.coli His6Cas1 
Cas1 was generated in the lab with several different tagging methods. His6Cas1 was 
found to be the easiest to handle and purify and is summarised in Rollie et al. (150) 
and Ivancic-Bace et al (268). His6Cas1 (pEB549) was transformed into IIB942. Cells 
were grown from overnight cultures to OD600= 0.5, before expression was induced 
with arabinose (arabinose inducible T7 promotor) and ITPG (0.5mM) for 3-6 hours. 
Cells were harvested by the normal centrifugation and resuspension step into His 
binding buffer.  
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After sonication and clarification, soluble proteins were loaded onto an equilibrated 
5ml HiTrap Chelation FF column, charged with Ni2+ ions. His6Cas1 eluted over an 
imidazole gradient (10-500mM). Fractions containing Cas1 were pooled and loaded 
directly onto a HI Load Superdex 200 26/60 column equilibrated in Buffer B. Fractions 
of His6Cas1 were collected over an isocratic gradient of 1 CV in buffer B and pooled. 
These were the loaded onto a 1ml Heparin column and Cas1 eluted within the NaCl 
gradient (150-1500mM). Protein was pooled, dialysed against Dialysis buffer 2 and 
stored in aliquots at -80°C. 
2.2.6.4 Purification of E.coli Cas1HisStrep 
Cas1HisStrep was already available cloned (pASB11, Cas1 in pQE-His1). pASB11 was 
transformed into T7express cells for optimal overexpression. Overnights were used 
to inoculate up to 4 litres of growth media. Cultures were grown to exponential 
phase OD600 of 0.6 at 37°C and expression was induced with IPTG (0.5mM) for 3-6 
hours at 30°C. Biomass was harvested and resuspended in Buffer A. After sonication 
and clarification soluble protein were loaded onto a 1ml Strep-Tactin SuperFlow Plus 
(Qiagen) column. Cas1HisStrep was eluted within a gradient of desthiobiotin (0-
2.5mM). Fractions containing Cas1 were then loaded directly onto 1ml HisTrap FF 
column, charged with Ni2+. Elution over imidazole gradient (10-500mM) liberated 
Cas1HisStrep. Pooled fractions containing Cas1 were then dialysed again Dialysis 
Buffer 2 overnight at 4°C, aliquoted and stored at -80°C. 
2.2.7 Protein crystallisation 
2.2.7.1 Minimal buffering conditions 
Cas8’ protein that had been expressed by the method outlined above, but in a 10 
litre fermentation reaction vessel, with vigorous agitation and aeration. This provided 
a large biomass for bulk purification. Cas8’ was expressed and purified this way. 
Minimum solubility parameters were then set up as the starting point for 
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crystallisation. The storage buffer for the protein was Dialysis Buffer 3 (20mM Tris-
HCl pH 8.0, 500mM KOAc, 1mM DTT, 0.1mM PMSF, 40% (v/v) Glycerol), so each 
constituent’s concentration was altered to get the minimum salt, glycerol and DTT 
while maintaining soluble protein, the conditions attempted are highlighted below in 
Table 7. 
Table 7. Buffer conditions trailed for Mth Cas8’ crystallisation. 
Buffer Condition KOAc (mM) DTT (mM) Glycerol (% v/v) 
1 275 1 40 
2 275 0 5 
3 500 1 22.5 
4 50 0 22.5 
5 500 1 5 
6 50 0 40 
7 500 0 40 
8 50 1 5 
9 275 0 22.5 
10 275 1 22.5 
2.2.7.2 Crystallisation 
Once the minimal conditions were set, crystal tray preliminary screens were set up, 
thanks to Richard Rymer of Panos Soultanas’ Lab in the Centre of Biomolecular 
Sciences (University of Nottingham) for assistance in the step up and analysis.  
2.2.8 In vitro protein-protein interactions assay 
2.2.8.1 In vitro pull down interactions between Mth proteins MBP-Cas5-Cas7 
and His-Cas8’ and E.coli proteins MBP-Cas3 and DNA Topoisomerase 
I. 
Buffers and Solutions 
Buffer A: 20mM Tris-HCl pH 8.0, 150mM NaCl, 1mM DTT, 0.1mM PMSF. 
Dialysis Buffer 3: 20mM Tris-HCl pH 8.0, 500mM KoAc, 1mM DTT and 40% (w/v) 
glycerol. 
Wash buffer (W): 20mM Tris HCl pH 8.0, 150mM NaCl, 1mM EDTA and 1% (v/v) 
Tween 20. 
Western Blocking Buffer (WBB): 50mM Tris HCl pH 7.6, 150mM NaCl and 0.1% (v/v) 
Tween 20, supplemented with 5% (w/v) milk powder. 
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This method is summarised in Cass et al. (144) and in the appendix; a full explanation 
of the method used is here. The gene encoding Cas5 (ORF Mth1087) was amplified 
from Methanothermobacter thermautotrophicus (Mth) ΔH genomic DNA by PCR, and 
the gene fragment cloned into pMal-C2x for expression of Mth Cas5 fused at its N-
terminus to E. coli maltose binding protein (MBP-Cas5). MBP tagging of Mth Cas5 
greatly improved its solubility and stability for expression in E. coli. Cas7 (ORF 
Mth1088) was amplified similarly to Cas5, for cloning into pCDF-1b generating a non-
tagged Cas7 protein. Co-expression of MBP-Cas5 and Cas7 in E. coli strain BL21 
Codon Plus was in broth containing additional glucose (0.2 % w/v), protein expression 
being induced by addition of IPTG (0.5 mM) at OD600 between 0.4-0.6. Cas5-Cas7 was 
purified as a complex through multiple steps on an AKTA-FPLC, followed using SDS-
PAGE as described in Co-purification of MBPCas5 and Cas7.  Briefly, clarified soluble 
proteins were loaded into a column containing 5ml amylose sepharose. MBPCas5 
and Cas7 co-eluted within a gradient of 0-5mM maltose in Buffer A and fractions 
containing MBPCas5-Cas7 were pooled and loaded onto 5ml Heparin HP column 
equilibrated in buffer A. MBPCas5-Cas7 co-eluted in a gradient of 150-1500mM NaCl, 
and fractions containing MBPCas5-Cas7 were pooled and dialysed into Dialysis Buffer 
3 for storage in aliquots at -80oC. 
MBPCas5-Cas7 was used to test for physical interaction with Cas8’. 50μl of amylose 
resin slurry was equilibrated in 100μl of wash buffer (W) and centrifuged at 700g for 
30 sec, supernatant removed and washing repeated five times. 20μg of MBPCas5-
Cas7, His6Cas8’ or MBPCas5 and Cas7 and His6Cas8b’ we added to the resin to a final 
volume of 500μl and end-to-end mixed for 2-4 hours at 4°C. Resin was pelleted as 
before and washed 3 times as previously. SDS-PAGE disruption buffer was added to 
resin pellet and boiled. First wash and pellet were analysed via SDSPAGE. 
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Two identically loaded SDS-PAGE gels were used for Coomassie staining or electro 
blotting onto PVDF to detect the presence of MBPCas5 or His6Cas8’ proteins via their 
affinity tags. Membranes were incubated overnight at 4°C in Western Blocking Buffer 
(WBB), before probing each separately with monoclonal antibodies against MBP 
(NEB), or His6 (Sigma). Washed membranes were then probed with HRP-conjugated 
anti-mouse antibody (against His6) or anti-goat antibody (against MBP) to develop 
using an ECL detection kit and imaged using FujiFilm LAS300 machine. The exact 
same method was used for testing the interaction between E.coli MBPCas3 or MBP- 
ΔC-Cas3 and DNA Topoisomerase I.  
2.2.8.2 Size exclusion chromatography 
For each assay, an analytical Superose 6 size exclusion column was equilibrated in 
running buffer (20mM Tris-HCl, 150mM NaCl, 1mM DTT, 0.1mM PMSF, 10% (v/v) 
glycerol); typically three times the void volume of the column (column volumes, CV) 
was used to equilibrate. The column was then loaded with a diluted 250μl input of 
molecular weight standards (BioRad), consisting of 5 proteins of known molecular 
weights. Molecular weight standards generated a standard curve plotting elution 
volume (Ve) verses protein molecular. This standard is then used as a reference when 
analysing sample molecular weights. 
SE was out on Mth Cas3 and the D347A mutant proteins. Each protein was incubated 
-/+ 10mM ATP and/or Mg2+, and then loaded and eluted from the Superose 6 
column. UV absorbance was analysed to predict elution volume and therefore a 
change in structure or oligomeric state. 
This method was also attempted for the interaction of Cas3 from E.coli and an 
interaction observed previously between Cas3 and Topoisomerase I. Combinations of 
mixed and individual proteins, 100μg of MBPCas3, MBP or His6TopoI were mixed for 
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30 minutes at room temperature before loading onto the SE column and eluted. 
Fractions were collected from this run and then analysed by SDS-PAGE, and then 
Western Blotting to detect a shift in elution of His6TopoI only when incubated with 
MBPCas3. This was also carried out with a mutant MBPCas3, that had the 
uncharacterised C-terminal domain deleted, referred to as ΔCMBPCas3. This protein 
was treated in the same way as the wild-type protein.  
This was used for the Mth proteins Cas5, Cas7 and Cas8’. Again combinations of the 
proteins were loaded onto a Superose 6 SE column and elution profiles were 
analysed relative to the molecular weight standards. The only difference here is that 
the buffer for elution was supplemented with 500mM KOAc rather than NaCl. 
2.2.8.3 Cross linking 
Proteins that are thought to interact were dialysed into a buffer suitable to carry out 
the cross linking experiment (20mM HEPES pH 8.0, rather than Tris-HCl). 20μg of 
each protein was then incubated in isolation and with predicted reaction partners 
with the addition of glutaraldehyde at increasing concentrations (0.0125, 0.125 and 
1.25mM). Reaction proceeded for 5 minutes at room temperature and then samples 
were prepared for SDS-PAGE. 
2.2.9 Nucleic acid substrates for in vitro biochemical assays 
Buffers and solutions 
Elution Buffer: 10mM Tris-HCl pH 7.5, 50mM NaCl  
2.2.9.1 Radiolabelling of Nucleic acid substrates 
Oligonucleotides were purchased from MWG and are listed in the appendix. Labelling 
of oligonucleotides and their annealing into substrates followed standard methods. 
Oligonucleotides were resuspended in nuclease-free water to a final concentration of 
600ng/μl. Single stranded nucleic acids were 5’ end-labelled with 32P from γ[32P]-ATP 
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using T4 polynucleotide kinase (PNK) (NEB) in a standard reaction set up as follows. 
300ng of substrate was incubated with a final concentration of 1 x T4 PNK buffer, 
γ[32P]-ATP (Perkin-Elmer) (approximately equimolar to DNA used) and T4 PNK. 
Reaction was incubated at 37°C for 30-60 minutes. Labelled oligonucleotide was 
purified from unincorporated γ[32P]-ATP in BioSpin6 columns (Bio-Rad), using the 
protocol provided. Prepared columns were loaded with 20-80µl of labelled nucleic 
acid substrate and separated by centrifugation at 1 x g for 2 minutes. Once purified 
from unincorporated γ[32P]-ATP, if a single stranded substrate it was now ready for 
assay. Forming of double stranded of branched and therefore multiple stranded 
substrates annealing was as follows. 300ng of labelled nucleic acid strand was mixed 
with 900ng of unlabelled oligonucleotide and incubated in 10mM sodium citrate 
buffer at 95°C for 10 minutes. The reaction was then allowed to cool to room 
temperature overnight to facilitate efficient annealing on substrate strands.  
2.2.9.2 Purification of labelled nucleic acid substrates 
Substrates that consisted of two of more oligonucleotides were purified by 
electrophoresis through 10% polyacrylamide/ 1x TBE electrophoresis, for 3 hours at 
120V and then excision of the appropriate band, detected on photographic film, and 
elution of DNA by diffusion into Elution Buffer at 4°C, for between 24-72 hours. 
2.2.10 Electrophoretic mobility shift assays (EMSA) 
Buffers and Solutions 
Buffer HB: 100mM Tris-HCl pH 7.5, 10mM DTT, 500μg/ml BSA and 30% (v/v) glycerol. 
TBE (Tris Borate EDTA): 89 mM Tris-HCl, 89 mM boric acid, 2 mM EDTA 
EMSAs mixed protein(s) with substrate in buffer HB, typically incubated at 44.8°C for 
10 min. Reactions were then mixed by pipetting and loaded directly into wells of a gel 
comprising 7% polyacrylamide in 1x Tris-Borate-EDTA (TBE) buffer. Protein-nucleic 
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acid complexes were separated by electrophoresis at 105V for approximately 170 
min in 1 x TBE running buffer, and detected by gel drying and phosphorimaging. 
Protein-nucleic acid complex formation was quantified compared to a no-protein 
control, using AIDA software to calculate the percentage of substrate bound, and 
plotting in Prism to determine binding affinity expressed as KD. KD is the 
disassociation constant for the reversible reaction M + L ⇌ ML, where M is 
macromolecule (protein), L is the free ligand (oligonucleotide) and ML is the 
macromolecule-ligand complex (held together by intermolecular interactions, not 
covalent bonding). KD can therefore be described as: 
KD= [M]eq x [L]eq 
            [ML]eq 
 
[M]eq can be referred to as [M free]. [M free] = [Mtotal – ML] 
[L]eq can be referred to as [L free]. [L free] = [Ltotal – ML] 
 
KD= ([Mtotal – ML]) x ([Ltotal – ML]) 
                             [ML] 
 
KD x [ML] = ([Mtotal – ML]) x ([Ltotal – ML]) 
KD x [ML] = [Mtotal][Ltotal] – [Ltotal][ML] – [Mtotal][ML] + [ML]
2
 
0 = [ML]2 – [Ltotal][ML] – [Mtotal][ML] - KD[ML] + [Mtotal][Ltotal] 
0 = [ML]2 – ([Ltotal] – [Mtotal] - KD) [ML] + [Mtotal][Ltotal] 
 
Therefore input this into the quadratic equation.  
If ax2 + bx + c = 0 then x = -b ± √(b2 – 4ac) 
    2a 
 
[ML] = ([Ltotal] – [Mtotal] - KD) ± √( [Ltotal] – [Mtotal] - KD)
2 – 4([Mtotal][Ltotal]) 
    2 
 
2.2.11 Nuclease assays 
Buffers and Solutions 
Buffer HB: 100mM Tris-HCl pH 7.5, 10mM DTT, 500μg/ml BSA and 30% (v/v) glycerol. 
TBE (Tris Borate EDTA): 89 mM Tris-HCl, 89 mM boric acid, 2 mM EDTA. 
Stop solution: 2.5% (w/v) SDS, 200mM EDTA and 10mg/ml proteinase K. 
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Nuclease assays are summarised in Cass et al. (144) for His6-Cas8’ and MBPCas5 and 
Cas7, and in Rollie et al. (150) and Ivancic-Bace et al (268) for His6-Cas1, described in 
more detail here. 
Mth His6-Cas8’ proteins and MBPCas5 and Cas7 were mixed with substrates (2 nM) in 
Buffer HB supplemented with either 10 mM MgCl2, 5 mM EDTA or nothing and 
incubated at a range of temperatures between 44.8-65°C for 10 min. Reactions were 
terminated by addition of 3 μl stop solution and loaded into 10% acrylamide-TBE 
non-denaturing gels, or 15% polyacrylamide/urea denaturing gels. Gels were dried, 
imaged and analysed as for EMSAs. E.coli His6-Cas1 proteins were assayed in the 
same manner, except incubation was at 37°C for 30 min. 
2.2.12 HeliCase unwinding Assay 
Buffers and Solutions 
Buffer HB: 100mM Tris-HCl pH 8.5, 10mM DTT, 500μg/ml BSA and 30% (v/v) glycerol. 
TBE (Tris Borate EDTA): 89 mM Tris-HCl, 89 mM boric acid, 2 mM EDTA. 
Stop solution: 2.5% (w/v) SDS, 200mM EDTA and 10mg/ml proteinase K. 
RecG or PriA proteins were incubated with various forked substrates (2nM) in buffer 
HB supplemented with 5 or 10mM MgCl2 and ATP for 10 minutes at 37°C. Reactions 
were terminated by addition of 3μl stop solution and loaded into 10% acrylamide-
TBE non-denaturing gels. Gels were dried, imaged and analysed as for EMSAs. 
2.2.13 Strand Exchange Assay 
Buffers and Solutions 
Buffer HB: 100mM Tris-HCl pH 7.5, 10mM DTT, 500μg/ml BSA and 30% (v/v) glycerol. 
TBE (Tris Borate EDTA): 89 mM Tris-HCl, 89 mM boric acid, 2 mM EDTA. 
Stop solution: 2.5% (w/v) SDS, 200mM EDTA and 10mg/ml proteinase K. 
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MBPCas5 and Cas7 or His6Cas7 were mixed with a DNA duplex with one strand 
labelled, and another oligonucleotide that if annealed would displace the labelled 
DNA strand. Protein(s) were mixed with the substrate in buffer HB and incubated for 
30mins at 44.8°C. Reactions were terminated with 3μl Stop solution and analysed by 
10% TBE non-denaturing gels. Gels were dried, imaged and analysed as for EMSAs. 
2.2.14 ATPase assay 
Buffers and Solutions 
ATPase Buffer: 100mM Tris HCl pH 8.5, 10mM DTT, 500μg/ml BSA and 30% (v/v) 
glycerol, 10mM MgCl2 and 10mM ATP. 
Stop solution: 0.0324% (w/v) malachite green, 1% (w/v) ammonium molybdate and 
1M NaCl (filtered). 
 
Colour stability solution: 34% (w/v) Citric acid 
Malachite green assays were used to measure ATP hydrolysis through the 
detection of liberated phosphate. 800µl reactions contained 10mM MgCl2 
and 10mM ATP and 0-1000nM Cas8b protein, and were incubated at 45oC 
for 30min, supplemented with 200ng of either ssDNA (crDNA1) or ssRNA 
(crRNA1). 100µl stop solution was added and incubated for 5 mins followed 
by addition of 100µl colour stability solution and incubation at RT for 30 
mins. Solutions were transferred to cuvettes and absorbance measured at 
660nm and corrected against a zero protein blank. Phosphate liberation 
subsequently quantified, by comparison to a standard curve generated 
using 0-100µM K2PO4.  
2.2.15 Transesterification Assay 
Buffers and Solutions 
Buffer HB: 100mM Tris HCl pH 8.5, 10mM DTT, 500μg/ml BSA and 30% (v/v) glycerol. 
TBE (Tris Borate EDTA): 89 mM Tris.HCl, 89 mM boric acid, 2 mM EDTA. 
Stop solution: 2.5% (w/v) SDS, 200mM EDTA and 10mg/ml proteinase K. 
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Initial Transesterification (TE) reactions were carried out on DNA flap substrates with 
His6Cas1 and Cas1HisStrep. Protein was incubated with the flapped substrate in 
buffer HB (needed to be pH8.5 as pH7.5 produced no activity), for 30 minutes at 
37°C. Reactions were stopped with 3μl of stop solution and loaded into 15% 
polyacrylamide/urea denaturing gels, 170V for 55 minutes.  
This assay was then developed to include Cas2 in the reaction mixture with Cas1 and 
also different substrates were used. Other replication fork structures were 
assembled as described in Nucleic acid substrates for in vitro biochemical assays. 
Further development of the TE reactions involved preincubation of the DNA 
substrates with RecG, PriA or SSB proteins, these conditions were identical to those 
used in the heliCase unwinding assays, subsequently Cas1 was added to these 
mixtures and the typical TE reaction was continued. In each of these examples 
reactions were and loaded into 15% polyacrylamide/urea denaturing gels and 
electrophoresed for 170V for 55 minutes. 
2.2.16 SpIN (Spacer integration) assay 
Buffers and Solutions 
Buffer SpIN: 100mM Tris HCl pH 8.5, 10mM MgCl2, 1mM KCl, 10mM DTT, 500μg/ml 
BSA and 30% (v/v) glycerol. 
TBE (Tris Borate EDTA): 89 mM Tris.HCl, 89 mM boric acid, 2 mM EDTA. 
Stop solution: 2.5% (w/v) SDS, 200mM EDTA and 10mg/ml proteinase K. 
Short radiolabelled duplex DNA substrates were created as described above. 
Substrates consisted of 29bp spacer sequence flanked by + or - PAM and AAM motifs. 
Cas1 and Cas2 (100 and 50nM respectively) were pre-incubated on ice for 15 
minutes. Spacer substrate was then added to the protein mix and further incubated 
on ice for 30 minutes. pJRW2 (plasmid containing E.coli CRISPR array and leader 
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sequence) was added to a final reaction volume of 20µl and incubated at 37°C for 5, 
10, 15, 20, 25 and 30 minutes. Reactions were then terminated by addition of STOP 
solution and samples loaded onto 1% (w/v) agarose gels. 10cm gels were 
electrophoresed for 1 hour 30 minutes at 100V.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
71 
3 Chapter 3: Analysis of Cas proteins from 
Methanothermobacter thermautotrophicus and 
Escherichia coli 
3.1 Overview 
This chapter details the plasmid constructs, protein expression profiling, protein 
purification and biochemical assays of Cas proteins from Methanothermobacter 
thermautotrophicus and Escherichia coli. All the produced plasmids were confirmed 
by restriction digestion and direct DNA sequencing. Cloning for protein expression 
also included engineering N- or C-terminal tags as described by the following 
abbreviations: His6 (hexahistidine), Strep (StrepTactin) and MBP (Maltose Binding 
Protein). Tags were utilised for affinity purification of Cas and other proteins using 
AKTA FPLC systems. Additional methods of purification were employed to remove 
remaining contaminants where possible. After purification, the identity of each 
protein was verified by mass spectrometry (thanks to David Tooth and the BSAU, 
Faculty of Medicine and Health Sciences, QMC, University of Nottingham).  
Table 8. Nomenclatures used for the CRISPR/Cas genes and proteins of Mth and E.coli. other synonyms 
exist but these are not used in this investigation for clarity.  
Gene Family name Mth Gene and protein names E. coli gene and protein names 
Cas1 Mth 1084, Cas1 Cas1 
Cas2 Mth 1083, Cas2 Cas2 
Cas3 Mth 1086, Cas3 Cas3 
Cas4 Mth 1085, Cas4 - 
Cas5 Mth 1087, Cas5 CasD, Cas5 
Cas6 Mth 1091, Cas6 CasE, Cas6e 
Cas7 Mth 1088, Cas7 CasC, Cse4 
Cas8 Mth 1090, Cas8’ and Mth 1089, 
Cas8’’ 
CasA, Cse1 and CasB, Cse2 
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3.2 Cloning of Cas genes from Methanothermobacter 
thermautotrophicus and purification of the encoded 
proteins 
3.2.1 Molecular cloning of Cas genes 
A summary of Mth Cas genes studied is presented diagrammatically within the Mth 
CRISPR-Cas system in Figure 3-1. Mth Cas genes are encoded by ORFs 1076-
1091.ORFs 1076-1082 encode the Type III-A Csm complex proteins, ORFs 1083 
(Cas2), 1084 (Cas1) and 1085 (Cas4) encode the adaptation machinery, ORF 1086 
encodes the interference (Cas3) protein and ORFs 1087-1091 encode the Type I-H 
Cascade proteins (Cas5, Cas7, Cas8’’, Cas8’ and Cas6). Each ORF was cloned into one 
of the following vectors: pET14b, pET-Duet, pET-ACYC, pMal-C2x, pCDF-1b or pQE-
HisStrep1. Details of all the relevant cloning carried out, including those of other 
members of the laboratory applicable to this study, are given in Table7. Specifically, 
plasmids titled pEB or pJLH were kind gifts from Edward Bolt and Jamieson Howard, 
respectively. All the primers used can be found in the appendix along with plasmid 
construction plans from PCR or plasmid excision and ligations. 
 
 
Figure 3-1. Schematic of the gene neighbourhood of the CRISPR-Cas system of Methanothermobacter 
thermautotrophicus, including Cas genes and CRISPR-1 array. This CRISPR system is a fusion of Type I-H 
and III-A found downstream of CRISPR-1 array encoding: Cas5, Cas7, Cas8’, Cas8’’ and Cas6 for the type 
I-H archaeal Cascade, Cas3 as the heliCase/nuclease that degrades invading DNA, Cas1 and Cas2 (and 
Cas4) as the adaptation machinery of both subtypes and Mth 1076-1082 encoding the Csm (Type III-A) 
interference complex (144). 
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Table 9. Summary of plasmid constructs generated and used from Methanothermobacter 
thermautotrophicus genes. pSDC (Simon David Cass), pEB (Edward Bolt), pJLH (Jamieson Leyland 
Howard). 
Plasmid 
construct name 
Gene ORF 
Number 
Plasmid Vector Affinity 
protein Tag 
pSDC25 Cas5 1087 pMal-C2x N-MBP 
pEB374 Cas5 1087 pET14-b N-His6 
pSDC13 Cas6 1091 pET14-b N-His6 
pSDC27 Cas6 1091 pMal-C2x N-MBP 
pEB388 Cas7 1088 pET14-b N-His6 
pSDC29 Cas7 1088 pQE-HisStrep1 C-His6-Strep 
pSDC31 Cas7 1088 pCDF-1b None 
pEB367 Cas8’ 1090 pT7-7 None 
pEB389 Cas8’ 1090 pET14-b N-His6 
pEB403 Cas8’ 
(K68A) 
1090 pT7-7 None 
pSDC41 Cas8’ 
(K68A) 
1090 pET14-b N-His6 
pEB404 Cas8’ 
(K117A) 
1090 pT7-7 None 
pSDC22 Cas8’ 
K117A) 
1090 pET14-b N-His6 
pSDC39 Cas8’ 
(D151G) 
1090 pET14-b N-His6 
pSDC43 Cas8’ 
(N153A) 
1090 pET14-b N-His6 
pSDC40 Cas8’ 
(E155A) 
1090 pET14-b N-His6 
pSDC43 Cas8’ 
(N536A) 
1090 pET14-b N-His6 
pSDC38 Cas8’ 
(S540A) 
1090 pET14-b N-His6 
pSDC44 Cas8’ 
(A540G) 
1090 pET14-b N-His6 
pSDC45 Cas8’ 
(L542A) 
1090 pET14-b N-His6 
pEB383 Cas8’’ 1089 pT7-7 None 
pSDC5 1076  pETDuet-1 N-His6 
pEB359 Cas3 1086 pET22-b None 
pSDC15 Cas1 1084 pCDF-1b N-His6 
pSDC16 Cas2 1083 pCDF-1b N-His6 
pSDC17 Cas1 + 
Cas2 
1084 + 1083 pCDF-1b N-His6 
pJLH7 Cas1 1084 pET14-b N-His6 
pJLH9 Cas2 1083 pET14-b N-His6 
3.2.1.1.1 Summary 
Optimisation of PCR, restriction digests and ligations were required for some of the 
constructs; this included annealing temperatures, extension times, digest length and 
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ligation temperature and time. Integral for progress of this study was obtaining 
recombinant soluble archaeal Cascade proteins Cas5, Cas6, Cas7, Cas8’ and Cas3. 
3.2.2 Recombinant over-expression of Mth Cas proteins  
Mth Cas proteins were expressed heterologously in E.coli host strains listed in Table 
4. All the genes cloned from Mth were in vectors with T7 RNA polymerase promoters 
and Lac operators, therefore, strains of E.coli engineered to encode IPTG inducible T7 
RNA polymerase for protein expression. This strategy was chosen as Cas3 and Cas8’ 
have already been produced in our laboratory through this method (143, 269). 
3.2.2.1 Pilot experiments for testing protein expression and solubility  
Each Mth Cas protein was tested for over-expression and solubility in E.coli to find 
the optimal conditions for protein purification. For brevity, only the procedure and 
outcomes for Cas1 protein are shown, as a representative of the tests that were 
carried out for each Cas protein. Cas protein expression was trialled in E. coli strains 
BL21AI and BL21Codonplus (C+), followed by assessment of protein solubility. Cas1 
protein over-expression was observed in both BL21AI and BL21C+ (Figure 3-2i and ii). 
BL21C+ was the expression strain carried forward to assess its solubility in this strain 
as slightly higher levels of protein were detected, the predicted Cas1 protein, 
indicated with an arrow, is clearly detectable in the S (soluble) 1 (Figure 3-2iii).  
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Figure 3-2. SDS-PAGE analysis of Cas1 protein (Mth ORF1084) in pilot protein over-expression and 
solubility of lysed cell extracts of E. coli. In panel i (strain Bl21 AI) and panel ii (strain C+) Cas1 over-
expression is compared in un-induced cells (-) and IPTG induced cells grown for either 2 hours (+) or 4 
hours post-induction (++) at 37°C. An arrow points to predicted Cas1 migrating at approximately 35 kDa 
(predicted MW= 33174 Da). In panel iii, BL21 C+ cells were lysed to compare soluble fraction (S1) with 
insoluble fraction (P1), identifying that Cas1 was present in S1, as indicated by the arrow. 
 
Figure 3-3. SDS-PAGE analysis of Cas1 (Mth ORF1084) and Cas2 (Mth ORF1083) proteins from pilot 
purifications by His Gravi-Trap. In panel i, Cas1 pilot purification is compared from biomass induced 
with IPTG at 30
°
C and 37°C. Lysed and centrifuged soluble fraction was loaded onto His Gravi-Trap (IN) 
and compared to flow through (FT), wash (W) and elution (E) for Cas1. An arrow points to Cas1 protein 
doublet detected in the elute migrating at approximately 35kDa. In panel ii, Cas2 pilot purification is 
compared from biomass induced with IPTG at 30
°
C, 37
°
C, 27°C and 22°C. Lysed and centrifuged soluble 
fraction was loaded onto His Gravi-Trap (TCE) and compared to pellet (P1), soluble material (S1), flow 
through (FT), wash (W) and elution (E) for Cas2. An arrow points to where Cas2 protein would be 
expected to elute of the column, migrating at approximately 9kDa. 
After attaining soluble protein, different induction temperatures were tested to 
potentially increase yield. In particular, lower temperatures slow translation speed 
and so allow rare codon matching and allow correct disulphide bond formation. For 
Cas1 and Cas2 proteins, initial screens of expression were undertaken at 30oC and 
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37oC, (Figure 3-3i and ii). Additional lowering of the incubation temperature of 
growing E. coli cells to 27oC and 22oC was also tested to help obtain soluble Cas2 
protein. Different growth conditions were tested, even if there was no detectable 
soluble protein purification was carried out by His-Gravity Trap. Following expression 
cell biomass was collected by centrifugation. After clarification (sonication and 
centrifugation) soluble fractions were subjected to His-gravity Trap purification. First, 
the soluble fraction in 0mM Imidazole buffer was applied to the column whereby all 
unbound protein was collected as the flow through fraction (FT). Next, non-
specifically binding proteins were released from the column with a low imidazole 
(5mM) wash (W). Finally, specifically bound proteins were eluted in high (500mM) 
imidazole buffer (E). A doublet was seen from Cas1 purification at 30°C and 37°C, this 
doublet likely being either a degradation product of Cas1, or a nickel rich 
contaminating protein such as SlyD (270), a known contaminant of His-Tagged 
protein purification following expression in bacteria. No Cas2 could be purified from 
biomass grown at any temperatures tested here, with arrows pointing to where 
purified Cas2 protein would have been expected (Figure 3-3ii). 
3.2.2.2 Further overexpression and purification tests 
The procedure detailed for Cas1 was also implemented on other Cas proteins that 
were to form part of this study. This is summarised for proteins Csx1, Csm2, Csm3, 
Csm4, Cas2, Cas1, Cas4, Cas5 and Cas7 (ORFs 1076, 1077, 1078, 1080, 1083, 1084, 
1085, 1087 and 1088) in Figure 3-4. In each Case un-induced (-) and induced (+) total 
cell extracts were compared after cell lysis by sonication and centrifugation to 
ascertain the level of expression. Expression was detected in BL21C+ cell extracts of 
each protein except Csx1 and Cas2.  The expressing ORFs of interest were further 
analysed to assess protein solubility. However, this revealed most of the proteins 
expressed in this screen were in fact insoluble, (Figure 3-5). Therefore, further 
 
 
77 
investigations were focused on Mth ORFs 1086-1091 (Cas3-Cas6), encoding a type I-H 
CRISPR interference system, given they could be successfully purified, (see next 
section). 
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Figure 3-4. Composite SDS-PAGE analysis of Mth Cas proteins (Mth ORF1076-1091) in pilot protein 
over-expression studies. In panels i and ii each gene construct was expressed in BL21AI and BL21C+ (top 
and bottom panel respectively). Cas proteins over-expression is compared in un-induced cells (-) and 
IPTG induced cells grown for either 2 hours (+) or four hours post-induction (++). An arrow points to 
predicted Cas proteins migrating at approximate Relative Molecular Masses (RMMs). Proteins that 
expressed are identified and indicated with arrows and asterisks.  
 
* 
* 
* 
* 
* 
* * 
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Figure 3-5. Composite SDS-PAGE analysis of Mth Cas proteins (Mth ORF1076-1091) in protein 
solubility screen. In each panel the indicated gene was expressed in BL21C+ and compared in un-
induced cells (-), IPTG induced cells grown for 2 hours (+) and pellet (P1) and supernatant (S1) after 
sonication and centrifugation. An arrow points to predicted Cas proteins migrating at approximate 
RMMs. Proteins that expressed are identified and indicated with arrows and asterisks. 
3.2.3 Purification of Methanothermobacter thermautotrophicus proteins 
3.2.3.1 Cas8’ and Cas7 
Cas7 and Cas8’ are predicted to form part of some Cascade complexes that are 
essential for interference during CRISPR-Cas immunity in bacteria and archaea.  Cas8’ 
(ORF 1089) and Cas7 (ORF 1088) have established protocols for expression and 
purification (269), which were adapted as described below.  
His6-Cas8’ was purified via Ni
2+ Chelating Column within an imidazole gradient (0-
500mM), (Figure 3-6i). Peak fractions were analysed by SDS-PAGE and selected 
fractions dialysed to remove high imidazole and NaCl. The protein was further 
purified and concentrated via Heparin within a NaCl gradient (100-1500mM), (Figure 
3-6ii). Peak fractions were processed and dialysed into storage buffer (containing 35-
40% glycerol, which disrupts the ice crystal lattice [cryoprotectant] and depresses 
freezing temperatures, reducing protein degradation in storage). All Cas8’ mutants 
* 
* 
* 
* 
* 
* 
* 
* 
* 
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generated from cloning were also expressed and purified using the same system 
outlined here. Fermentation growth of cells expressing Cas8’ was attempted to 
generate sufficient protein for crystal trials. Cas8’ was purified with an additional size 
exclusion chromatography (SEC) between the Chelating and Heparin columns. Once 
purified, each Cas8’ protein was analysed by SEC to confirm monomer peak elution, 
in agreement with previous methods (269), (Figure 3-6iii).  
 
 
Figure 3-6. SDS-PAGE analysis of the purification of His6Cas8’ expressed in E.coli BL21C+. (i) After 
sonication and centrifugation soluble material (IN) was subjected to Affinity chromatography (HisTrap) 
and fractions were compared for Cas8’ contents, flow through (FT), wash (W) and UV trace peaks during 
imidazole gradient (0-500mM). (ii) Cleanest fractions containing Cas8’ were pooled and dialysed to 
remove high salt before being subjected to a second affinity column (Heparin) and fractions were 
compared for Cas8’ contents; flow through (FT), wash (W) and UV trace peaks during NaCl gradient 
(150-1500mM). Pooled fractions were dialysed for storage and subjected to size exclusion 
chromatography (Superdex 260/60).  (iii) UV-trace from analytical size exclusion chromatography 
plotting UV absorbance against elution volume during a 1column volume (~23ml) elution. Elution profile 
was compared to molecular weight standards to approximate the size of the purified protein shown in v. 
Cas8’ 
Cas8’ 
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Figure 3-7. SDS-PAGE analysis of the purification of His6Cas7 expressed in E.coli BL21C+. (i) After 
sonication and centrifugation soluble material (IN) was subjected to affinity chromatography (His Trap) 
and fractions were compared for Cas7 contents; flow through (FT), wash (W) and UV trace peaks during 
imidazole gradient (0-500mM). (ii) Cleanest fractions containing Cas7 were pooled and dialysed to 
remove high salt before being subjected to a second affinity column (Heparin) and fractions were 
compared for Cas7 contents, flow through (FT), wash (W) and UV trace peaks during NaCl gradient (150-
1500mM). (iii) Final purified protein prepared for storage. 
His6Cas7 was overexpressed and purified in the same manner as Cas8’ (Figure 3-7). 
However, elution of His6Cas7 from the heparin column was detected in two peaks. 
This is a result of Cas7 forming two possible species with different affinities for the 
heparin matrix, possibly through formation of a multimer that alters affinity binding 
to the heparin matrix. 
3.2.3.2 Cas5 and Cas6 
Cas5 and Cas6 are the two remaining predicted elements of the Mth type I-H 
archaeal Cascade. Neither Mth Cas5 nor Cas6 proteins have been previously 
investigated although analogous proteins CasD and CasE in E.coli have been found to 
be essential for CRISPR interference. 
Successful Cas5 and Cas6 over-expression was achieved from pET vectors (Figure 
3-4), however, all protein were deemed insoluble. Although both Cas5 and Cas6 
could be solubilised in 6M urea, re-folding (through iterative dialysis to remove urea) 
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proved difficult due to each protein aggregating again into insoluble material at 
lower urea concentration. As an alternative MBP tagged Cas5 and Cas6 were tested, 
as it is a common method used to increase protein solubility and stability in E. coli 
expression systems. MBP-Cas6 expressed as a soluble protein and was purified via 
affinity purification through amylose sepharose, eluting within a maltose gradient (0-
3.0 mM). Further purification through Heparin resin and elution within a NaCl 
gradient (150-1500mM) generated pure MBP-Cas6 (Figure 3-8). On the other hand, 
attaining soluble MBP-Cas5 required its co-expression with untagged Cas7, which 
presumably stabilised Cas5 against aggregation through Cas5-Cas7 complex 
formation. The simultaneous expression of MBP-Cas5 and Cas7 generated enough 
soluble material to successfully purify Cas5 and Cas7, (Figure 3-9). 
 
Figure 3-8.  SDS-PAGE analysis of the purification of MBP-Cas6 expressed in E.coli BL21C+. (i) After 
sonication and centrifugation soluble material (IN) was subjected to affinity chromatography (Amylose) 
and fractions were compared for Cas6 contents, flow through (FT), wash (W) and UV trace peaks during 
maltose gradient (0-30mM). (ii) Cleanest fractions containing Cas6 were pooled and subjected to a 
second affinity column (Heparin) and fractions were compared for Cas6 contents, flow through (FT), 
wash (W) and UV trace peaks during NaCl gradient (150-1500mM). (iii) Final purified MBP-Cas6 protein 
prepared for storage. 
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Figure 3-9. SDS-PAGE analysis of the purification of MBPCas5-Cas7 co-expressed in E.coli BL21C. (i) 
After sonication and centrifugation soluble material (IN) was subjected to affinity chromatography 
(Amylose) and fractions were compared for Cas5-Cas7 contents, flow through (FT), wash (W) and UV 
trace peaks during maltose gradient (0-30mM). (ii) Cleanest fractions containing Cas5-Cas7 were pooled 
and subjected to a second affinity column (Heparin) and fractions were compared for Cas5-Cas7 
contents, flow through (FT), wash (W) and UV trace peaks during NaCl gradient (150-1500mM). (iii) Final 
purified MBP-Cas5 and Cas7 proteins prepared for storage. (iv) Western blot analysis of MBPCas5 and 
Cas7 compared to His6Cas7, probed with anti-MBP and anti-Cas7 (Mth 1088) antibodies. 
3.2.3.3 Purification of Mth Cas3 protein 
Purification of Cas3 (ORF 1086) was modified from the method in Howard et al, 2011. 
Figure 3-10 follows the published method and Figure 3-11 details the outcome of the 
modified protocol. In both Cases, supernatant from lysed and clarified E.coli cells 
over-expressing Cas3 was passed through heparin to remove contaminating DNA 
interacting proteins (such as nucleases) followed by a series of hydrophobic and 
anion exchange columns (Q-sepharose, phenyl-sepharose and DEAE-sepharose). The 
optimised purification involved elongation of the Q-sepharose wash step, collection 
of smaller fractions and proceeding to the next step with only fractions containing 
Cas3 protein at optimal yield and homogeneity. 
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Figure 3-10. SDS-PAGE analysis of the purification of Cas3 expressed in E.coli BL21C+. (i) After 
sonication and centrifugation soluble material (IN) was subjected to anion exchange chromatography 
(Q-sepharose) and fractions were compared for Cas3 contents, flow through (FT), wash (W) and UV 
trace peaks during NaCl gradient (150-1500mM). (ii) Cleanest fractions containing Cas3 were pooled and 
subjected to hydrophobic interaction chromatography  (HIC) (Phenyl-sepharose)  and fractions were 
compared for Cas3 contents, flow through (FT), wash (W) and UV trace peaks during NaCl gradient 
(1500-0mM). (iii) Cleanest fractions containing Cas3 were pooled and subjected to a second anion 
exchange chromatography column (DEAE sepharose) and fractions were compared for Cas3 contents, 
flow through (FT), wash (W) and UV trace peaks during NaCl gradient (150-1500mM). Pooled fractions 
were dialysed for storage of Cas3 wild-type (iv, lane 1), H66G (iv, lane 2) and D347A (iv, lane 3). 
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Figure 3-11. SDS-PAGE analysis of the optimised purification of Cas3 expressed in E.coli BL21C+. (i) 
After sonication and centrifugation, soluble material (IN) was subjected to anion exchange 
chromatography (Q-sepharose) and fractions were compared for Cas3 contents, flow through (FT), 
extended wash (W) and UV trace peaks during NaCl gradient (150-1500mM). (ii) Cleanest fractions 
containing Cas3 were pooled and directed subjected to hydrophobic interaction chromatography  (HIC) 
(Phenyl-sepharose)  and fractions were compared for Cas3 contents, flow through (FT), wash (W) and 
UV trace peaks during NaCl gradient (1500-0mM). (iii) Cleanest fractions containing Cas3 were pooled 
and directed subjected to a second anion exchange chromatography column (DEAE sepharose) and 
fractions were compared for Cas3 contents, flow through (FT), wash (W) and UV trace peaks during NaCl 
gradient (150-1500mM). Pooled fractions were dialysed for storage of Cas3 wild-type, 1μg and overload 
(iv, lanes 1 and 2), and D347A (iv, lanes 3 and 4). 
3.2.3.3.1 Summary 
Purification of Mth Cas5, Cas6, Cas7 and Cas3 proteins allowed the analysis of 
archaeal CRISPR-Cas interference reactions in vitro. The high yield of Cas8’ protein 
obtained enabled preliminary crystal trials, but at the time of writing these trials have 
been unsuccessful. 
3.3 Biochemical analysis of Methanothermobacter 
thermautotrophicus Cascade proteins  
3.3.1 Cas5, Cas6 and Cas7 preliminary activity tests 
Cas7 (Csa2, E.coli equivalent) proteins perform helical ‘wrapping’ of crRNA forming 
the Cascade core (213). Indeed, Cas5 (CasD) atomic resolution structures revealed 
that essential contacts are made with the crRNA 5’ handle and the PAM region of the 
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invaded duplex (128). Therefore, purified Cas7 was analysed by EMSA to determine 
functional parameters for RNA and DNA binding. His6Cas7 was titrated into ssDNA, 
ssRNA and dsDNA in buffers with and without Mg2+. The presence of Mg2+ 
marginally improved the binding of Cas7 as evidenced by the detection of specific in 
gel complexes at a lower Cas7 concentration (Figure 3.12i middle lanes). However, 
this observation was not reproduced in all experiments (Figure 3-12i right hand 
lanes) indicating that the effect of Mg2+ on Cas7 interaction with ssDNA is not a 
strong one. Importantly, the salt used during Cas7 purification provedto be a critical 
determinant in crRNA binding. Specifically, only Cas purified and assayed in 
Potassium acetate (KOAc) was able to form specific in gel complexes with ssRNA 
(right hand panel, Figure 3-12ii), when compared to reactions in Sodium chloride 
(NaCl) where none were detected (left hand panel, Figure 3-12ii). The importance of 
acetate salts was also apparent in dsDNA binding. Cas7 bound dsDNA 10x more 
effectively in potassium acetate (Figure 3-12iii, right panel) with the reaction 
saturating at 10nM rather than 100nM seen with Cas7 in NaCl (Figure 3-12iii, left 
hand panel). 
Cascade complexes catalyse interference by invading crRNA into a homologous 
duplex DNA thus creating an R-loop. The stability of an interference R-loop is derived 
from RNA-DNA hybridisation over at least 30 base-pairs, the exact length depending 
on the length of a spacer sequence transcribed from a CRISPR locus. RNA-DNA 
hybridisation in the R-loop has the effect of displacing a single strand of the original 
duplex DNA, exposing it to the nuclease and ATP-dependent transloCase activity of 
Cas3. MBPCas5 and Cas7 were investigated for their ability to displace ssDNA from a 
duplex DNA with a short mismatched region. Displacement of one strand was 
observed at 100nM MBPCas5-Cas7, (Figure 3-13, bottom panel).  This was not seen 
with Cas7 in isolation (top panel) at the same concentrations. The strand 
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displacement activity required ATP (right hand lanes of bottom panel), though the 
highest concentrations of Cas5 and Cas7 actually manifested with decreased activity. 
Cas8’ was also tested for ATP dependant strand displacement activity as previously 
reported (269), but no displacement was detected (data not shown).  
 
Figure 3-12.EMSA analysis of titrating Cas7 into ssDNA, ssRNA and dsDNA substrates in different salts. 
In panel i, Cas7 was used at 0, 25, 50, 100, 200, 400, 800 and 1000nM with 5nM ssDNA in reactions 
containing 125mM NaCl and either 10mM EDTA (-Mg
2+
) or 10mM MgCl2 (+Mg
2+
). In ii, Cas7 was used at 
0, 100, 200, 400 and 800nM with 5nM of ssRNA in a reaction containing 125mM NaCl or 125mM KOAc 
and 10mM MgCl2. In iii, Cas7 was used at 0, 10, 20, 50, 100, 200, 400, 800 and 1000nM with 5nM dsDNA 
in a reaction containing 125mM NaCl or 125mM KOAc and 10mM MgCl2. In reactions containing NaCl 
the protein was purified in a buffer containing 150mM NaCl and for KOAc protein buffer contained 
500mM KOAc. Each panel shows phosphorimages of native TBE gels separating unbound substrate, in 
well aggregates (A) and specific in gel complexes (C) or each substrate end labelled with 
32
P as indicated 
by (•). These gel images are representative of assays that have been carried out in duplicate. 
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Figure 3-13. Native-PAGE separating assays of titrating Cas7 and MBPCas5-Cas7 into partial duplex 
substrates to identify strand displacement activity. In the top panel Cas7 was used at 0, 10, 20, 50, 100, 
200, 400, 600 and 800nM with 5nM partial duplex in a reaction containing 125mM KOAc, 10mM MgCl2 
and -/+ 10mM ATP. In the bottom panel MBPCas5-Cas7 was used in the same conditions but at 0, 10, 
20, 50, 100, 200 and 400nM. ‘Boil’ lanes represent zero protein samples heated to 95°C for 5 mins 
before loading. Each panel shows phosphorimages of native TBE gels separating partial duplex and 
linear ssDNA as indication with each substrate end labelled with 
32
P as indicated by (•). These gel images 
are representative of assays that have been carried out in duplicate.  
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Figure 3-14. Nuclease assays and EMSA analysis of titrating Cas6 into long pre-crRNA and short mature crRNA 
respectively.. In panel i, Cas6 was used at 0, 10, 50, 100, 200, 400 and 800nM with 5nM of pre-crRNA in reactions 
containing 125mM KoAc and either 0 MgCl2, 10 mM MgCl2 or 10mM MgCl2 and 10mM ATP. In ii, Cas6 was used at 0, 
0.25, 0.5, 1, 2, 4, 8, 16, 32, 64, 128, 254, 500, 750 and 1000nM with 5nM mature crRNA in reactions containing 
125mM KoAc and 10mM MgCl2. Panels i and iii, show phosphorimages of native TBE gels separating Cas6 nuclease 
products of pre-crRNA (i) and binding shifts of crRNA (ii), in well aggregates labelled (A). Each RNA end was labelled 
with 32P as indicated by (•).These gel images are representative of single assays.  
Cas6 family enzymes are nucleases that target pre-crRNA for maturation. Mature 
crRNA is assembled into Cascade interference complexes. In E.coli, Cas6 matures pre-
crRNA by cleavage at stem loop structures formed from the repeat sequence of 
transcribed CRISPRs. Cas6 family enzymes show variation in their catalytic 
mechanism reflecting the diversity of CRISPR systems. E.coli Cas6 (Cas6e or CasE) is 
an integral part of the Cascade complex as it processes crRNA and forms a 3’ cap. 
However, other Cas6 proteins, including those of some CRISPR type I-B systems 
process pre-crRNA into crRNA and then transfer crRNA to Cas7 and are not part of 
the Cascade complex. 
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Because of the varied activities of Cas6 proteins, purified Mth MBPCas6 was tested 
for nuclease activity on pre-crRNA and binding to mature crRNA. MBPCas6 showed 
increased nuclease activity in an Mg2+ dependent manner (Figure 3-14I, left versus 
middle lanes). On the other hand, addition of ATP decreased RNase activity (right 
hand lanes), possibly through ATP sequestering Mg2+ away from Cas6. Moreover, 
EMSAs were carried out to ascertain Cas6 binding to short synthetic RNA molecules. 
No specific in-gel shifts were observed when Cas6 was titrated into RNA, only in-well 
protein-RNA aggregates (A), (Figure 3-14ii). Therefore Mth Cas6 cleaves pre-crRNA 
into mature crRNA but does not bind to this mature product. 
3.3.2 Analysis of the oligomeric state of an archaeal Cas3 
Cas3 has 3’ to 5’ ATP dependent ssDNA translocating activity that is required for 
interference in type I CRISPR systems. The oligomeric state of DNA 
transloCases/heliCases has for some years been recognized as an important factor in 
determining their mechanism. For example, Rep-UvrD family heliCases are ATP 
dependent transloCases (271-273). HeliCases such as HerA function as hexameric 
rings while others like UvrD have reported activity as monomers or dimers (274-276). 
The E.coli NER heliCase UvrD acts as a homodimer that enables ATP hydrolysis and 
substrate specific binding. Untagged Mth Cas3 was purified and analysed to discern 
its oligomeric state using Superose-6 analytical gel filtration in various conditions.  
Additionally, ATPase defective D347A (Walker B motif mutation) Cas3 was purified 
and analysed for comparison with wild-type Cas3. Following gel filtration, plotting the 
retention volume (Vo) (x-axis of Figure 3-15i) against the molecular weight standards 
(BioRad) gave a prediction of the molecular weight of Cas3 as ~125kDa in conditions 
containing no additives (Figure 3-15ii). Peak shifts were observed following the 
addition of ssDNA (pink and orange traces). These shifts corresponded to a doubling 
in the molecular weight (from ~125kDa to ~245kDa) suggesting Cas3 either formed a 
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dimer or two separate Cas3 molecules bound ssDNA.  Interestingly, identical results 
were observed for both the wild-type protein and the D347A mutant. Additionally, 
Mth Cas3 D347A elutions were analysed by SDS-PAGE. Whereas in the Cas3 protein-
only gel the elution peak was in lane 10 only (Figure 3-16i), this peak shifted to 
include also lanes 6 and 7 when Cas3 was pre-incubated with ssDNA (EB44) (Figure 
3-16v and vii). This suggested a 1ml difference in Cas3 elution supporting the UV 
peak shift that was observed. With the addition of ATP there was no obvious 
difference in elution profiles, though Cas3 did diffuse over several fractions (Figure 
3-16ii, iv, vi and viii).  When incubated with a plasmid (pUC19, Figure 3-16iii and iv), 
some Cas3 formed unresolvable aggregates (light blue and purple traces) at 6ml 
(Figure 3-15i), while the remaining peak was more diffuse. In several gels additional 
proteins were present, where were most likely degradation products of Cas3 itself as 
they had been present both at the beginning and at the end of the experimental 
assays. 
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Figure 3-15. Analytical size exclusion chromatography profiling of Cas3. (i) 50μg of Cas3 was pre-
incubated with the indicated substrates, -/+ 5mM ATP, 2mg pUC19 and -/+ 5mM ATP, 5nM ssDNA 
(EB44) and -/+ 5mM ATP and finally, 50nM EB44 and -/+ 10mM ATP (vii and viii). Each mixtures was 
loaded in a volume of 300μl onto a Superose 6 size exclusion column and eluted over an isocratic 
gradient of 1CV (22ml) and UV traces compiled.(ii) Peaks observed for Cas3 and Cas3 plus ssDNA were 
then compared for difference in elution volume. Log (Mwt) of the standards were plotted against the 
elution peaks of Cas3 to approximate the change in kDa of the eluting protein from 125kDa to 245kDa. 
 
i 
ii 
 
 
93 
 
Figure 3-16. SDS-PAGE analysis of Cas3 D347A protein detected in analytical size exclusion 
chromatography. In each size exclusion elution 50μg of Cas3 was pre-incubated with the indicated 
substrates, -/+ 5mM ATP (i and ii), 2mg pUC19 and -/+ 5mM ATP (iii and iv), 5nM EB44 and -/+ 5mM ATP 
(v and vi) and finally), 50nM EB44 and -/+ 10mM ATP (vii and viii). Each mixture was loaded and eluted 
over an isocratic gradient of 1CV (22ml). Proteins from each fraction were then precipitated by TCA 
precipitation and analysed by SDS-PAGE. Cas3 protein alone elutes in fraction 10 (i) and becomes more 
diffuse with ATP (ii). With addition of ssDNA (EB44) a distinct second peak is observed in lane 7 (v and 
vii).  
3.4 Cloning of E.coli Cas genes and purification of the encoded 
proteins  
E.coli K-12 MG1655 contains a CRISPR Type I-E system, which has 8 Cas genes: Cas1, 
Cas2, Cas3, CasA, CasB, CasC, CasD and CasE, located adjacent to a CRISPR locus 
(CRISPR-1). E.coli Cascade is similar to archaeal Cascade (213), and has similarly 
named proteins: Cas5 (CasD), Cas7 (CasC) and Cse2 (CasA/Cas8 family) (128, 129, 
264, 277). AS in Archaea, Cas3 is not an integral part of Cascade but is recruited by 
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Cascade to degrade the targeted DNA. Cas1 and Cas2 proteins are required for 
adaptation, and are functionally linked to Cascade-Cas3 reactions by an unknown 
mechanism during ‘primed’ adaptation (126). As part of the research included in this 
thesis plasmid constructs were generated to over-express E. coli Cascade, Cas1, Cas2 
and Cas3 proteins with the aim of analysing primed adaptation in vitro and in genetic 
studies. The majority of this molecular cloning was carried out by Edward Bolt, Alex 
Hughes and Anna-Sophie Brinkmann who kindly provided plasmids labelled EB, AH 
and ASB, respectively and are summarised in Table 10. Whereas the production of 
the E. coli Cas proteins, including the study of Cas3, is reported in this chapter, the 
major results of this thesis relating to activities of E. coli Cas1 and Cas2 are presented 
in Chapter 5. 
Table 10. Summary of plasmid constructs generated and used from E.coli  genes. pSDC (Simon David 
Cass), pEB (Edward Bolt), pAH (Alex Hughes), pASB (Anna-Sophie Brinkmann). 
Plasmid 
Construct name 
Gene Plasmid Vector Affinity protein Tag 
pEB499 CasC pMal-C2x N-MBP 
pSDC3 CasD pET14-b N-His6 
pSDC4 CasE pET14-b N-His6 
pAH1 Cas3 pMal-C2x N-MBP 
pEB358 ΔC-Cas3 pMal-C2x N-MBP 
pEB505 Cas1 pET14-b N-His6 
pASB8 Cas2 pQE-HisStrep1 C-His8-Strep 
pASB11 Cas1 pET14-b N-His6 
pASB12 Cas2 pQE-HisStrep1 C-His8-Strep 
pEB488 TopoI pET14-b N-His6 
 
3.4.1 Overexpression  
For MBPCas3 and MBPCasC, previously established expression and purification 
protocols were followed (in house). Briefly, DH5α cultures expressing either 
MBPCas3 or MBPCasC were grown to OD600=0.6 and expression induced for only 
30mins at 37°C with 0.5mM IPTG, generating soluble proteins for purification. On the 
other hand, CasD and CasE were expressed in BL21C+ cells, which resulted in soluble 
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CasE but insoluble CasD (Figure 3-18). Insoluble CasD was dissolved in 6M urea for 
refolding and purification.  
Work of PhD student colleague (Sophie Brinkmann) had provided the optimised over-
expression method for E.coli Cas1 and Cas2 proteins. Cas1 was produced as a soluble 
protein with either hexa-histidine tag (His6-Cas1) in the strain IIB964 or with tandem 
C-terminal octa-histidine and StrepTactin tags (Cas1-Strep-His8) in the strain 
T7express. Expression was optimal when cells were grown at 30°C following 
induction of expression. Hexa-histidine tagged E. coli Cas2 (His6-Cas2) also expressed 
as a soluble protein in the strain T7express.  
3.4.2 Purification of E.coli Cas proteins 
3.4.2.1 Purification of E.coli Cas3 
MBP-Cas3 was expressed for 30 minutes only due to the toxic effects and undesirable 
proteolysis of Cas3 associated with expression times >1 hour. Nonetheless, this still 
yielded sufficient intact MBPCas3 for purification via AKTA FPLC. A four step 
purification was performed to enhance the purity of the final protein preparation 
(Figure 3-17). Firstly, an affinity chromatography step employing amylose Sepharose 
was used to bind the MBP-tagged protein, eluting it over a maltose gradient (0-3mM) 
(Figure 3-17i). This was followed by ion exchange chromatography employing DEAE 
sepharose (anion exchanger) and elution within a NaCl gradient (150-1500mM) 
(Figure 3-17ii), though lower molecular weight contaminants were still observed 
throughout this step. Finally, affinity chromatography using amylose sepharose was 
again employed to further remove contaminants and degradation products (Figure 
3-17iii). Indeed, it has been shown that the main contaminating protein of 
approximately 60kDa is a truncated or degraded MBPCas3 protein (as identified by 
western blot analysis with anti-MBP primary antibody) (143). 
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Figure 3-17. Purification of E.coli MBPCas3. (i) After sonication and centrifugation soluble material (IN) 
was subjected to Affinity chromatography (Amylose) and fractions were compared for Cas3 contents, 
flow through (FT), wash (W) and UV trace peaks during maltose gradient (0-30mM). (ii) Cleanest 
fractions containing Cas3 were pooled and directly subjected to a second affinity column (Heparin), flow 
through containing Cas3 was collected and then subjected to anion exchange chromatography (DEAE 
sepharose) and fractions were compared for Cas3 contents, flow through (FT) and UV trace peaks during 
NaCl gradient (150-1500mM). (iii) Cleanest fractions containing full length Cas3 were pooled and directly 
subjected to a third affinity column (Amylose) and fractions compared as before. Pooled fractions were 
dialysed for storage and 1μg and overload analysed for protein quality before storage.  
3.4.2.2 Purification of E. coli CasD and CasE proteins 
Insoluble His6-CasD was refolded after dissolution in 6M urea and subsequently 
purified by His Gravi-Trap nickel-binding chromatography (Figure 3-18I and ii). The 
methodology used was identical to the Chelating column detailed for Mth Cas1 
protein (Figure 3-3).  Soluble His6-CasE was also purified through His Gravi-Trap 
nickel-binding chromatography (Figure 3-18i).  
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Figure 3-18. SDS-PAGE analysis of E.coli CasD and CasE proteins from pilot purification by His Gravi-
Trap. In panel i, CasD and CasE pilot purifications of lysed and centrifuged soluble material loaded onto 
His Gravi-Trap (IN) and compared to flow through (FT), wash (W) and elute (E) fractions. An arrow points 
to CasE protein detected in the elute migrating at approximately 26kDa. (RMM=22293). No CasD was 
detected in the eluate. In panel ii, CasD pilot purification of soluble material (S1) and re-solubilised pellet 
material in 6M urea (S3) loaded onto His Gravi-Trap (IN) and compared to flow through (FT), wash (W) 
and elute (E) fractions. An arrow points to CasD protein detected in the elution of the S3 fraction 
migrating at approximately 30kDa (RMM=25209). 
 
3.4.2.3 Purification of E. coli Cas1 and Cas2 proteins 
Cas1 and Cas2 purified proteins were generously provided by Anna-Sophie 
Brinkmann for further study. 
3.4.2.3.1 Summary 
Successful purification of E. coli Cascade, Cas1 and Cas2 allowed further analysis of E. 
coli CRISPR immunity in vitro, with emphasis on studies of Cas1-Cas2 presented in 
Chapter 5. Cas3 was briefly analysed as described below in cooperation with a fellow 
PhD student (Jamieson Howard). 
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3.5 In vitro pull down interactions of E.coli Cas3 and DNA 
Topoisomerase I 
A bacterial-2-hybrid screen of E.coli Cas3, carried out by Jamieson Howard (as 
detailed in his thesis: (278), identified DNA Topoisomerase I (TopoI) as a candidate 
Cas3 interacting partner. DNA Topoisomerase I alters the topomeric (number of coils) 
or supercoiled DNA by cleaving a single strand hence relaxing the super-coil. This is 
important during DNA replication and transcription where the unwinding of DNA by 
heliCases at the replication fork causes the DNA ahead of it to become over coiled 
Removal of this coiling is essential as otherwise a build-up of torsional tension would 
eventually halt DNA and RNA polymerase action. TopoI interaction with Cas3 was 
tested with in vitro analytical size exclusion chromatography though no robust data 
was generated. Therefore, an alternative strategy where the affinity tags of each 
protein were exploited was employed. MBPCas3 immobilised on amylose resin was 
mixed with His6TopoI. His6TopoI co-eluted with MBPCas3 in stoichiometric amounts 
when MBPCas3 was stripped from the amylose resin (Figure 3-19ii, lane E). Although 
some His6TopoI was present in the wash (W) fraction (lane W); including in controls 
where His6TopoI was mixed with the MBP tag only, His6TopoI was absent from the 
elution (E) lanes in these controls. Therefore, it could be concluded that MBPCas3 
formed a stable binding contact between the amylose resin and His6TopoI. In the 
previous bacterial-2-hybrid data (278), An additional mutant Cas3 protein (ΔC-Cas3) 
was employed in the aforementioned bacterial-2-hybrid screen (278). ΔC-Cas3 is an 
E.coli Cas3 gene that is truncated by approximately 500 bp at the C-terminus, so the 
protein lacked the at the time mysterious C-terminal domain. Interestingly, this Cas3 
mutant no longer showed an interaction with TopoI in the screen. Similarly, this 
thesis corroborated that ΔC-MBPCas3 ΔC-MBPCas3 did not support this interaction 
as TopoI was only detected in flow-through and wash fractions (Figure 3-19iv, FT and 
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W). Reciprocal binding experiments proved unreliable as MBPCas3 bound 
significantly to nickel resin also in the absence of His6TopoI. 
 
Figure 3-19. Pull down interaction assays between MBPCas3, His6TopoI and ΔC-MBPCas3. (i) MBPCas3 
and ΔC-MBPCas3 were purified by affinity chromatography as summarised in the section: Purification of 
E.coli Cas3, His6TopoI was purified the same way as Mth His6Cas7. Approximately 1μg of each protein is 
shown for reference. (ii) 100μg of MBPCas3 and His6TopoI were premixed at room temperature for 
30mins with equilibrated amylose resin. Slurry mix was added to a disposable self-pour gravity column. 
Fractions were collected of flow-through (FT), wash (W) with amylose column binding buffer and eluted 
(E) with 3mM maltose. (iii) Control pull down assays using 100μg of His6TopoI or His6TopoI and MBP 
(maltose binding protein) and fractions collected. (iv) 100μg of ΔC-MBPCas3 and His6TopoI were 
premixed as before and fractions collected. Samples of each fraction were analysed by SDS-PAGE and 
stained with Coomassie Brilliant Blue.  
3.6 Discussion 
This chapter focused on the molecular cloning, expression, purification and 
preliminary characterisation of Cas proteins from Mth and E.coli. Of particular 
interest are the CRISPR Type I interference and adaptation proteins from both 
organisms. Similar methods were utilised for the optimisation of over-expression of 
both Mth and E.coli proteins, this included temperature and duration of expressions. 
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Once soluble protein was detected affinity purification was carried out to generate 
pure recombinant proteins for in vitro analysis.  
Expression and purification of Mth proteins in E.coli came with several caveats: 
insolubility of various archaeal proteins was the most difficult to overcome. Cas5 and 
Cas6 proteins precipitated and were insoluble except in high urea concentrations. 
Generation of MBP fusion constructs and co-expression of MBP-Cas5 with Cas7 
alleviated the solubility problems (Figure 3-9). Recombinant proteins of the archaeal 
Type I-H Cascade complex were now available for in vitro reconstitution and analysis 
(Figure 3-6, Figure 3-7, Figure 3-8 and Figure 3-9). Recombinant Mth Cas8’, Cas5 and 
Cas7 are further studied in Chapter 4. E.coli Cas1 and Cas2 are investigated in 
Chapter 5. 
3.6.1 Mth Cas5, Cas6 and Cas7 initial biochemical tests 
The CRISPR-Cas mechanism requires Cas6 to process pre-crRNA into mature crRNA 
either as part of the Cascade complex in E.coli or as a separate processing unit in Sso. 
Mth Cas6 is a metal dependent endonuclease like other Cas6 proteins (153, 154, 199-
201), generating distinct nuclease products. In this study Mth Cas6 does not interact 
with processed crRNA but does cleave pre-crRNA (Figure 3-14). Therefore the role of 
Cas6 may be to cleave and then transfer crRNA to the Mth archaeal Cascade 
complex.  
Archaeal Cas5 and Cas7 proteins, having been investigated in Sso, are known to form 
ribonucleoprotein filaments (213). Cas5 acts as the anchor for Cas7 helical extension 
along the RNA molecule. Whereas Cas5 is important in the seeding of R-loop 
formation, Cas7 forms the structural core of the Cascade complex (139, 159, 279). 
This study found that Cas7 binds to ssDNA, ssRNA and dsDNA (Figure 3-12I, ii, iii). 
Importantly, the choice of the salt component in buffers was found to have 
 
 
101 
significant impact on in vitro biochemical assays of the different Cas proteins. 
Potassium acetate (KOAc) is the physiological salt for Mth proteins. There was 
substantial 10 x increase in binding affinity to dsDNA between the proteins purified 
and assayed in KOAc, versus NaCl (Figure 3-12iii). It has been reported previously that 
Cas8’ (Nar71) has strand displacement activity (269). This activity was detected in 
NaCl, in the assays presented here KOAc was used where no displacement activity 
was detected by Cas8’. This chapter did show that MBPCas5 in association with Cas7 
carried out strand displacement, known to be essential for R-loop formation in the 
presence of both Mg2+ and ATP (Figure 3-13). (162, 226). The ATP dependence 
observed in these assays was consistent with the same requirements seen with other 
stand invading proteins such as RecA. The lack of strand displacement activity in 
Cas8’ is in line with the recent identification of CasA’s (analogous to Cas8’) role in 
CRISPR interference which suggests that Cas8’ identifies PAM and stimulates Cas3 
degradation of ssDNA. Therefore, Cas8’, together with Cas5 and Cas7, which have 
demonstrable strand displacement activity, act in unison to seed strand displacement 
and stabilise R-loop formation  
3.6.2 Cas3 oligomeric state and interaction partners 
CRISPR Type I systems recruit the heliCase/nuclease Cas3 to the Cascade complexes 
after stable R-loop formation. In E.coli CasA identifies the PAM sequence and 
stimulates Cas3 mediated degradation of the invading genetic element (162, 163). 
However, from the available co-crystal structure of the C-terminal domain of Cas3 
with Cascade only limited mechanistic conclusions can be drawn because only part of 
the Cas3 protein is present. Therefore, the present study employed size exclusion 
chromatography to analyse the mode of Cas3 binding to DNA molecules. Both Wild 
type and D347A proteins elute at approximately double the molecular weight of Cas3 
with DNA present. Two possibilities explain this observation; two Cas3 monomers are 
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binding independently to the short DNA molecule, or like other heliCase/nucleases 
two Cas3 proteins surround the DNA molecule in a ring-like conformation facilitating 
translocation.  
The interference proteins of CRISPR immunity are expressed upon infection (146, 
169). When this infection is novel to the cell, disruption of invading DNA metabolism 
or viral lytic pathways allows acquisition of a novel spacer for targeted degradation. It 
has been postulated that Cas proteins are involved in this ‘facilitation’ stage of 
CRISPR immunity (266). This idea combines is further supported by previous work in 
our laboratory which showed the Cas3 and DNA topoisomerase I interaction through 
Bacteria-2-Hybrid and the positive effect of Cas3 on TopoI activity in converting 
supercoiled plasmid to relaxed (unpublished work carried out by Jamieson Howard). 
In the context of viral infections, this would be significant in restricting invader 
replication as phage O and P proteins require negatively supercoiled DNA for binding 
and replication initiation (97-99). Indeed, this study confirmed Cas3 could interact 
with TopoI both in vivo and in vitro. Moreover, the aforementioned Bacteria-2-Hybrid 
screen revealed a C-terminal region truncated Cas3 mutant (ΔC-Cas3) could no longer 
support this interaction. Indeed, the results from this chapter showed ΔC-Cas3 did 
not interact with TopoI and predictably did not stimulate the relaxation activity of 
TopoI. Therefore, it is the C-terminal region of Cas3 which mediates Cas3-TppoI 
interaction. The C-terminal region of Cas3 is possibly the location for several protein-
protein interactions, supporting multiple interactions with host factors and other Cas 
proteins (CasA) important for CRISPR immunity, host processes or selfish protection 
of the CRISPR MGE (162, 265).  
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4 Biochemical analysis of archaeal Cas8 in CRISPR 
interference 
4.1 Summary  
The work presented in this chapter forms the core of a research paper on the role of 
Methanothermobacter thermautotrophicus Cas8’ protein in CRISPR interference, 
which can be found attached at the end of this thesis (144). The work presented in 
section 4.2.5.4 and Figure 4-23 (panel ii) was performed and analysed by Karina Haas 
and Britta Stoll from the collaborating Dr. Anita Marchfelder’s research group at the 
University of Ulm, Germany. 
4.1.1 Cas8’ – Current understanding of the signature gene of the 
Methanothermobacter thermautotrophicus Type I-H CRISPR-Cas 
immune system 
Cas8 is essential for CRISPR interference in Haloferax volcanii, a discovery made 
when sequencing CRISPR-Cas loci from Hvo clones that had lost CRISPR interference 
(280, 281).  Sequencing of CRISPR-Cas regions of these clones identified that either 
mutations in Cas3 or Cas8 genes, chromosomal deletions or reshuffling, in each Case 
abolished interference. This provided insight for the importance of Cas8 proteins for 
achieving effective CRISPR immunity.  Mth ORF 1090 had been previously 
investigated in the Bolt laboratory following its identification in biochemical screens 
for novel DNA heliCases in archaea (269). The protein product of ORF 1090 was 
named Nar71, later defined as the CRISPR protein Cas8b, and now called Cas8’. In 
preliminary experiments in our laboratory, Cas8’ was found to be a weak nuclease on 
DNA flayed duplex and 3’flap structures. Additionally, Cas8’ displayed ATP-dependent 
strand displacement activity, that was abolished when poorly hydrolysable ATPγS 
was used. However, Cas8’ nuclease activity on RNA substrates had not been 
assayed(269). 
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4.1.2 Aims 
The aim of this part of the project was to corroborate in vivo data stemming from 
research of our collaborators at the University of Ulm, identifying the importance of 
Hvo Cas8 in interference with in vitro biochemical  characterisation of the Mth Cas8’ 
protein . To achieve this, Cas8 was characterised through mutational analysis to 
determine its significance/ role in the CRISPR interference in Mth and Hvo archaeal 
Cascades.  
4.2 Results  
4.2.1 Substrate structure specificity of Cas8’ 
Previous analysis of Cas8’ nucleic acid processing activity had been limited to 
branched DNA molecules given these were the substrates employed in the screening 
procedure to identify novel proteins (269). The importance of Cas8’ in CRISPR 
interference, identified by genetic analysis by our collaborators, led us to re-examine 
the nucleic acid binding and nuclease activities of purified Cas8’ using RNA and other 
DNA substrates. To this end, EMSAs titrating Cas8’ into various substrates, ranging 
from simple single stranded to complex duplex or triplex molecules, were performed 
in triplicate. Representative gels of EMSAs with each substrate and the corresponding 
quantitative analyses can be seen in Figure 4-1. A summary in Table 11 shows the 
dissociation constants (KD values) attained from these assays using 
Y = Bmax*X/(Kd + X), where Bmax is the substrate concentration at which highest 
binding efficiency is observed. These assays revealed Cas8’ interacted very weakly 
with ssDNA, ssRNA and flayed duplex (Figure 4-2,panels i, ii and iv, respectively), 
which precluded the determination of a valid KD in these instances.. However, for the 
purpose of completion, aproximate KDs which were in the range of 269-400nM, have 
been included in Table 11 to allow comparison with the KD values of other substrates. 
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On the other hand, Cas8’ bound with substantially higher affinity to simple duplex 
and flapped structures. Indeed, KD values between 20-50 nM were obtained for 
duplex, partial duplex and various flapped RNA and DNA substrates (Figure 4-2, panel 
iii, v and xiii, ix and respectively). Interestingly, Cas8’ bound more complex structures 
with even higher affinity, as shown by the KDs between 4 and 10 nM. Moreover, the 
pattern of binding to both D-loop and R-loop also differed from the other substrates 
(Figure, panels vii and viii). Specific distinct in-gel complexes were apparent with 
these triplex substrates indicating stable binding, whereas other simpler substrates 
only gave in-well aggregates, typical of non-specific protein-DNA interactions. 
Table 11. Summary of Cas8’ binding affinities to nucleic acid substrates quantified from EMSAs. KD 
values were calculated from quantification of triplicate assays. 
Substrate KD 
ssDNA 300 ± 6.3nM 
ssRNA >400nM 
Linear duplex 20.4 ± 4.4nM 
Flayed duplex 269 ± 6.7nM 
3’DNA/DNA flap 19.8 ± 0.9nM 
3’RNA/RNA flap 46.8 ± 2.8nM 
3’RNA/DNA flap 49.5 ± 3.4nM 
Open loop 20.7 ± 2.2nM 
D-loop 9.0 ± 2.2nM 
R-loop 4.7 ± 0.35nM 
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Figure 4-1. EMSAs of Cas8’ titrated into various generic nucleic acid substrates. Cas8’ was titrated at 0, 
1.56, 3.125, 6.25, 12.5, 25.0, 50.0, 100, 150, 200, 250, 300, 350, 400, 450, 500 600nM to 5nM substrate 
in reactions containing 10mM EDTA. Representative phosphorimages of native TBE gels and resulting 
quantified binding isotherm plots, displaying percentage substrate bound against Cas8’ concentration,  
are shown. Cas8’ formed distinct complexes with Open loop (v), D-loop (vi) and R-loop (vii), compared to 
the remaining DNA substrates with which it only formed aggregates (i-iv). Binding affinities for each 
substrate were calculated from three independent EMSAs plotted on a single graph with standard error. 
In panels viii, ix and x, Cas8’ was used at 0, 1.56, 3.125, 6.25, 12.5, 25.0, 50.0, 100, 200, 400 and 800nM 
in reactions containing 10mM EDTA with 5nM substrate which was either (viii) DNA-DNA flap,(ix) RNA-
DNA hybrid flap and (x) RNA-RNA flap. The calculates KD values are summarised in Table 1 . In each Case 
the 
32
P labelled strand is marked by • or *. 
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4.2.1.1 Summary 
Mth Cas8’ bound branched DNA and RNA substrates with highest affinity. Lowest KDs 
were observed for D- and R-loops, which are structures similar to those involved in 
CRISPR interference. Interestingly, Cas8’ binding preference was to substrates 
containing RNA specifically in duplex for rather than ssRNA only. 
4.2.2 PAM sensitivity of Cas8’ 
Archaeal Cas8’ has been predicted to be able to recognize invader DNA, analogously 
to Cse1 (CasA) in E. coli Cascade. When the invader DNA sequence is complementary 
to a crRNA molecule an R-loop is formed in association with a Cascade complex. 
Therefore, this hypothesis was to be tested by assaying the binding of Mth Cas8’ to 
R-loop substrates with different PAM sequences. To this end, candidate Mth PAMs 
for incorporation into these R-loop substrates were selected via bioinformatics 
analysis of the 123 spacers found in the Mth genome. First, the online database, 
CRISPRfinder, containing all sequenced prokaryotic genomes and all CRISPR-like 
repeat regions with associated genes, was used to identify said spacer sequences 
from Mth. Next, each spacer was compared to all known nucleotide sequences by 
BLAST analysis. Perfect and near perfect sequence alignments of spacers with known 
nucleic acid sequences were used to determine the source of the spacer and 
therefore the DNA sequence flanking it, from this flanking sequence PAM sequences 
were identified.  A full list of the perfect matches with their associated sequences is 
given in Therefore the sequence 5’-CCC-3’ was selected as the PAM to be 
incorporated into R-loop substrates and conversely, incorporation of the sequence 
5’-AAA-3’ would denote substrates lacking PAM. The intermediate PAM sequences  
5’-CTC-3’ and 5’-TTG-3 were also generated.  
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Table 12, whereas spacers which had 1– 9 mismatches are listed in the appendix. 
Interestingly, even though the BLAST searches performed were against the whole 
nucleotide library, all perfectly matched sequences were originating from phage or 
prophage sequences. Finally, collating the information from seven identical and 104 
mismatched (1-9 mismatched bp) hits from 123 spacers gave a predicted PAM of 5’-
CCN (Figure 4-2).  
 
Figure 4-2. Bioinformatics analysis of Methanothermobacter thermautotrophicus (Mth) CRISPR-Cas 
PAM sequence from genealogical context. Plasmid/phage sequence matching the spacers with up to 9 
mismatches allowed identification of a putative PAM for Mth (5’CCN) which was found to be in 
agreement with a previous study. 
Therefore the sequence 5’-CCC-3’ was selected as the PAM to be incorporated into R-
loop substrates and conversely, incorporation of the sequence 5’-AAA-3’ would 
denote substrates lacking PAM. The intermediate PAM sequences  5’-CTC-3’ and 5’-
TTG-3 were also generated.  
Table 12. Spacers that perfectly matched known nucleotide sequences by nBlast of 
Methanothermobacter thermautotrophicus CRISPR-1 sequences. Genomic context was identified and 
putative PAM sequences shown 5’ – 3’. 
Spacer 
No 
Sequence nBlast match PAM 
6 AAGCGCCGGGCAGACAGCACACAT
ACAAGACTTCACAA 
Methanothermobacter 
 wolfeii prophage psiM100 
CCC 
8 TGATGTTGGGAAGGTTTGGCCATC
TGAATGATTTGA 
Methanothermobacter  
wolfeii prophage psiM100 
GTA 
17 TATCATCACGCTTGAAGAGTATAAT
AAAGTTGTTAAGA 
Methanothermobacter  
wolfeii prophage psiM100 
GTA 
22 AGTATGTGCAGTATCCTCTCTATGT
CCCCTTCATTC 
Methanobacterium phage 
 psiM2 
CCT 
24 AATATTGAAACGTTCAAGGACATG
TTGAAGAGGTATG 
Methanobacterium phage 
 psiM2 
CCT 
28 AGTATGTGCAGTATCCTCTCTATGT
CCCCTTCATTC 
Methanobacterium phage  
psiM2 
CCT 
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74 CGGGGAGAGTCTGACATTCTTGAA
GTAGAACCTCCCC 
Methanothermobacter 
 wolfeii prophage psiM100 
CCC 
 
 
 
 
 
 
Figure 4-3. Quantified EMSA data of Cas8’ titrated into various substrates with or without PAM. Cas8’ 
was used at 0, 1.56, 3.125, 6.25, 12.5, 25.0, 50.0, 100, 120, 200, 250, 300, 350, 400, 450, 500 and 600nM 
with 5nM substrate (i and iv = R-loop, ii and v = linear duplex and iii and vi = open loop) in reactions 
containing 125mM KOAc and 10mM EDTA. Graphs were plotted as percentage of substrate shifted 
compared to 0 protein control (as quantified by 2D densitometry) against up to 200nM concentration of 
Cas8’. Standard error (error bars) and KD were calculated from duplicate gel quantifications.  
Of note, only structures physiologically relevant to CRISPR inference intermediates 
such as dsDNA, open duplex and R-loops were synthesised. Subsequently, PAM-
sequence specific binding by wild-type Cas8’ protein could be tested by EMSA 
analysis. The KD values of binding to the said substrates with and without selected 
PAM were determined (Figure 4-3). The simplest substrate, duplex DNA, manifested 
with a twofold decrease in KD values, going  from KD of 18.3 ± 0.9nM without PAM 
(Figure 4-4, panel v) to KD of 9.1 ± 1.2nM with PAM (Figure 4-4, panel ii). Similarly, 
Cas8’ binding of open loops showed a preference for sequences including PAM 
 R-loop                        Linear Duplex                     Open Loop 
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(Figure 4-4, panel iii) over those lacking PAM (Figure 4-4, panel vi) with the 
corresponding KD values of 13.9 ± 0.2nM and 18.3 ± 0.8nM, respectively. However, 
the most profound difference was observed for Synthetic R-loops with PAM which 
displayed an 8-fold increase in binding affinity to Cas8’ compared to R-loops without 
PAM, KD of 5.3 ± 0.6nM (panel i) versus KD of  40.7 ±1nM (panel iv), respectively. Next, 
intermediate PAM sequences were used to detect subtle differences in binding of 
Cas8’ to R-loops (Figure 4-4). The R-loop with the PAM sequence 5’-TTG-3’ (Figure 4-
5, panel iii) showed a higher KD of 9.8 ± 0.4nM, which was relatively close to that 
obtained for  the main  PAM (CCC) substrate (KD of 4.9 ± 0.6nM, Figure 4-3 panel i). 
On the other hand, for the R-loop with the 5’-CTC-3 sequence’, a  KD of 29.7 ± 1.0nM 
was calculated which corresponded to a binding affinity intermediate between  the 
R-loops with (CCC) and without (AAA) PAMs (Figure 4-5, panel iv).   
The effect of PAM on Cas8’ binding affinity was also tested on a physiological 
invading substrate, a plasmid, where an R-loop forms in CRISPR interference. 
Therefore, pUC19 derivatives containing a spacer (that would facilitate the synthetic 
crRNA annealing) and with or without PAM were created. Cas8’ was tested for 
differences in binding affinity to the different plasmids. However, similar affinities 
were detected between these plasmid substrates (data not shown). 
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Figure 4-4 Binding isotherms from quantified EMSA assays with Cas8’ titrated into alternate PAM 
substrates. Cas8’ was used at 0, 1.56, 3.125, 6.25, 12.5, 25.0, 50.0, 100, 120, 200, 250, 300, 350, 400, 
450, 500 and 600nM with 5nM substrate (I and ii = open loop, iii and iv = R-loop) in reactions containing 
125mM KOAc and 10mM EDTA. Graphs were plotted as percentage of substrate shifted compared to 0 
protein control against up to 200nM Cas8’ concentration. Standard error (error bars) and KD were 
calculated from triplicate gel quantification.  
 
 
4.2.2.1.1 Summary 
Recombinant Mth Cas8’ assayed in vitro, responded to the presence of a PAM 
sequence via altered binding affinity to all substrates tested, though with varying 
degree. Indeed, this effect on Cas8’ affinity was particularly important with branched 
substrates such as the open duplex and R-loops. However, the most notable effect of 
the PAM sequence was observed in Cas8’ binding to the R-loop substrates. Finally, it 
could be ascertained that different PAM sequences also affected the binding 
properties of Cas8’ and are discussed later in greater detail. 
4.2.3 Nuclease activity of Cas8’ 
For the biochemical analysis of Cas8’ enzymatic mechanisms were investigated. 
These included but were not limited to ligase, primer extension, strand displacement 
and nuclease activities. Cas8’ had been previously shown to cleave DNA flaps in a  
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Magnesium-dependent manner (269). Therefore, this was the starting point of the 
enzymatic characterisation of Cas8’. 
4.2.3.1 Optimisation of nuclease reactions in vitro 
In agreement with a previously published study, Cas8’ nuclease activity was observed 
on the 3’ DNA flap region of a flayed duplex substrate, this activity was dependent on 
the presence of magnesium also, (Figure 4-5, panels i and ii). Interestingly, when the 
substrate was labelled on the RNA strand hybridised to a DNA strand the nuclease 
activity was enhanced, again in a magnesium dependent manner (Figure 4-5, panel iii 
and iv). 
 
Figure 4-5. Nuclease assays titrating Cas8' into RNA flap substrates, testing metal dependency of the 
nuclease activity. In panels i and iii Cas8’ was used at 0, 50, 100, 200, 400, 600, 800 and 1000nM with 
5nM of substrate. In panels ii and iv reactions additionally contained 10 mM MgCl2. Each reaction was 
incubated at 45°C for 30 mins. All panels show phosphorimages of denaturing urea gels separating Cas8’ 
nuclease products of the 3’RNA flap substrate. DNA was end labelled with 
32
P as indicated by (•) in 
panels i and ii, RNA was labelled in panels iii and iv. 
Cas8’ nuclease activity was compared using ssDNA, ssRNA and linear duplexes. ssRNA 
nuclease activity of Cas8’ peaked at 600nM whereby all the primary substrate was 
degraded (Figure 4-6, panel ii), whereas ssDNA was poorly degraded even at the 
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highest concentrations used (Figure 4-6, panel i). No similar nuclease activity was 
observed on linear duplex or plasmid DNA (both single stranded [panel v] and duplex 
plasmid [panel iv]). Plasmid duplex DNA shifted from relaxed (R) to super coiled (SC), 
indicating Cas8’ may act as a ligase converting nicked relaxed plasmid into SC. Duplex 
DNA also decreased in a Cas8’ -dependent manner (panel iii), which was indicative of 
degradation occurring at the labelled end of the substrate. In time-course analysis, 
nucleolytic activity of Cas8’ was strongest on RNA substrate (Figure 4-7, panel ii) over 
the DNA 3’ flapped substrate (Figure 4-7, panel i).   
As Mth is a moderate thermophile with an intracellular acetate concentration of 
approximately 700mM, an essential precursor for methanogenesis, the impact of 
varying salt and temperature in the nuclease reaction conditions on Cas8’ nuclease 
activity was investigated. Initially, Cas8’ was purified and dialysed into a buffer 
containing 150mM sodium chloride. Nuclease assays were performed on 3’ flapped 
RNA and DNA substrates in 125mM potassium acetate. The result was reduction of 
Cas8’ nuclease activity, comparing lane 7 of Figure 4-7, panels i and ii with lane 3 or 
Figure 4-8, panels i and iii. Nuclease cleavage assays were then carried out on 
proteins both purified and assays in potassium acetate at 65°C, RNA flapped 
substrate nuclease activity was enhanced while DNA activity remained inhibited 
(Figure 4-8, panels ii and iv). 50nM Cas8’ completely degraded the 3’RNA flap initial 
substrate whereas DNA nuclease activity was still <50% at 1000nM. 
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Figure 4-6. Nuclease assays titrating Cas8’ into RNA and DNA substrates. In panels i-iv Cas8’ was used 
at 0, 50, 100, 200, 400, 600, 800 and 1000nM with 5nM of DNA in reactions containing 10 mM MgCl2. In 
panel v, Cas8’ was used at 10, 100, 1000nM. Panels i, ii, and iii show phosphorimages of urea gels 
separating Cas8’ nuclease products of, respectively, ssDNA, ssRNA and duplex DNA, each end labelled 
with 
32
P as indicated by (•). Panels iv and v are images of ethidium bromide stained agarose gels to 
separate products of Cas8’ activity on duplex or ssDNA plasmid. 
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Figure 4-7. Nuclease time course assay of Cas8’ on 3’ flapped DNA and RNA substrates. Cas8’ was used 
at 100nM in reactions containing 10mM MgCl2 on 5nM 3’DNA (i) and RNA (ii) flapped substrates. 
Reactions were incubated at 44.8°C and time points were evaluated at 0, 30, 60, 90, 150, 300, 600, 1200 
and 1800 seconds. Panels show phosphorimages of urea gels separating Cas8’ nuclease products of 
ssDNA and ssRNA respectively.  Each substrate was labelled with 
32
P as indicated (•). 
 
 
Figure 4-8. Nuclease assays of Cas8’activity in varied salt and temperature reaction conditions. Newly 
purified Cas8’ protein that was stored in 500mM KOAc and tested for nuclease activity on 3’ DNA and 
RNA flapped substrates at two temperatures: 44.8° and 65°C. In panels i-iv Cas8’ was used at 0, 50, 100, 
200, 400, 600, 800 and 1000nM with 5nM of DNA in reactions containing 10 mM MgCl2 and 125mM 
KOAc. Phosphorimages of urea gels separating Cas8’ nuclease products of 3’DNA flap (I and ii) and 
3’RNA flap (iii and iv) are show. Each substrate was end labelled with 
32
P as indicated by (•). 
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Figure 4-9. Head-to-head assays titrating Cas8’ into labelled ssRNA and ssDNA or vice-versa. In panels I 
and ii, Cas8’ was used at 0, 50, 100, 200, 400, 600, 800 and 1000nM with 5nM each of labelled and 
unlabelled substrate in reactions containing 10 mM MgCl2 and 125mM KOAc. Panels i and ii show 
phosphorimages of urea gels separating Cas8’ nuclease products of ssDNA (crDNA1) and ssRNA 
(crRNA1), respectively. The substrate end was labelled with 
32
P as indicated by (•). Comparisons of 
cleavage activity of labelled ssRNA with non-labelled ssDNA (iii) and vice versa (iv). (v) Final comparison 
showing that ssRNA was degraded with ssDNA but cleavage of ssDNA was inhibited when ssRNA was 
present. 
It seemed significant that despite the varying assay conditions used to test Cas8’ 
nuclease activity, RNase function was in each Case the affinity and nuclease activity 
were higher for RNA than DNA. To test the relative activities of Cas8’ on RNA (crRN1) 
and DNA (crDNA1) a head-to-head competition assay was used incubating, 
radiolabelled ssRNA (Figure 4-9, panels I and iii) with equimolar amounts of identical 
unlabelled DNA substrate, and vice versa (Figure 4-9, panels ii and iv). In these assays 
there were similar levels of RNA degradation, but when the DNA was labelled, the 
nuclease activity was lower, indicating that Cas8’ preferentially binds and processes 
RNA (Figure 4-9, panel v). 
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4.2.3.2 Substrate specificity of Cas8’-mediated nucleolytic cleavage 
In EMSAs, Cas8’ was found to bind to 3’flapped structures of all RNA and DNA 
variations (Figure 4-1, panels viii, ix and x). Therefore, its nuclease activity was tested 
to identify a structural preference, if any, for cleaving specific substrates. Indeed, 
there were distinct differences in Cas8’ nuclease activity when it was titrated into 
various flapped substrates. Cas8’ showed ~5% cleavage activity on 5’ and 3’DNA flaps 
at 1000nM (Figure 4-10, panels i and iii), and no activity on 3’RNA/RNA flaps at any of 
the concentrations tested (Figure 4-10, panel iv). However, there was 100% cleavage 
of the initial 3’RNA flaps already at 50nM Cas8’ (Figure 4-10, panel ii). Importantly, 
Cas8’ generated discrete cleavage products with both DNA and RNA substrates in 
these reactions. For DNA three and RNA four distinct cleavage products are seen. In 
previous published work on Cas8’, DNA endonuclease activity was lost with the 
addition of ATP. Therefore, the nuclease activity of Cas8’ on RNA flaps was also 
tested in the presence of ATP.  The addition of ATP enhanced endonucleolytic 
processing of the RNA to the final degraded product, even at low (50nM) 
concentrations only one product is observed (Figure 4-11). Whereas, in previous 
assays without ATP this only occurred at 800 or 1000nM concentrations of Cas8’ 
(Figure 4-10 panel ii). 
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Figure 4-10. Nuclease assays titrating Cas8’ into various flapped substrates. In panel’s i-iv Cas8’ was 
used at 0, 50, 100, 200, 400, 800 and 1000nM with 5nM of DNA in reactions containing 10 mM MgCl2 
and 125mM KoAc. Panels i-iv show phosphorimages of urea gels separating Cas8’ nuclease products of 
5’DNA flap (i), 3’RNA flap (ii), 3’DNA flap (iii) and 3’RNA/RNA flap (iv), respectively, each end labelled 
with 
32
P as indicated by (•) 
 
Figure 4-11. Nuclease assay comparison of Cas8’ activity + or -ATP. Cas8’ was used at 0, 50, 100, 200, 
400, 600, 800 and 1000nM with 5nM of DNA in reactions containing 10 mM MgCl2, 10mM ATP and 
125mM KOAc, showing a phosphorimage of a urea gel separating Cas8’ nuclease products of 3’RNA flap, 
end labelled with 
32
P as indicated by (•). Comparison of quantified overall cleavage from initial 3’RNA 
substrate +/- ATP, using data from Figure 4-10 with standard error. 
4.2.3.2.1 Summary 
The in vitro analysis of Cas8 nuclease activity suggested a role in processing of single 
stranded RNA (Figure 4-6, panel ii and Figure 4-10, panel ii). Moreover, assessment of 
different reaction conditions revealed acetate salts and a temperature of 65oC 
(Figure 4-8, panels ii and iv) stimulated Cas8’ activity, in line with expected 
physiological conditions of Mth. 
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4.2.4 ATPase activity of Cas8’ 
ATPase assays were carried out using the Malachite Green colorimetric analysis 
method, detecting phosphate group liberation from ATP (282). Cas8’ was titrated 
into the reaction mixture and hydrolysed ATP was quantified against a standard 
curve of known phosphate concentrations. ATPase activity was detected in a Cas8’ 
concentration dependant manner, Figure 4-12i. A time course analysis of Cas8’ 
ATPase activity was carried out with a low concentration of Cas8’, as the reaction 
would not saturate. 50nM of Cas8’ was used to understand the kinetics of Cas8’ ATP 
hydrolysis, (Figure 4-12ii). This time course analysis showed that ATPase assays have 
many variables that make time course analysis difficult. Therefore, end point assays 
were carried out to compare different assay conditions with Cas8’. The relative 
ATPase activity of Cas8’ was compared with the addition of 5nM ssDNA or ssRNA. 
ATPase activity was enhanced in the presence of ssDNA but not ssRNA, (Figure 
4-12iii). 
 
Figure 4-12. ATPase assays of wild-type Cas8’ activity with or without ssDNA or ssRNA. Cas8’ ATPase 
activity was analysed by Malachite Green colorimetric Assay (282). (i) A concentration titration was 
initially carried out containing 0, 5, 10, 20, 40, 80, 160, 320 and 640nM Cas8’. Reactions were 
terminated by the addition of Malachite Green solution after 10 minutes and OD measured at 595nm. 
(ii) A single concentration of Cas8’ (50nM) was used in a time course analysis over 45 minutes. Time 
points were taken at 0, 30, 60, 150, 300, 600, 900, 1200, 1500 and 2400 seconds. All assay points show a 
mean value from duplicate assays with standard error. (iii) Cas8’ ATPase hydrolysis when in the presence 
of 5nM ssDNA or ssRNA. Each reaction was incubated for 1500 seconds with 50nM Cas8’. Assays were 
carried out in duplicate and calculated as an activity relative to Cas8’ wild-type protein without 
oligonucleotide.  
4.2.5 Targeted mutagenesis of Cas8’ to investigate its catalytic activity 
RNA nuclease activity of Mth Cas8’ was investigated in more detail by generating 
Cas8’ mutations that we predicted may abrogate catalytic function in vitro. At this 
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stage, work from the Marchfelder laboratory had demonstrated by genetics analysis 
that Hvo Cas8 was essential for CRISPR interference (280). A collaboration was set up 
between Dr. Edward Bolt, Dr. Anita Marchfelder, Karina Kaas and Simon Cass to 
assess the roles of Cas8 in more detail, including introduction of conserved amino 
acid residue mutations in Mth and Hvo Cas8 and analysis of the effect of said 
mutations. 
 
Figure 4-13. Clustal X alignment of amino acid sequences of Haloferax volcanii (Hvo) Cas8 and 
Methanothermobacter thermautotrophicus (Mth) Cas8’. Amino acids highlighted to the right of the 
alignment were conserved in both sequences and were subject to genetic analysis in Haloferax and 
those underlined in bold were studied both genetically in vivo and biochemically in vitro. 
Cas8 family proteins are diverse, leading to low overall sequence conservation and to 
lack of any recognizably conserved common domain when assessed by presently 
available sequence databases. This is typified by the Cas8 proteins from Mth and Hvo 
which share only 30% amino acid identity. However, pairwise alignment of Hvo and 
Mth Cas8, did reveal conserved amino acid motifs which could be targeted by 
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mutagenesis (Figure 4-13).From the sequence homology a region of conservation 
between Mth Cas8’ αα 15-155 and 530-550 were the targets of mutants. Specifically, 
conserved residues within Mth Cas8’ amino acid sequences 151-155 and 530-550 
were selected: D151(G), N153(A), E155(A), N536(A), S540(A), L542(A) and Y548(A) to 
be mutated to alanine(A) or glycine (G), used together with the previously available 
K68A and K117A point mutants (269).  
All the Cas8’ point mutations were successfully generated except the Y548A 
mutation, which could not be made despite multiple attempts, for reasons unknown. 
The point mutants were then overexpressed as soluble proteins, except the S540A 
mutant. In situations where no protein expression was detected the alanine encoding 
codon was subsequently mutated to encode glycine. The D151G mutant generated 
soluble protein that could be purified whereas mutation of S540A to A540G yielded 
no protein expression for unknown reasons. The remaining Mth Cas8’ proteins K68A, 
K117A, D151G, N153A, E155A, N536A and L542A were expressed and purified using 
the same method as for wild-type Cas8’ (Figure 4-14, see section 3.2.3).  
 
Figure 4-14. SDS-PAGE analysis of Mth Cas8’ wild-type and mutant purified proteins. Following 
identically performed purifications for all proteins 1-2μg of each His6-Cas8’ protein was assessed by SDS-
PAGE and stained by Coomassie Brilliant Blue. 
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4.2.5.1 Analysis of ATPase activity of Cas8’ wild-type and mutant proteins 
The ATPase activities of the purified Cas8’ mutant proteins were determined and 
expressed relative to the ATPase activity obtained for the wild-type Cas8’protein 
which was set to 1 (Figure 4-15). K117A and D151A both appeared to have severely 
reduced ATPase activity with approximately 0.2 of the relative activity of the Cas8’ 
wild-type protein. K68A, N153A, E155A, N536A and L542A mutants all showed similar 
activity to the wild-type protein varying from 0.78 (L542A) to 1.4 (N153A).  
 
Figure 4-15. ATPase assay of Cas8’ wild-type protein and Cas8’ mutant proteins. 50nM of Cas8’ 
proteins were tested for ATP hydrolysis activity by Malachite Green colorimetric assay as in Figure 
4-12iii. Relative activity of mutants was calculated using the wild-type protein ATPase activity as 
reference. Each mutant was assayed in duplicate and whiskers show standard deviation from the mean. 
4.2.5.2 Binding of mutant Cas8’ proteins to 3’RNA/DNA Flap substrate 
Binding assays with wild-type Cas8’ showed preferential binding to substrates with 
flapped regions, particularly flapped structures and D- and R-loops. Cas8’ also 
demonstrated nuclease activity, of particular interest was the RNase activity on a 3’ 
RNA/DNA flap. To this end, wild-type Cas8’ and mutant proteins were tested for 
binding the 3’RNA/DNA flap substrate. Interestingly, the binding characteristics of 
mutant proteins differed to wild-type. The amount of substrate bound was expressed 
in percentage and plotted against concentration of Cas8’ protein (Figure 4-16) with 
the resulting calculated KD values tabulated  (Table 13. KD values for Cas8’ proteins 
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binding to 3’RNA/DNA flap substrate from EMSA analysis. KDs were determined from 
triplicate EMSAs quantified by 2D densitometry.). These assays were carried out 
prior to the identification of the optimal salt condition. Therefore, the reactions are 
in NaCl containing buffers rather than the optimised KOAc buffers. As a result there 
are differences seen between the wild-type Cas8’ KD values calculated here when 
compared to previous values, shown in Figure 4-1. As expected following the 
mutation of conserved residues mutant Cas8’ proteins manifested with varied 
binding affinities to the substrate when compared to the wild-type protein. The 
mutant proteins K117A (Figure 4-16iii) and D151G (Figure 4-16iv) bound the 
substrate most similarly to wild-type, though KD values showed slightly reduced 
binding affinity for K117A, and even more so for D151G. In contrast, all other Cas8’ 
mutant proteins presented with improved binding to the 3’RNA/DNA substrate. KD 
values indicated 3-fold increase in binding affinity of the N536A mutant, with other 
mutants following in the order of increasing affinities, L542A, E155A and K68A (Figure 
4-16viii, vi and ii). The highest, 17-fold increase in binding affinity was observed for 
the mutant N153A (Figure 4-16v).  
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Figure 4-16. EMSA analysis titrating Cas8’ into 3’RNA/DNA substrate. Cas8’ was used at 0, 0.1, 0.2, 0.4, 
0.8, 1.6, 3.2, 6.4, 12.8, 25.6, 51.2, 102.4, 204.8, 409.6, 819.2 and 1638.4nM with 5nM substrate in 
reactions containing 10mM EDTA. Each protein was assayed in at least duplicate (usually triplicate): 
Wild-type (i), K68A (ii), K117A (iii), D151G (iv), N153A (v), E155A (vi), N536A (vii) and L542A (viii). Section 
A shows phosphorimages of native TBE gels separating bound and unbound substrate species and 
aggregates and in gel bands respectively. Section B shows binding isotherms with percentage of 
substrate shifted, as quantified 2D densitometry plotted against Cas8’ concentration. Binding isotherms 
were plotted with standard error and the calculated KD values summarised in Table 13. 
 
. 
 
B 
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Table 13. KD values for Cas8’ proteins binding to 3’RNA/DNA flap substrate from EMSA analysis. KDs 
were determined from triplicate EMSAs quantified by 2D densitometry. 
 
 
 
 
 
 
4.2.5.3 RNA nuclease activity of Cas8’ proteins 
As each mutant protein either maintained or enhanced its binding affinity for the 
substrate compared to the wild type Cas8’ protein, the next step was to examine the 
impact of the mutations on the nuclease activity of the mutant proteins. Specifically, 
RNA nuclease activity was assayed using the same 3’RNA/DNA substrate as in the 
prior binding affinity assays (EMSAs).  Previous experiments showed that Cas8’ 
nuclease activity was dependent on the inclusion of magnesium in the reaction 
conditions (see Figure 4.5). Therefore, also in these nuclease assays, EDTA was 
occluded and reactions were supplemented with magnesium chloride to allow the 
magnesium-dependent nuclease activity of Cas8’ to be analysed. Given that at the 
time of these assays it had been determined by other experiments that potassium 
acetate salts potentiated the nuclease activity of Cas8’, these tests were also carried 
out in potassium acetate instead of sodium chloride.  
Here, representative denaturing urea gels showing the labelled RNA strand of the 
3’RNA/DNA flap substrate and the resultant smaller-sized products of the nuclease 
activity  of each mutant Cas8’ protein are presented (Figure 4-17). Despite most of 
the mutants showed enhanced binding to the substrate, their nuclease activity was 
attenuated compared to the wild-type protein. The two mutants K117A and D151G 
which bound the substrate with lower affinity than the wild-type Cas’ protein lacked 
Cas8’ KD 
Wild Type 598.7 ± 12.1 nM 
K68A 94.1 ± 7.2  nM 
K117A 623.6 ± 9.4  nM 
D151G 779.7 ± 7.5  nM 
N153A 36.3 ± 4.3  nM 
E155A 135.4 ± 10.9  nM 
N536A 222.2 ± 16.7 nM 
L542A 175.2 ± 15.0 nM 
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nuclease activity entirely (Figure 4-17, panels iii and iv, respectively).  On the other 
hand, the L542A mutant which had higher binding affinity was also nuclease 
defective (Figure 4-17viii). The remaining mutant proteins, arranged in the order of 
increasing binding affinities, N536A, E155A, K68A and N153A, all manifested with 
detectable nuclease activity. However, quantitative analysis revealed all activities 
were clearly lower than the wild-type protein, though to varying degrees. For 
example, the mutants N153A and E155A still successfully cleaved approximately 75% 
of the substrate, K68A approximately 50% whereas the activity N536A was almost 
abolished. This indicates that each of these residues plays a different role in 
maintaining the appropriate conformation of the Cas8’ protein to correctly interact 
with and process the substrate.  
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Figure 4-17. Nuclease assays titrating Cas8’ wild-type and mutant proteins into 3’RNA/DNA flap 
substrate. Cas8’ proteins were used at 0, 50, 100, 200, 400, 600, 800 and 1000nM with 5nM substrate in 
reactions containing 125mM KOAc and 10mM MgCl2. Each protein was assayed in at least duplicate 
(usually triplicate). Section A displays representative gels of nuclease assays with: wild-type (i), K68A (ii), 
K117A (iii), D151G (iv), N153A (v), E155A (vi), N536A (vii) and L542A (viii). These are phosphorimages of 
urea gels separating Cas8’ nuclease products of 3’RNA/DNA flap, each end labelled with 
32
P as indicated 
by (•). Section B shows percentage of substrate degraded as determined by quantification using 2D 
densitometry with corresponding standard error.  
 
 
 
B 
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4.2.5.4 In vitro EMSA analysis of Mth Cas8’ proteins binding to R-loops 
Previously, the recombinant Mth Cas8’ mutant proteins were assessed by EMSA 
assays for binding to 3’RNA/DNA flap substrate (see section 4.2.5.3). Therefore, here 
these assays were recapitulated to evaluate the binding behaviour of the Cas8’ 
mutant proteins to synthetic R-loops. Of note, the R-loop substrate used was 
inclusive of a PAM sequence.  Representative EMSA gels and the resulting quantified 
binding isotherms can be seen in Figure 4-18A&B. Wild-type Cas8’ bound the R-loop 
substrate with the affinity corresponding to KD of 4.7 ± 0.6nM (Figure 4-1). All Cas8’ 
mutants also showed binding to the generic R-loop substrate, albeit with lower 
affinity than that observed for the wild-type protein. The proteins that showed the 
largest decreases in binding affinity were K68A, E155A, K117A and L542A. The 
calculated KD of these mutants gave an 8 to 10 fold change in binding affinity: 38.1 ± 
1.5nM, 41.4 ± 1.2nM, 44.3 ± 1.4nM and 53.3 ± 9.2nM, respectively. These apparent 
disassociation constants were still relatively high and still generated some substrate-
specific shift patterns typical of the wild-type protein. The remaining mutants bound 
the R-loop substrate with intermediate binding affinity, showing an approximate 2-3 
fold decrease in their disassociation constants. The nuclease-defective D151G Cas8’ 
mutant bound the R-loop substrate with a KD of 16 ± 1.4nM, while the remaining two 
nuclease-active proteins had a slightly higher level of binding.  Specifically, the 
mutants N153A had a KD of 14.8 ± 6.6nM, and N536A a KD of11.4 ± 1.3nM. Similarly 
to the binding to 3’RNA/DNA flap substrate, single point mutations of the Mth Cas8’ 
protein affected the binding to synthetic R-loops. Nonetheless, all of the mutants 
could still interact with the substrate, albeit with increased apparent disassociation 
constants. 
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Figure 4-18. EMSA analysis titrating Cas8’ wild-type and the various Cas8’ mutants into generic R-loop 
substrate. Cas8’ was used at 0, 0.1, 0.2, 0.4, 0.8, 1.6, 3.2, 6.4, 12.8, 25.6, 51.2, 102.4, 204.8, 409.6, 819.2 
and 1638.4nM with 5nM substrate in reactions containing 125mM KOAc and 10mM EDTA. Each protein 
was assayed in at least duplicate (usually triplicate): wild-type (i), K68A (ii), K117A (iii), D151G (iv), 
N153A (v), E155A (vi), N536A (vii) and L542A (viii). Section A shows phosphorimages of native TBE gels 
separating bound and unbound substrate species and aggregates and in gel bands respectively. Section 
B shows binding isotherms with percentage of substrate shifted, as quantified by 2D densiometry 
(AIDA), with corresponding error bars plotted against Cas8’ protein concentration. The calculated KD 
values are summarised in Table 14. 
B 
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Table 14. KD values for Cas8’ proteins binding to R-loop substrate obtained from EMSA analysis. KDs 
were determined from at least duplicate EMSAs quantified by 2D densitometry. 
 
 
 
 
 
Previously, the recombinant Mth Cas8’ mutant proteins were assessed by EMSA 
assays for binding to 3’RNA/DNA flap substrate (see section 4.2.5.3). Therefore, here 
these assays were recapitulated to evaluate the binding behaviour of the Cas8’ 
mutant proteins to synthetic R-loops. Of note, the R-loop substrate used was 
inclusive of a PAM sequence.  Representative EMSA gels and the resulting quantified 
binding isotherms can be seen in Figure 4-18A&B. Wild-type Cas8’ bound the R-loop 
substrate with the affinity corresponding to KD of 4.7 ± 0.6nM (Figure 4-1). All Cas8’ 
mutants also showed binding to the generic R-loop substrate, albeit with lower 
affinity than that observed for the wild-type protein. The proteins that showed the 
largest decreases in binding affinity were K68A, E155A, K117A and L542A. The 
calculated KD of these mutants gave an 8 to 10 fold change in binding affinity: 38.1 ± 
1.5nM, 41.4 ± 1.2nM, 44.3 ± 1.4nM and 53.3 ± 9.2nM, respectively. These apparent 
disassociation constants were still relatively high and still generated some substrate-
specific shift patterns typical of the wild-type protein. The remaining mutants bound 
the R-loop substrate with intermediate binding affinity, showing an approximate 2-3 
fold decrease in their disassociation constants. The nuclease-defective D151G Cas8’ 
mutant bound the R-loop substrate with a KD of 16 ± 1.4nM, while the remaining two 
nuclease-active proteins had a slightly higher level of binding.  Specifically, the 
mutants N153A had a KD of 14.8 ± 6.6nM, and N536A a KD of11.4 ± 1.3nM. Similarly 
to the binding to 3’RNA/DNA flap substrate, single point mutations of the Mth Cas8’ 
Cas8’ KD 
Wild Type 4.7 ± 0.2nM 
K68A 38.1 ± 1.6nM 
K117A 44.3 ± 9.4nM 
D151G 16.0 ± 1.4nM 
N153A 14.8 ± 6.6nM 
E155A 41.4 ± 1.2nM 
N536A 11.4 ± 1.3nM 
L542A 33.1 ± 1.3nM 
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protein affected the binding to synthetic R-loops. Nonetheless, all of the mutants 
could still interact with the substrate, albeit with increased apparent disassociation 
constants. 
 
  
4.2.5.5 In vivo genetic analysis of conserved Cas8 point mutations in 
Haloferax volcanii 
Parallel in vivo studies on the function of Cas8 in Haloferax volcanii CRISPR 
interference were carried out entirely by Karina Haas from the collaborating research 
group of Dr. Anita Marchfelder at the University Of Ulm, Germany. In Karina’s study, 
point mutations in conserved residues, analogous to the mutations in Mth Cas8’ 
generated as part of this study, were made in Hvo Cas8. To assess the competence of 
the mutant Cas8 proteins to adequately activate CRISPR interference, their 
functionality was tested via heterologous expression in a stable strain lacking wild-
type Cas8 protein. In brief, ∆Cas8 cells were first transformed with a plasmid 
(pTA927) containing either wild type Cas8 (Cas8+), or a mutant Cas8. Next, to provoke 
an immune reaction, strains were transformed with a second plasmid (pTA352) 
carrying a protospacer flanked by either PAM3 (TTC) or PAM9 (ACT), hence 
mimicking an invasive element. Only Cas8 proteins with sufficient functionality were 
then able to organize a functional Cascade targeting Cas3 for degradation of the 
invading plasmid.  After a set time of incubation, the cultures were then plated onto 
media that selected for a marker contained on the second “invading” plasmid. If the 
CRISPR system of interference was active then this plasmid would have been 
destroyed, resulting in no colonies being observed on the plate. Based on the 
transformation efficiency of such cultures, the interference capability of each Cas8 
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mutant was then scored as either “reduced interference”, “interference” or “no 
interference”. Each assay was repeated in triplicate and only 100-fold differences in 
transformation efficiency were considered to be ineffective interference. The 
resulting data were collected and analysed fully by Karina Haas and can be seen 
presented in Table 15. All Cas8 mutant proteins presented with high transformation 
rates which suggested that the second “invading” plasmid was not being degraded by 
the CRISPR immune response due the reduced the efficacy of interference.  
Of note, the results of this assay need to be interpreted with caution as 
spontaneously occurring mutations in essential DNA sequences might give false 
positive interference results. Indeed, the key role of Cas8 proteins in interference 
was discovered by genome sequencing of one such mutation (280).  
Table 15. Effect of Cas8 mutations on plasmid interference in Haloferax volcanii. ∆Cas8 cells were first 
transformed with plasmid (pTA927) containing either wild type Cas8 (Cas8
+
), or a mutant Cas8 that 
encodes the amino acid substitution listed. To provoke an immune reaction, strains were transformed 
with a second plasmid (pTA352) carrying a protospacer flanked by either PAM3 (TTC) or PAM9 (ACT). 
Reduction of transformation rate was determined relative to transformation with a plasmid lacking 
protospacer-PAM sequence. Reduction in efficiency of transformation in the range 0.05-0.5 was 
classified as “reduced interference” and reduction by less than 0.04 as “interference”. “No interference” 
indicates that transformation efficiency was high, comparable to plasmid lacking PAM-protospacer. This 
work is exclusively the work of Karina Haas, from Dr. Anita Marchfelder’s research group at the 
University of Ulm, Germany.  
First transformation plasmid  Reduction of transformation rate with invader plasmid by 
factor 
pTA352-PAM3 pTA352-PAM9 
--- no interference no interference 
pTA927-Cas8b 0.0003  
(interference) 
0.0006  
(interference) 
pTA927-K111A no interference no interference 
pTA927-R126A no interference no interference 
pTA927-R189A 0.007  
(interference) 
0.01  
(interference) 
pTA927-D230A no interference no interference 
pTA927-N232A 0.2  
(reduced interference) 
0.004  
(interference) 
pTA927-E234A 0.005  
(interference) 
0.004  
(interference) 
pTA927-N625A no interference no interference 
pTA927-L627A no interference no interference 
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pTA927-S629A 0.02  
(interference) 
0.01  
(interference) 
pTA927-L631A 0.001  
(interference) 
0.007  
(interference) 
pTA927-Y637A no interference  no interference 
 
4.2.5.6 Characterisation of Cas8’ N153A binding to generic substrates and 
sensitivity to PAM 
In vivo analysis of Hvo Cas8 mutants in interference reactions, using two “invader” 
plasmid versions carrying a protospacer flanked by different PAM sequences 
identified that mutant Cas8 N232A could support interference against one “invader 
“plasmid but not the other. Plasmids used in these assays had one of six possible Hvo 
PAMs, which indicated that Cas8 N232A could discern only some PAM sequences, 
but not others, which would have then reflected in variable interference that was 
observed. Therefore, to understand whether this residue played a similar role in PAM 
recognition in Mth Cas8’, the equivalent mutant N153A protein was analysed for its 
ability to bind different DNA PAMs. These were determined from bioinformatics 
analysis of Mth spacers (see Figure 4-2) and here the main PAM (CCC) and two others 
(PAM2-CTC and PAM3-TTG) were tested in binding assays (EMSAs).  However, first 
the substrate for which the N153A mutant had the highest affinity had to be 
determined, which was then to be carried forward for PAM sensitivity testing. Thus, 
the N153A mutant was tested for binding to generic RNA and DNA substrates (linear 
duplex, flapped duplex and an R-loop) and compared to the wild-type Cas8’ protein. 
The binding isotherms of either wild-type Cas8’ or N153A mutant with the individual 
substrates can be seen in Figure 4-19 with the resulting calculated KD values 
summarized in Table 15.  These binding assays showed that the N153 mutant bound 
to the duplex substrate with lower affinity than the wild type protein (81.8 ± 2.8nM 
versus 20.4 ± 0.6nM) (Figure 4-19 panels i and ii). Next, given that the best-fit line of 
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binding isotherms to flayed duplex was linear for both proteins, the KD values could 
not be calculated in this instance and the binding affinities could not be established 
and subsequently compared (Figure 4-19, panels iii and iv). Finally, N153A had a high 
affinity for binding to R-loops which was also comparable to that of the wild-type 
Cas8’ (5.3 ± 0.3nM versus 4.7 ± 0.2nM) making it the ideal candidate substrate 
(Figure 4-19, panels v and vi). Therefore, the ability of N153A to recognize different 
PAM sequences was examined using R-loop substrate variations either lacking PAM 
or including one of three different selected PAM sequences. 
Wild-type Cas8’ bound to R-loops with (CCC) or without (AAA) PAM with apparent 
dissociation constants of 5.3nM and 40.7nM, respectively, demonstrating an 8-fold 
increase in binding affinity in the presence of a PAM sequence (See Figure 4-3). 
However, the N153A mutant Cas8’ displayed opposing behaviour, binding to R-loops 
with PAM with lower affinity (KD = 31.6nM) than to R-loops without a PAM sequence 
(KD= 12nM) (Figure 4-20i and ii, Table 16). Thus, Cas8’ N153A binding to R-loop 
substrates incorporating PAM2 (CTC) or PAM3 (TTG) were also assessed and 
compared to the pattern of binding affinity previously obtained for the wild type 
Cas8’ protein (see Figure 4-4 iii and iv) . From these assays it became evident that the 
N153A mutation completely altered the affinity at which the Cas8’ protein bound the 
different R-loops. The preferential PAM binding of the wild type protein was 
determined to be PAM (CCC) > PAM3 (TTG) > PAM2 (CTC) > no PAM (AAA), whereas 
the N153A Cas8’ trend was shown to be no PAM (AAA) > PAM2 (CTC) > PAM (CCC) > 
PAM3 (TTG), as deduced by comparing the respective KD values (Table 16). 
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Figure 4-19. EMSA analysis of titrating wild-type Cas8’ and point mutant N153A to generic DNA and 
RNA substrates. Cas8’ proteins were used at 0, 0.1, 0.2, 0.4, 0.8, 1.6, 3.2, 6.4, 12.8, 25.6, 51.2, 102.4, 
204.8, 409.6, 819.2 and 1638.4nM with 5nM substrate in reactions containing 125mM KOAc and 10mM 
EDTA. Each pair of binding isotherms compares Cas8’ wild-type to the N153A point mutant as a 
percentage of substrate shifted quantified by 2D densitometry. Binding isotherms allowed 
determination of with standard error and KDs. A summary of KDs determined can be seen in Table 16. 
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Figure 4-20. EMSA analysis of titrating Cas8’ N153A into R-loop substrates containing various PAM 
sequences. In all panels part (.a) Cas8’ N153A was used at 0, 0.1, 0.2, 0.4, 0.8, 1.6, 3.2, 6.4, 12.8, 25.6, 
51.2, 102.4, 204.8, 409.6, 819.2 and 1638.4nM with 5nM substrate in reactions containing 125mM KOAc 
and 10mM EDTA. Each phosphorimage of native TBE gel shows separation of unbound, specifically 
shifted and in well aggregated substrate. Assays were carried out in at least duplicate (usually triplicate), 
representative gels are shown for: N153A – PAM (i.a), + PAM (ii.a), PAM2 (iii.a) and PAM3 (iv.a). 
Percentage of substrate shifted was quantified by 2D densitometry (AIDA) to determine KDs with 
standard error (.b). A summary can be seen in  
 
 
141 
 
Table 16. Summary of KDs for Cas8’ wild-type and Cas8’ N153A proteins binding to generic DNA and 
RNA substrates. KDs were determined from duplicate EMSAs quantified by 2D densitometry.  
Substrate Cas8’ Cas8’N153A 
Duplex 20.4 ± 0.6 nM 81.8 ± 2.8 nM 
Flayed Duplex - - 
R-loop 4.7 ± 0.2 nM 5.3 ± 0.3 nM 
 
Table 17. Summary of KD values for Cas8’ N153A binding to R-loops with various PAM sequences. KDs 
were determined from at least duplicate EMSAs quantified by 2D densitometry. 
PAM KD 
AAA (-)  12.0 ± 0.4 nM 
CCC (+) 31.6 ± 0.9 nM 
CTC 14.8 ± 1.0 nM 
TTG 52.3 ± 1.4 nM 
 
4.2.5.6.1 Summary 
A compilation of selected mutations in several conserved residues made in both the 
Mth and Hvo Cas8 genes allowed the in vitro biochemical characterization of Mth 
Cas8’ protein and in vivo genetic analysis of Hvo Cas8. The Mth Cas8 mutants all 
showed decreased binding affinity to all of the oligonucleotide substrates tested 
(Figure 4-16 and Figure 4-18). Similarly, there were detectable changes in their 
nuclease and ATPase activity (Figure 4-15 and Figure 4-17). On the other hand, the in 
vivo analysis of Hvo Cas8 raised N232A as a PAM insensitive mutant (Table 13). This 
was corroborated with the analogous Mth Cas8 mutant, N153A, which displayed 
abnormal binding preference to R-loops with different PAM sequences when 
compared to the wild-type protein (Figure 4-20). 
4.2.6 Binding affinity of Cas8’ wild type and N153A proteins to 5’ Handle 
R-loop 
The R-loops used previously contained perfectly matched RNA that completely 
complemented one of the DNA strands to form an R-loop. This is not the complete 
physiological CRISPR/Cas interference Cascade R-loop. The crRNA consists of a 5’ 
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handle, complement region and normally a 3’ tail containing a stem-loop structure. 
So a more relevant structure was tested, this time containing the typical 8 nucleotide 
5’ handle sequence from the repeat sequence from Mth CRISPR locus. This structure 
was generated both with and without PAM sequences. When these substrates were 
assayed by EMSA analysis for Cas8’ wild-type and the Cas8’ mutant N153A binding 
the PAM sequence proved to have a lesser effect on binding affinity (
 
Figure 4-21). Indeed, wild-type Cas8’ had similar binding to both 5’ Handle R-loop 
derivatives with corresponding KD values of  4.1 ± 0.1nM  with PAM and 3.1 ± 0.1nM 
without PAM (Figure 4-21, panels i and ii, Table 17). These apparent dissociation 
constant values were consistent with the KD value obtained in previous experiments 
with classical R-loop with PAM (KD of 5.3nM, see Figure 4-1). Of note,  the R-loop 
substrates, used here and in previous experiments, had the same PAM sequence 
though differed structurally with the 5’ Handle R-loop substrate containing an 
additional 5’ RNA flap region at the PAM branch point. Therefore, this suggested that 
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in physiological conditions, the correct confirmation/structure of the R-loop 
substrate, i.e. the presence of a 5’ RNA flap, seems to be more important for 
establishing a high binding affinity between Cas8’ protein and the substrate than the 
PAM sequence. Thus, in vivo, PAM sequence most likely fulfils other roles, as 
explored later.  
Likewise, the Cas8’ N153A  mutant responded to the 5’ handle structure inclusive of 
PAM in a very similar manner to the wild-type protein with a KD of 4.4 ± 0.3nM versus 
the wild-type protein’s KD of  4.1 ± 0.1nM (Figure 4-21iii, Table 17). However, the 5’ 
handle substrate lacking PAM showed a decreased binding affinity with a KD of 9.8 ± 
1.0nM (Figure 4-21iv, Table 17). This KD reflects a similar value to the simple R-loop 
substrate, 12.0 ± 0.4nM (Table 17). Therefore, with the physiological substrate, the 
N153A mutation only had a subtle effect on the binding potential of the protein 
which became apparent solely in the absence of a PAM sequence. While it abolished 
the ability of the protein to appropriately discern the different PAM sequences in a 
complete R-loop, obtaining the highest binding affinity in the absence of PAM (Table 
18), in the presence of a 5’ handle on the substrate, the PAM sequence had a positive 
effect on the binding affinity which became similar to that of the wild-type protein.  
On the other hand, the wild-type protein bound the 5’ handle substrate with the 
same affinity irrespective of PAM.  
Table 18. Comparative KD affinities of Cas8’ Wild-type protein to N153A point mutant to 5’handle R-
loop substrates + and – PAM. KDs were determined from at least duplicate EMSAs quantified by 2D 
densitometry. 
 Cas8’ +PAM+5’handle R-loop -PAM+5’handle R-loop 
Wild-type 4.1 ± 0.1 nM 3.1 ± 0.1 nM 
N153A 4.4 ± 0.4 nM 9.8 ± 1.0 nM 
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Figure 4-21. EMSA analysis of titrating wild-type Cas8’ and the point mutant N153A into R-loop 
substrates with (CCC) or without (AAA) PAM and a 5’handle. Cas8’ proteins were used at 0, 0.1, 0.2, 
0.4, 0.8, 1.6, 3.2, 6.4, 12.8, 25.6, 51.2, 102.4, 204.8, 409.6, 819.2 and 1638.4nM with 5nM substrate in 
reactions containing 125mM KOAc and 10mM EDTA. Each phosphorimage of native TBE gel shows 
separation of unbound, specifically shifted and in-well aggregated substrate (A). Assays were carried out 
in at least duplicate (usually triplicate), representative gels are shown for: Wild-type R-loop + PAM + 
5’handle (i), Wild-type R-loop - PAM + 5’handle  (ii), N153A R-loop + PAM + 5’handle (iii), N153A R-loop - 
PAM + 5’handle (iv). Percentage of substrate shifted was quantified by 2D densitometry (AIDA) and 
plotted against Cas8’ concentrations to determine standard error and KDs (B). A summary of the 
calculated KD can be seen in Table 18. 
A 
B 
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4.2.6.1 Nuclease degradation of crRNA in R-loops 
Previous experiments established that the preferentially bound substrate of Cas8’ 
was RNA, either a 3’ or 5’ flap (see Figure 4-1). Therefore, it was desirable to 
determine whether Cas8’ was cleaving at this site of the substrate.  Specifically, the 
physiologically relevant 5’ handle R-loop was tested to see if Cas8’ could be expected 
to act/cleave on the 5’ flap of the crRNA in vivo. To this end, Cas8’ was titrated into 
this R-loop in acetate salt and analysed as in the previous nuclease assays (Figure 
4-17). However, this assay revealed that even with increasing Cas8’ concentrations 
the substrate was not being degraded (lanes 6-9, Figure 4-22). Thus, in the next step 
the nuclease activity of Cas8’ was tested on a modified version of the 5’ handle R-
loop substrate where the strand of DNA that had been displaced to form the R-loop 
was removed, therefore mimicking the Cas3-mediated degradation of this strand 
which occurs in vivo. Here, clear increasing degradation was observed in Cas8’ 
concentration-dependent manner (lanes 2-4, Figure 4-22). To ensure that the 
observed cleavage was specifically due to the activity of the protein, a previously 
characterized nuclease deficient mutant was used at the highest concentration of 
wild-type Cas8’ as control. Indeed, the Cas8’ D151G mutant showed no nuclease 
activity as would have been expected, (lane 5, Figure 4-22). 
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Figure 4-22. Nuclease assay titrating Cas8’ into RNA substrates physiologically relevant to CRISPR 
interference. Wild-type Cas8’ was used at 0, 50, 100 and 200nM and Cas8’ D151G at 200nM with 5nM 
substrate in reactions containing 125mM KOAc and 10mM MgCl2. Phosphorimage of urea gel separating 
Cas8’ nuclease products of the 5’ handle R-loop substrates. The RNA strand radiolabelled with 
32
P as 
denoted by * is in red. Wild-type Cas8’ had RNA nuclease activity on 5’ RNA handle in a flap substrate 
(lanes 1-4), whereas the nuclease defective Cas8’ D151G did not (lane 5). Wild type Cas8’ was inactive as 
a nuclease on the same RNA strand within an R-loop substrate (lanes 6-9). 
4.2.6.1.1 Summary 
R-loops with a 5’ handle, the physiological substrate for Cas8’, stimulate the binding 
of the wild-type protein (Figure 4-21i). However, the N153A mutant protein is 
sensitive to the 5’ handle substrate, as seen by lower disassociation constants (Figure 
4-21iii) and less sensitive to PAM (Table 17). This supported the idea that Cas8’ had 
structural and sequence specificity. This study found that Cas8’ could only degrade 
crRNA from a synthetic R-loop when a strand of DNA has been displaced or degraded 
(by Cas3) (Figure 4-22), which is discussed later.   
4.2.7 Physical association of Cas8’ with archaeal Cascade proteins Cas5 
and Cas7 
Cas5 and Cas7 are integral to bacterial and archaeal Cascade complexes and have 
been shown to function with Cas8 during CRISPR interference (128). In crystal 
structures of the ‘large’ subunit (CasA/Cas8) shows interactions with Cas5, Cas7 and 
the crRNA 5’ handle (162). Through the collaboration with Anita Marchfelder’s 
research group at the University of Ulm, Germany and work carried out by Britta 
Stoll, FLAG-tagged Cas7 expressed in Hvo was used as bait to identify interacting 
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partners. Therefore, a physical interaction between Cas8’ and Cas5-Cas7 was tested 
in vitro. First, Mth Cas7 was co-purified with Cas5, an N-terminal fusion to E. coli 
maltose binding protein (MBP) after being overexpressed recombinantly in E. coli 
BL21C+  via affinity chromatography (Figure 4-23i). Similarly, Mth Cas8’ was also 
purified with an N-terminal His tag (Figure 3-6). In vitro pull down assays, using such 
purified MBPCas5-Cas7 immobilised on amylose resin as bait with His6Cas8’ as prey, 
were then performed to ascertain whether there was a direct interaction. Indeed, 
immunoblotting of the fraction eluted off this amylose with anti-MBP and anti-His 
antibodies clearly indicated that MBPCas5-Cas7 interacted physically with His6Cas8’ 
(Figure 4-23iiI, top panel, lane 8). This interaction was specific as in the control pull-
down where amylose resin was pre-incubated with bovine serum albumin, no Cas8’ 
was detected in the elution fraction (Figure 4-23iii, top panel, lane 6). Of note, an 
identical result was obtained either with or without pre-incubation of Cas5-Cas7 with 
crRNA1 (Figure 4-23iv). However, this pull-down assay indicated only a weak physical 
interaction of Cas8’ with Cas5-Cas7 as a maximum of approximately 10% of Cas8’ 
input could be detected as binding to MBPCas5-Cas7 under the conditions used. 
Moreover, the reciprocal pull-down assay using Ni2+-NTA immobilised Cas8’ as bait 
with MBPCas5-Cas7 in solution could not be performed  as MBPCas5-Cas7 was non-
specifically interacting with the Ni2+-NTA resin itself. Next, the ability to directly 
interact with MBPCas5-Cas7 was also tested for the Cas8’ mutant proteins which 
have showed loss of function phenotype in previous experiments. The mutants 
examined included the nuclease inactive Cas8’ proteins (D151G and N536A), as 
assessed in vitro, and the CRISPR interference defective Cas8 protein, (also the PAM 
insensitive mutant, N153A), initially identified by in vivo genetic analysis in Hvo. 
However, all the selected mutant Cas8’ proteins bound to MBPCas5-Cas7 comparably 
to the wild-type Cas8’ protein (Figure 4-23iv).  
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Figure 4-23. Analysis of Cas8 protein interaction with Cas5-Cas7 from Hvo and Mth. (i) Coomassie 
stained SDS-PAGE gel of approximately 2μg of recombinant Mth MBPCas5-Cas7 and His6Cas8, used in 
subsequent pull down assays. (ii) Coomassie stained SDS-PAGE profile of proteins co-purifying with Flag-
Tagged Cas7 expressed in Haloferax cells. Cas8 was detected by mass spectrometry. This work was 
carried out by Britta Stoll of Anita Marchfelder’s research group at the University of Ulm, Germany. (iii) 
Reconstitution of physical interaction between purified Mth Cas8’ (20μg) with purified complex of 
affinity tagged Methanothermobacter Cas5-Cas7 (20μg). Upper panel shows Western blot using anti-
(His)6 antibody to detect (His)6Cas8’, and the lower panel used anti-MBP antibody to detect MBP in 
MBP-Cas5-7. “Input” is a duplicate loading of total amount of used Cas8’ (upper panel) or Cas5-7 (lower 
panel). Cas8’ was detected in the elution (E) after binding to amylose-MBPCas5-7 (lane 8) but was 
absent from the elution of amylose pre-bound with bovine serum albumin (BSA, lane6). (iv) Repeat of 
(iii) lanes 7 and 8 but with preincubation of 100ng crRNA1. Additionally, Cas8’ mutant proteins D151G, 
N153A, N536A were also assessed for binding to MBPCas5-Cas7 and where found to interact similarly to 
wild-type Cas8’. 
 
Following the verification of interaction of Cas8’ with Cas5-7, the impact of this 
interaction on the binding affinity of Cas8’ to various R-loop structures with or 
without PAM was then tested by EMSAs. First, Cas5-Cas7 complex was assessed for 
its binding characteristics to R-loops with or without PAM. MBPCas5-Cas7 bound the 
R-loop structure and formed in well aggregates. Approximately all R-loop was bound 
at 100nM Cas5-Cas7 (Figure 4-24i). This allowed the determination of a baseline 
binding affinity of Cas5-Cas7 to the R-loop substrates. Next, a set concentration of 
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Cas8’ was added to the reaction mixtures containing increasing concentrations of 
Cas5-Cas7 and either standard R-loop substrate with/without PAM or 5’ handle R-
loop substrate also with/without PAM. Representative phosphorimages of TBE gels 
of EMSAs are shown in panels of part A of Figure 4-24 with their corresponding 
quantified binding isotherms displaying percentage of substrate bound plotted 
against Cas5-Cas7 concentration in part B. Using standard R-loop substrate, Cas8’ 
stimulated total substrate binding in the presence of a PAM sequence though had 
little effect on binding to the R-loop lacking PAM (Figure 4-24ii and iii). On the other 
hand, Cas8’ enhanced the binding affinity of Cas5-Cas7 to 5’handle R-loops 
irrespective of the PAM sequence, although a more significant difference in binding 
was observed with the 5’ handle R-loop substrate containing PAM (Figure 4-24iv and 
v). These same assays, though with standard R-loop substrate only, were then also 
repeated with the Cas8’ point mutant N153A, which has been shown to have an 
altered PAM sensitivity (see Table 17). Similarly to the results obtained with the wild-
type Cas8’, the Cas8’ N153A mutant had limited effect on MBPCas5-Cas7 binding to 
R-loop substrate without PAM (Figure 4-24vi). However, the binding to the PAM R-
loop substrate was enhanced even in the presence of this PAM insensitive mutant 
which was comparable to the increase seen with the wild-type protein, though only 
at higher concentrations of Cas5-7 (comparing Figure 4-24v [wild-type] to Figure 
4-24vii [N153A]).  
Next, the binding characteristics of the Cas8’ and Cas5-Cas7 complexes with the R-
loop was analysed to identify any difference in in gel species observed. Significantly, 
when identical EMSAs where Cas5-Cas7 and Cas8’ were mixed, analysis of these 
EMSAs was carried out either using the normal radiographic development method or 
via Western blot following transfer onto PVDV membrane to identify MBPCas5-Cas7 
with anti MBP antibody. This analysis revealed Cas5-Cas7 at both, 10nM and 100nM, 
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formed in-well protein-DNA aggregates with 8% and 67% of substrate, respectively 
(labelled A, lanes 1 and 2 Figure 4-25). Similarly, Cas8’ alone (5nM) bound 55% of the 
substrate in distinct complexes (labelled B in lane 3 Figure 4-25). However, a new 
complex (complex C) arose when Cas8’ (5nM) was pre-mixed with Cas5-7 (10 or 
100nM), binding 90-100% of the substrate (lanes 4 and 5, Figure 4-25). This 
confirmed that Cas5-Cas7 formed a distinct complex in EMSAs that was not an 
aggregate and was dependent on Cas8’. 
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Figure 4-24. EMSA analysis of titrating MBPCas5-Cas7 into wild-type Cas8’ and the Cas8’ point mutant 
N153A into various R-loop substrates. MBPCas5-Cas7 was used at 0, 3.9 7.8, 15.6, 31.25, 62.5, 125, 250 
and 500nM with 5nM substrate in reactions containing 125mM KOAc and 10mM EDTA. (i.a) 
Representative phosphorimage of native TBE gel of MBPCas5-Cas7 binding to R-loops forming only in 
well aggregates, quantified by 2D densitometry for – (i.b) and + PAM (i.c), to determine binding 
isotherms. MBPCas5-Cas7 titrations were then premixed with or without Cas8’ (2.5nM) and equivalent 
titrations were carried out – PAM (ii), + PAM R-loop (iii), -PAM +5’handle (iv) and +PAM +5’handle R-
loop (v Relative increases in binding were compared – and + Cas8’, seen in (.b) graphs with standard 
error.  ). MBPCas5-Cas7 titrations were then also carried out premixed with or without Cas8’ (2.5nM) on 
the same – PAM (vi) and + PAM (vii) R-loop substrates. 
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Figure 4-25. EMSA and Western blots for detection of Cas5-7 in a Cas8’ dependent in-gel complex. 
Lanes 1-5 (left panel) show phosphorimaged EMSA complexes arising from reactions binding of Cas5-7 
(complex A) or Cas8’ (B complexes). A new complex C was observed when Cas5-7 and Cas8’ are present. 
Western blotting detected MBPCas5-7 (anti-MBP) in complex C (lanes 8 and 9), as well as complex A 
(lanes 6, 8 and 9). 
4.3 Discussion 
Cas8 proteins and other ‘large’ subunit proteins of Cascade complexes have been 
implicated as the guide module of Type I interference complexes (162, 163, 226, 227, 
264). Indeed, the E. coli ‘large’ subunit CasA identifies correct PAM sequence and 
activates Cas3-mediated degradation of the invading nucleic acid. Therefore, in this 
study, the role of Cas8 in Mth CRISPR interference was studied in greater detail in 
parallel to a similar study in Hvo being carried out by a collaborating research group 
led by Dr. Anita Marchfelder at the University Of Ulm, Germany. This parallel study 
generated different point mutations in conserved residues of Cas8 and using in vivo 
genetic analysis identified which of these resulted in loss of CRISPR interference in 
Haloferax volcanii (Hvo) (see Table 15). Similarly, conserved residue mutational 
analysis of Mth Cas8 was performed in the scope of this study whereby nucleic acid 
binding and processing by Cas8’ was examined. Mth Cas8’ has binding specificity for 
branched nucleic acid substrates, specifically those containing a single RNA strand. 
 
 
154 
This is in line with the predicted role in CRISPR interference and the various DNA and 
DNA/RNA structures that would be expected to form in an effective immune 
response (see Figure 4-1). Cas8’ was also shown to be sensitive to PAM sequence 
flanking an R-loop, important for a complete interference reaction (see Figure 4-3, 
Figure 4-4). However, the binding affinity of Cas8’ was less sensitive to PAM 
sequence than the 5’ handle R-loop substrate, (Figure 4-19). An interesting ssRNA 
nuclease activity was detected in vitro (Figure 4-5), which was disrupted following 
mutation of K117, D151, N536 and L542 residues (Figure 4-17).  
When tested on generic substrates, Cas8’ could bind all DNA and RNA structures. 
However, the majority of these substrates resulted in in-well protein-DNA 
aggregation (Figure 4-1). The native intracellular conditions (acetate salts) of Mth 
may cause in vitro proteins to become non-specifically adhesive. Only when generic 
D- and R-loops were used as substrates for binding in EMSAs did specific species 
become apparent (Figure 4-1vi and vii). This indicates that Cas8’ has a binding 
specificity dependent on the substrate structure, such that these branched DNA 
structures are preferentially bound, in concurrence with previously published work 
(269). Further analysis revealed that the bioinformatically deduced PAM 5’-CCN-3’ 
(Figure 4-2 and Table 11) could stimulate binding to both duplex and R-loop 
substrates (Figure 4-3). Binding assays revealed specific nucleic acid binding and PAM 
sensing by Cas8’, both in isolation (Figure 4-3) and when mixed with Cas5-Cas7 
(Figure 4-24). In each Case apparent binding affinity increased in substrates with 
PAM over those without (Figure 4-3 and Figure 4-4). Following mutation of a 
conserved asparagine: N153 in Mth and N232 in Hvo, subtle PAM-induced 
behaviours were discovered from both in vivo genetic interference reactions (Table 
15) and EMSAs (Figure 4-20). Furthermore, these EMSAs demonstrated a perturbed 
interaction of this Cas8 mutant with PAM containing substrates either in isolation or 
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when in complex with Cas5-Cas7 in a reconstituted archaeal Type I Cascade (Figure 
4-24vi and vii). Indeed, binding to R-loop substrates inclusive of PAM was enhanced 
in the presence of the Cas8’-Cas5-Cas7 complex when compared to either Cas5-Cas7 
or Cas8’ alone (Figure 4-24i, iii and v). However, such increase in binding affinity was 
not seen with R-loop substrates without PAM, total amounts of substrate bound 
remained similar (Figure 4-24i, ii and iv). Interestingly, in these assays Cas8’ appeared 
responsible for the conversion of Cas5-Cas7 protein aggregates into distinct binding 
complexes, as shown by the specific species C identified by western blot analysis 
(Figure 4-25). This suggests that Cas8’ coordinates the assembly of Cas5-Cas7 
precisely on the substrate, which would explain the improved specific binding seen 
when the Cas8’-Cas5-Cas7 complex is assessed in binding assays. Analogously to the 
positioning of E.coli CasA relative to CasD (Cas5e), within the E.coli Cascade structure 
which bind at the branch point of the R-loop and detect PAM sequence for the 
specific stabilisation of the R-loop and recruitment of Cas3. It is therefore likely that 
the interaction between Cas8’ and Cas5-Cas7 is important for PAM sensing, 
activating precise Cascade nucleic acid binding, stable R-loop formation and target 
degradation (162, 176, 280, 283).  It is now thought that the Cas8’ N153 residue may 
act in a similar way to that of the asparagine residue that is located in L1 loop of the 
CasA protein from E.coli (227).  
 
 
 
156 
 
Figure 4-26. Structural predictions of Mth Cas8’ from amino acid sequences. Electrostatic surface 
charge of CPHmodel structure of Cas8’ (<0.001% confidence) (i). The generated PDB file of this model 
was used to identify possible DNA binding channels in the Cas8’ protein using MOLE. An example of two 
linked channels found in this Cas8’ structure which are located close to key conserved residues (ii). For 
example, Mth N153 residue is shown as a stick amino acid as it is relevant to establishing substrate PAM 
sensitivity (iii). 
As at the time of writing this thesis, no Mth Cas8 structures have been yet published, 
different homology modelling servers were employed to obtain a plausible structural 
model. However, only CPHmodel successfully generated at least a partial predicted 
structure (Figure 4-26i). Next, MOLE software was used to predict possible binding 
tunnels or surface ligand binding regions. The most interesting hit from this analysis, 
shown in Figure 4-26ii, identified a tunnel through which ssDNA/RNA could 
potentially traverse the Cas8 protein. Interestingly, The N153 PAM sensitive residue, 
highlighted as a stick amino acid in Figure 4-26iii, is located at the entrance of this 
tunnel, and may therefore affect the binding of Cas8’  to R-loop structures. Indeed, 
mutation of the analogous conserved residue, N131A, in E. coli perturbed the 
interaction of Cascade with Cas3 and disrupted the degradation of the target (227). 
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The in vivo genetic analysis of Cas8 mutations in Hvo, carried out by the collaborating 
research group in Germany, identified residues Asp 230 and Asn 625 as important to 
CRISPR interference given their mutation abolished interference activity (Table 15). In 
agreement with this observation, the corresponding Mth Cas8’ residues, Asp 151 and 
Asn 536, abolished the previously detected ssRNA nuclease activity (Figure 4-17I, iv 
and vii). Loss of nuclease function was apparent also with the Mth K117A mutant, 
however this residue is not conserved in Hvo which precluded a comparison between 
the two organisms. Importantly, Cas8’ degraded both 3’ and 5’ ends of ssRNA, 
exhibiting endonuclease activity because of the generation of discrete cleavage 
patterns rather than a ladder effect of the labelled strand being cleaved at specific 
intervals (Figure 4-10). It was not possible to ascertain RNase activity for the Hvo 
Cas8 in in vitro reactions. A wide range of conditions were tested here, including high 
and low salt, alternate metal ions and anions. The absence of activity is possibly 
because of the instability of the purified Hvo protein on storage, delivered as a gift 
from Dr. Anita Marchfelder’s research group. It cannot therefore be concluded that 
this loss of RNase activity in Mth Cas8’ D151G and N536A can be directly linked to 
Hvo Cas8 D230A and N625A loss of genetic interference. However, this correlation is 
at least intriguing. It has been shown previously that deletion of Cas8 from Hvo did 
not affect the maturation of pre-crRNA into mature crRNA, as assessed by northern 
blotting for crRNA (129, 280). Indeed, following correspondence with Dr. Anita 
Marchfelder at the University of Ulm, Germany and Dr. Thorsten Allers at the 
University of Nottingham about other predicted nucleases in Hvo, potential 
candidates that could further mature the 3’ terminus of the pre-crRNA were 
recognized . This maturation would occur after Cas6- mediated cleavage of the initial 
full length transcript, independently of Cas8 in Hvo. Moreover, given that 5’ handles 
are essential for interference it seems highly unlikely that these structures are the 
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target of the Cas8’ cleavage activity during crRNA maturation. Therefore, the 
functional significance of Cas8 RNase activity in the context of CRISPR immunity 
remains elusive, though two possible roles are proposed here. Firstly, there is the 
potential of a recycling role. Cas8’ failed to cleave a 5’ handled RNA when in an R-
loop (Figure 4-22ii), though following the removal of the displaced strand of DNA 
forming the R-loop, RNA cleavage proceeded as expected (Figure 4-22i). Therefore, 
following successful recruitment of Cas3 and transfer of the correct information 
necessary to target invading nucleic acids, this RNA degradation may initiate the 
clearing of the Cascade complex. Secondly, this RNase activity of Cas8 may be 
required in some other aspect of cellular RNA metabolism in these organisms that is 
indirectly important for CRISPR Type I systems, or a cellular role. This was briefly 
investigated here by DNA damage assays. Hvo strains, a wild-type and ΔCas8 were 
subjected to DNA damage from UV irradiation and DNA chemical cross-linking by 
Mitomycin C. Both of these however resulted in no alteration to DNA damage 
sensitivity (data not shown). There was also to possibility that the predicted 
‘resolvase’ activity reported previously could have had a cellular benefit (269) as 
some DNA repair pathways include RNA molecules that act as primers.  
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5 Cas1 and Cas2 facilitation of primed and naïve 
adaptation in CRISPR-Cas immunity 
5.1 Summary 
In this chapter, the ongoing work in characterisation of the biochemical activities of 
Cas1 and Cas2 proteins in CRISPR adaptation was described together with the 
collaborative effort to identify and analyse host factors that may contribute to this 
mechanism. At the time of this study, no mechanistic detail was known about CRISPR 
adaptation. However, the fact that CRISPR-Cas immune system of prokaryotes is built 
on the capture and integration of invading genetic elements into CRISPR loci by Cas1 
and Cas2 proteins had been widely accepted (67, 126, 148, 173, 184, 267). 
Adaptation can be stimulated by inefficient interference (‘primed’), or can act 
independently (‘naïve’). ‘Primed’ adaptation re-establishes immunity against the 
invader that had previously evaded interference through mutation in PAM or 
protospacer sequences.  Primed adaptation requires Cas1, Cas2, Cas3, Cascade and a 
spacer that is complementary or closely matches the protospacer sequence, as has 
been shown genetically (268). On the other hand, naïve adaptation is catalysed by 
Cas1 and Cas2, independently of Cascade both in vivo and in vitro (118, 148, 184). 
E.coli adaptation requires the functional complex of catalytically active Cas1, and 
Cas2 ([Cas1]4-[Cas2]2) (148). This complex generates a new spacer-repeat pair at the 
zero position of the chromosomal CRISPR locus. It is proposed that a series of 
targeted transesterification reactions inserts a protospacer at cruciform structures 
formed by CRISPR repeats (150, 184). Though the mechanism of protospacer capture 
remains elusive, the major source of new spacer DNA in naïve adaptation is the ter 
and Chi sites, likely at stalled replication forks (67).  This discovery also identified the 
role of RecBCD complex in naïve adaptation as a mechanism of targeting non-self 
DNA. RecBCD degrades linear DNA until reaching a Chi site. Prokaryotic genomes 
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have a high density of Chi sites which restricts the amount of free DNA that can be 
used in spacer acquisition. As most plasmids and viral DNA enter cells in a linear 
unprotected form, immediate degradation of the DNA upon cell entry is possible. 
Moreover, plasmid and viral DNA will be extensively replicated therefore increasing 
to likelihood of stalled replication forks. Stalled replication forks arise when the 
progression of the replication machinery is halted. This can be from a DNA lesion/ 
mutation or DNA bound protein, such as RNA polymerase. RecBCD is required for the 
remodelling of replication forks and along with RecG and PriA restart replication once 
the blockage has been removed or resolved. 
5.1.1 Aims 
To understand CRISPR adaptation the catalytic specificity of target capture and 
protospacer integration involving Cas1 and Cas2 needed to be determined. 
Understanding Cas1 nuclease ‘nicking’ and/or transesterification activity and its 
importance for processing blocked or broken replication forks was the main aim of 
this section of research. Further, the requirements of Cas2 and other host factor 
effects on Cas1 were also studied for these reactions. The resulting findings were 
then to be used for the proposal of a model of naïve and primed adaptation. 
5.2 Results 
5.2.1 Binding specificity of Cas1 and Cas1-Cas2 
Previously, Cas1 has been shown to directly interact with forked substrates and 
Holliday junctions (118, 148). However, these results were obtained with 20-500 fold 
excess of protein over DNA substrates (ranging from 100nM - 2μM). Therefore, as 
part of this study, purified His6Cas1 protein from E.coli was tested for DNA fork and 
Holliday junction binding at more physiological concentrations (0-25nM). Cas1 
monomer, used at 0.1-25nM, bound DNA forks containing 25 nucleotide (nt) of 
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ssDNA (‘Fork-1 or Fork-2’) forming a stable complex (X) (lanes 1-12, Figure 5-1i). 
However, less than 5% of the equivalent fork substrates, either fully base-paired or 
so-called Holliday junctions (Fork-3), were bound (lanes 13-24, Figure 5-1i). Fork-1 
and Fork-2 have opposite polarities, Fork-1 with a 5’ ssDNA flap and Fork-2 with a 3’ 
ssDNA region. Next, the binding of His6Cas2 alone and in conjunction with Cas1 was 
tested. Whereas Cas2 alone did not bind fork substrates, pre-incubation of Cas1 with 
Cas2 before addition to forked DNA gave a super-shifted complex in EMSAs (Complex 
Y) (lane 3, Figure 5-1ii). As a control for the specificity of the binding complexes 
observed, the putative DNA binding mutant Cas1 R84A was also included in the study 
(148). Indeed, this mutant could not bind to the Fork-1 substrate nor form super-
shifted complex Y in the presence of Cas2 (lane 6, Figure 5-1ii). Complex Y formation 
represents a stable binding of Cas1 and Cas2 with the DNA, supporting the need for a 
Cas1-Cas2 complex for CRISPR adaptation.  
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Figure 5-1. DNA binding by E. coli Cas1 and Cas2. (i). EMSAs of Cas1 binding to DNA substrates end 
labelled with 
32
P (*). Cas1 monomer protein concentrations are indicated above the panels, in reactions 
containing 6nM of DNA. ‘X’ indicates stable Cas1-DNA complex observed with forks containing ssDNA 
regions. (ii). EMSAs of Cas1, Cas2 and Cas1 pre-mixed with Cas2, binding to fork-1, at protein monomer 
concentrations indicated above the panel, in reactions containing 6nM of end labelled DNA (*). ‘X’ 
marks defined Cas1-DNA complex, and ‘Y’ indicates a second complex requiring the presence of Cas2 for 
Cas1 fork binding. Lanes 5 and 6 show that when R84G Cas1 mutant protein (25nM), unable to bind to 
fork DNA was pre-incubated with Cas2 complex Y is not formed. R84G Cas1 mutant protein (25nM) was 
pre-incubated with Cas2. 
5.2.2 Nuclease and transesterification activity of Cas1 
Reported catalytic activities of Cas1 were investigated on DNA forked substrates 
(207). Cas1 proteins were assessed with both N-terminal hexahistidine and C-
terminal hexahistidine-StrepTactin tags, in Case the process of tagging the proteins at 
one or other terminus affected the biochemical properties of Cas1. Cas1 nuclease 
(nicking) and transesterase activity was detected via urea denaturing gels to show 
nuclease degradation (Figure 5-2I, left panel) or transesterification elongation of the 
labelled DNA strands (Figure 5-2i, right panel). The location of the histidine tag on 
Cas1 was found to have critical impact on the activity of protein. Specifically, the 
catalytic activity of His6Cas1, in terms of it functioning both as a nuclease and a 
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transesterase, on the Fork-1 substrate was at least 10 fold higher than Cas1-His-Strep 
(Figure 5-2I, left and right panels). Therefore, all further nuclease assays with the 
different DNA fork substrate variations were performed with His6Cas1, hereafter 
referred to simply as Cas1. Cas1 nicking was observed on Fork-1 strand containing a 
25nt ssDNA region (Figure 5-2i and iii) and also on Fork-1a, a derivative of Fork-1 with 
only a 4nt ssDNA region at the branch point (lane 1, Figure 5-2iv). Of note, Cas1 
nicking activity on fork-1 and fork-1a yielded different nuclease products of 18nt and 
26nt, respectively, from the ssDNA region of each labelled strand (lanes 1 and 6, 
Figure 5-2iv). In contrast, Cas1 showed no activity on Fork-2 (Figure 5-2iii, right 
panel). Though the ssDNA region of the Fork-2 substrate was identical sequence-wise 
to Fork-1, it had opposite polarity which suggested substrate polarity was an 
essential criterion for substrate cleavage by Cas1. Similarly, no nuclease degradation 
of Holliday junction substrates was observed. However, there was a possibility 
cleavage simply occurred on a different strand. Therefore, each strand was labelled 
in turn and reassessed for Cas1 nuclease activity with each. Regardless of which 
strand labelled simply no nicking activity was observed for this kind of substrate, fully 
base paired fork structure or Holliday junction strands (Figure 5-2v).  
Next, as Cas1 and Cas2 are known to form a complex in E.coli and were indeed found 
to form a stable complex with DNA substrates in vitro (Figure 5-1), Cas1 nicking 
nuclease activity was also tested in the presence of Cas2. First, Cas2 was assayed on 
its own with either Fork-1 or Fork-2 but showed no nuclease activity which was 
consistent with its lack of binding (lanes 4 and 8, Figure 5-2iii and Figure 5-1). Next,  
Cas1 was pre-incubated with Cas2, yet no stimulation of nuclease activity was 
detected with either of the same substrates (lanes 3 and 7, Figure 5-2iii).  
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Transesterification was also tested on fork-1, 1a and 2 substrates and other 
replication forks with varied leading or lagging strand gaps (2 and 4nts) in time-
course assays (Figure 5-3). Urea gels were then used to resolve the extension of the 
labelled DNA strand to a 50mer. Cas1 transesterified fork-1 and fork-1a (Figure 5-3i 
and iv and Figure 5-2ii, right panel). All other assessed substrates did not generate 
any extension products. As a control for the reaction, catalytically inactive Cas1 
D218A mutant was also included in the assay and, as expected, yielded no products 
on fork-1 (Figure 5-3 viii). Cas1 nuclease and transesterification activity within the 
ssDNA region of fork-1 and of replication fork with a 4nt lagging strand gap (Fork-1a) 
showed that a free 3’ –OH end was required for the transesterification reaction to 
occur and no DNA end was required to load Cas1 for the equivalent nuclease activity. 
The nuclease and transesterification activity observed for Cas1 was consistent with 
the known in vivo role of Cas1 and Cas2 in spacer acquisition. Indeed, an in vitro 
assay of spacer acquisition (SpIN) showed that in the presence of Cas1, a short piece 
of labelled duplex DNA was integrated into a plasmid (pJRW2) which contained the 
chromosomal CRISPR leader and an entire locus from E. coli (Figure 5-4). Moreover, 
upon introduction of Cas2, Cas1 was stimulated such that this in vitro spacer 
acquisition became more efficient as assessed over the time-course shown by 
comparing integrated plasmid product at the top of the left panel to the right panel 
(Figure 5-4). 
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Figure 5-2. DNA nuclease and transesterification activity of Cas1 and Cas2. (i) Products from fork DNA 
(6 nM) cleavage by Cas1 proteins (0, 2.5, 12.5 and 25nM) shown in phosphorimages of denaturing urea 
gels. Cas1 activity on the labelled strand (*) yielded 18nt length products from fork-1. (ii) Products from 
transesterification of the leading strand generating a 50nt product, extending the labelled strand. (iii) 
Products from Cas1 cutting fork-1 and fork-2 after pre-incubation with Cas2. (iv) Mapping of the 
nuclease products from Fork-1 and -1a. (v) Nuclease products of Cas1 fork nicking activity not detected 
of Holliday junction of fully base paired forks. 
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Figure 5-3. Time course analysis of Cas1 transesterification on replication fork-like substrates. Each 
panel shows phosphorimages of denaturing urea gels of reactions containing 25nM Cas1 with 6nM DNA 
substrate in 125mM NaCl and 10mM MgCl2. A master reaction was set up in each Case from which 
samples were removed and terminated at time points 0, 30, 60, 120, 300, 600. 900 and 1800 seconds. In 
each Case, the leading strand is labelled (*) and transesterification products are seen in i and iv; all other 
panels including that of the catalytically inactive Cas1 mutant D218A (viii) show no transesterification. 
 
Figure 5-4. Spacer integration (SpIN) assay of short duplex DNA into plasmid. Phosphorimages of 
agarose gels to detect integration of an end labelled (*) 35 base pair duplex DNA into plasmid pJRW2 
catalysed by Cas1 (100 nM) or Cas1 and Cas2 (100 and 50 nM respectively) incubated for 5, 10, 15, 20, 
25 and 30 minutes. 
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5.2.3 RecG and PriA genetic interactions and attenuation of Cas1 
activities. 
The experimental work in this section were generated as a result of genetic analysis 
carried out by Ivana Ivancic-Bace at the University of Zagreb, Croatia, who 
investigated adaption in E.coli strains deleted for genome stability and maintenance 
encoding genes to identify which of these were possible factors contributing to the 
adaptation process. Here is a short summary of the data generated and presented in 
a collaborative publication.  
These genetic tests identified the differential requirements for both primed and 
naïve adaptation mechanisms. Primed adaptation was tested with chromosomally 
inducible Cas1, Cas2, Cas3, Cascade and a CRISPR spacer (spT3) that targets the 
essential R gene of virulent lambda phage. Naïve adaptation only expressed Cas1 and 
Cas2 proteins from inducible plamids. Most deletions of associated DNA repair and 
metabolism genes had no observable effect on CRISPR array expansion (spacer 
acquisition).  However, this could be restored with plasmid complementation.  
Interestingly, though heliCase inactive PriA K230R restored the normal CRISPR 
expansion phenotype, the heliCase inactive RecG Q640R could not. RecG rescues 
stalled replication forks and dissociates R-loops, promoting genome stability in most 
bacteria. PriA restarts arrested DNA replication forks by both heliCase-dependent 
and independent pathways that interact with RecG. RecG and PriA act as antagonists 
to balance replication and prevent pathological excessive replication. DNA 
polymerase I is a gap-filling DNA repair enzyme. ΔpolA abolished expansion but 
ΔrecG was able to acquire spacers normally. ΔpriA could not be tested as PriA was 
required for plasmid propagation. Additionally, naïve adaptation was found to be 
sensitive to deletion of RecB (ΔrecB). RecB is part of the RecBCD complex that 
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initiates homologous recombination at DNA breaks, creating a substrate for RecA to 
generate D-loops. 
 
Figure 5-5. EMSA analysis of titrating RecG into various DNA substrates. In panels i – iv RecG was used 
at ; 0, 3.9, 7.8, 15.625, 31.25, 62.5, 125, 250 and 500nM with 6nM Replication fork (2nt lag gap) in 
reactions containing 125mM NaCl and 10mM EDTA. (v) RecG proteins were used at 0, 100, 200, 400 and 
800nM 500nM with 5nM DNA substrate in reactions containing 125mM NaCl and 10mM EDTA. Each 
panel is a phosphorimage of native-PAGE (TBE) gel with specific in gel complexes formed with substrates 
labelled with 
32
P (*). 
From the genetic analysis carried out the biochemical importance of RecG and PriA in 
primed adaptation was therefore investigated for attenuation or activation of Cas1 
catalytic activities. The role of RecB is currently thought to act in a model discussed 
later and was not the focus here. Historical protein stocks of RecG, PriA and various 
characterised mutants were available as a generous gift from the Robert Lloyd 
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research group, University of Nottingham (284). Activity of these proteins was 
checked through EMSA analysis of RecG proteins (Figure 5-5) and heliCase unwinding 
assays on both RecG and PriA (Figure 5-6). In binding assays, RecG formed specific in-
gel complexes with all the substrates tested (Figure 5-5). Specifically, 50% of 2nt 
lagging gap substrate was bound at 125nM RecG (Figure 5-5, panel iv) which was 
two-fold higher than the binding to the other substrates (replication fork, fork-1 and 
nicked duplex) (Figure 5-5i-iii). Subsequent EMSAs with RecG mutants (∆wedge, 
R548A and Y580A) on 2nt lagging gap substrate detected similar binding to the wild-
type protein except for the Δwedge mutant, previously characterised as having 
abolished DNA binding activity, which failed to bind the substrate (Figure 5-5v).  
 
Figure 5-6. DNA heliCase/unwinding assays titrating RecG or PriA into varied DNA replication fork-like 
substrates. In panels i and ii RecG or PriA protein was used at 0, 3.9, 7.8, 15.625, 31.25, 62.5, 125, 250 
and 500nM with 6nM DNA in reactions containing 125mM NaCl, 10mM MgCl2 and 10mM ATP. 
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Reactions were terminated by addition of 10mg/ml proteinase K and 10mM EDTA. Each panel shows 
phosphorimages of native-PAGE (TBE) gels and the species of DNA substrate generated were identified 
by size and 
32
P end labelled (*) DNA. 
Next, unwinding activity assays showed RecG had 5’ – 3’ heliCase activity, forcing 
complex DNA structures completely apart, as the major product observed was  linear 
ssDNA (Figure 5-6i). On the other hand, PriA has a 3’ DNA terminus binding pocket 
that loads on DNA for 3’ – 5’ unwinding, which was consistent with the partial duplex 
product being formed from the leading strand gap replication fork substrate but not 
the lagging strand substrate (Figure 5-6ii, left hand side and right hand side titrations, 
respectively). Therefore, both RecG and PriA proteins could separate strands of 
different replication fork-like complexes (Figure 5-6). While RecG completely unwinds 
the substrates to minimal ssDNA, PriA 3’ – 5’ heliCase activity results in a partial 
duplex or 5’ flapped substrate, which allows fork resetting and replication restart in 
vivo. 
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Figure 5-7. The effect of RecG and PriA on the catalytic activity of Cas1. Each panel shows a 
phosphorimage of a denaturing urea gel separating different species of the 
32
P labelled (*) DNA strand. 
Panels i and ii show transesterification products and iii shows nuclease products. (i) Cas1 was used at 0, 
12.5 and 25nM with or without RecG or PriA at 25nM. (ii) Cas1 was used at 25nM with 25nM of each 
RecG protein (wild-type, ∆Wedge, R682L, Y690A). (iii) Cas1 was used at 25nM and RecG or PriA were 
titrated in at 10 and 25nM. Whereas RecG decreased overall activity of Cas1 but PriA completely 
abolished activity of Cas1. Each reaction contains 6nM DNA substrate in reactions containing 125mM 
NaCl, 10mM MgCl2 and 10mM ATP. 
RecG and PriA are involved in replication fork stability and overall replication rate, 
therefore, either protein could promote Cas1 nuclease nicking or transesterification 
activity. First, the latter was tested by adding either RecG or PriA to the replication 
fork with 4nt lagging strand gap (Fork-1a) which had been previously determined to 
be the preferred substrate for Cas1 mediated transesterification(see Figure 5-3). 
RecG reduced Cas1 transesterase activity by ~50% (lanes 4 and 5, Figure 5-7i) 
whereas PriA completely abolished transesterification (lanes 6 and 7, Figure 5-7i). 
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PriA had the very same effect also on Cas1 nuclease activity.  Whereas RecG only 
reduced Cas1 nuclease activity (lanes 3 and 4, Figure 5-7iii), PriA abrogated it 
altogether (lanes 5 and 6, Figure 5-7iii). Loss of Cas1 activity in the presence of PriA 
was surprising, as the majority of the PriA unwinding assay products, which were 
identical to fork-1, would have been expected to undergo transesterification and 
nicking by Cas1. As PriA acts as a molecular scaffold to which other proteins are 
recruited so it may bind to the 3’-OH required by Cas1.  
In addition to the wild-type RecG, Cas1 transesterase activity on fork-1a was also 
assessed with the different RecG mutants (Figure 5-7ii, bottom panel). RecG R682L 
mutant reduced Cas1 activity by approximately 50%, similarly to the wild-type 
protein (lanes 3 and 5, Figure 5-7ii). Interestingly, RecG Y690A had no impact on Cas1 
activity (lane 6, Figure 5-7ii). Similarly, RecG Δwedge, which is known to be unable to 
bind the substrate, did not interfere with Cas1 (lane 4, Figure 5-7ii). Next, the ability 
of RecG and the different RecG mutants to create a suitable substrate for 
transesterification from a fully base paired replication fork was examined(Figure 
5-7ii, top panel). However, no extension of the labelled strand was detected with 
either of the RecG proteins. 
5.3 Discussion 
The aim of this section of work was to identify the enzymatic processes of Cas1 and 
Cas2 that may be essential to spacer acquisition in the CRISPR immune response and 
to generate a model for the mechanism. Adaptation is achieved by two distinct 
routes: naïve, which requires only Cas1 and Cas2 and is independent of CRISPR 
interference, and primed, which is stimulated by Cascade-Cas3 incomplete 
interference reactions. Genetic analysis carried out in Croatia by Ivana Inancic-Bace 
identified differential requirements of host non-Cas proteins essential for CRISPR 
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adaptation. Deletions of recB or polA were found to abolish naïve adaptation in 
corroboration with published data that suggests the host repair complex RecBCD is 
needed for naïve adaptation in E.coli to generate the protospacer substrate for 
integration in the CRISPR array (67). On the other hand, the host requirements 
identified for primed adaptation were:  PolA, RecG and PriA (268). This indicated 
these were two distinct pathways, requiring different host proteins for CRISPR 
adaptation. 
A model is presented in Figure 5-8 which illustrates the coordination of naïve and 
primed adaptation via different enzymatic requirements for transesterification and 
nuclease cleavage. The model relies upon stalled replication fork remodelling and 
repair, in the process of which a protospacer substrate for Cas1-Cas2 is generated. 
This is because RecG, PriA, RecBCD and PolA are all involved in genome repair and 
stability in E.coli, which occurs at stalled replication forks. The model consists of 
three parts: (a) primed protospacer generation, Cascade R-loop complexes stall 
replication forks. RecG and PriA stimulate fork remodelling and blockage removal, 
exposing DNA for Cas1 mediated capture of the protospacer DNA (Figure 5-6). Cas3 
nuclease activity, essential for primed adaptation, may generate the protospacer 
substrate as with RecBCD in naïve acquisition (65, 67). (b) In the second possible 
pathway RecBCD processes DNA ends at sites of DNA damage and collapsed 
replication forks. Cas1 nicking/nuclease activity described as part of this study could 
orchestrate the collapse of stalled replication forks themselves and with other 
nucleases generate the protospacer (Figure 5-2i). (c) In both primed and naïve 
adaptation, a conserved route is followed after the protospacer-Cas1-Cas2 complex is 
formed. A series of transesterification reactions insert the protospacer at R1 of the 
CRISPR array (Figure 5-2ii and Figure 5-4), followed by PolA gap-filling, as in 
nucleotide excision repair (285). 
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Figure 5-8. Model for spacer acquisition by capture and integration of invader DNA by targeting of 
blocked or collapsed DNA replication forks in E. coli. (A) In primed adaptation Cascade R-loop 
complexes that cannot stimulate invader degradation arrest advancing replication forks. Fork re-
activation is triggered and controlled by RecG and PriA, removing the R-loops and remodeling the 
blocked fork. Cas1 can then access the invader fork substrate for DNA capture, collapsing the invader 
replication fork. Further nucleolytic processing of DNA, possibly by Cas1 cutting a fork more than once, 
or by other nucleases (Cas3) may be required to liberate DNA for Cas1-Cas2 capture. Specific targeting 
of invader DNA by Cascade ensures non-host targeting. (B) Naïve adaptation relies upon invader DNA 
damage and hijacked host DNA repair enzymes (RecBCD) stimulating repair. Degradation by RecBCD 
liberates DNA for Cas1-Cas2 capture. (C) Cas1-Cas2 and protospacer DNA then follow the same method 
of insertion by a series of transesterification reactions. DNA polymerase I (PolA) is required for both 
naïve and primed adaptation. PolA comes into play after new spacer integration is successfully catalysed 
by Cas1 (S1’) at structures formed in CRISPR repeats (e.g. R1). Integration leaves DNA gaps flanking the 
new spacer, requiring synthesis of new repeat DNA, which is catalysed by PolA in a reaction similar to 
‘gap filling’ DNA repair.  
The exact mechanism of Cas1 nuclease and transesterification activity in CRISPR 
spacer acquisition is still unknown.  For spacer integration a free 3’-OH at the CRISPR 
R1 must be present. Cas1 has a distinct preference for binding to replication-fork like 
structures with branched ssDNA regions (Figure 5-2v), displaying robust catalytic 
activity on these substrates, (Figure 5-2 and Figure 5-3). This supports the model for 
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primed protospacer capture, whereby Cas1 facilitates spontaneous integration into a 
CRISPR array, as seen in the SpIN assay (Figure 5-4). However, in vitro conditions do 
not allow further understanding of Cas1 activity in protospacer capture due to the 
close similarities between substrates. Order of addition assays were carried out with 
RecG, PriA and single stranded binding protein (SSB) to identify interactions that 
affected Cas1 activity. Results observed showed no difference in Cas1 activity to the 
data presented in Figure 5-7.  PriA complete inhibition of Cas1 activities is surprising 
given that PriA is required genetically for primed adaptation (268). Again limitations 
of in vitro analysis on small substrates means that PriA is most likely bound to the 3’ 
end of DNA at the branch point, out-competing Cas1 and blocking access for Cas1 
catalytic transesterification or nuclease activity. Further experiments to ascertain if 
the primed model is correct would require in vitro reconstitution of the E.coli 
replisome, induced Cascade-Cas3 R-loop blockages and identification of spacer 
acquisition requiring RecG and/or PriA for replication fork remodelling properties 
(286-290). 
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6 Discussion 
This study focused on the generation of recombinant purified proteins for analysis in 
in vitro biochemical assays to better understand the mechanistic details of the 
CRISPR/Cas adaptive immune system of prokaryotes. The rapidly evolving CRISPR 
research field has led to the application of this understanding for technological 
advances in genome engineering and regulation, CRISPR/Cas9. On the other hand, 
many of the remaining unknown mechanisms of CRISPR immunity have been 
overlooked. One example is the analysis of archaeal Cascade complexes and 
comparing these to the well-defined model of E.coli. In coordination with this study, 
the large Cascade protein Cas8 was identified as essential for in vivo CRISPR 
interference (work carried out in Dr. Anita Marchfelder’s research group at The 
University of Ulm, Germany), and now a model of this mechanism is presented. 
Through in vitro analysis Cas8 proteins bound with a high specificity to R-loop 
structures (analogous to those present in CRISPR interference), and of particular 
importance, this apparent binding affinity is influenced by PAM sequence. Cas8 
proteins also function in cooperation with other Cascade proteins suspected to form 
the Mth archaeal Cascade complex; Cas5 and Cas7. These discoveries correlate with 
data that was published at a similar time for the interaction partners and PAM 
recognition mechanism of CasA, the large Cascade protein from E.coli. Interestingly, 
the asparagine mutant from Mth and Hvo tested showed PAM sensitivity, similarly, 
an asparagine residue of CasA is essential for the stabilisation of CasA, CasD (Cas5) 
and CasC (Cas7) interactions and the stimulation of Cas3 ssDNA degradation. Cas3, 
the targeted ssDNA endo- and exonuclease identifies a new class of programmed 
nucleases. Unlike the well-known restriction endonucleases commonly used for 
molecular cloning that cleave in a sequence specific manner, Cas3 identifies a 
correctly formed stabilised R-loop with crRNA and a Cascade complex to initiate 
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cleavage. The developed understanding of both bacterial and archaeal CRISPR 
interference mechanisms strongly implies diversity in protein sequences and 
structures with overal process conservation. This indicates a convergent evolution of 
CRISPR immune systems that regulate horizontal gene transfer. The restriction of the 
transfer of oligonucleotide information (DNA and RNA) has to share some 
mechanistic details as the fundamental reactions are the same.  
One line of reasoning is that CRISPR evolved from a selfish transposon-like element 
containing Cas1-Cas2. Cas1 and Cas2 are common between all active CRISPR systems 
and are predicted to have a conserved spacer acquisition mechanism. One possibility 
for the origin of this is genome rearrangement and integration of novel gene 
sequences into the transposable element of the Casposon. As a result, investigations 
of spacer acquisition allow understanding of mobile and selfish genetic element 
evolution. With predicted models and the one suggested in this study, these 
elements utilise host DNA replication machinery as either a binding scaffold or 
provide the initial substrate for spacer integration. This integration event is thought 
to have a similar mechanism to retroviral integrases, but with a slightly different goal: 
CRISPR systems create a library of recently exposed DNA sequences whereas viral 
integrates rely upon integration to avoid detection and replicate. These mechanisms 
are similar as they both require host factors for stabilisation into the host genome. 
With a full CRISPR immune system the benefits of spacer integration and inference of 
invading genetic elements is apparent, a viability advantage for controlling genetic 
material size within a cell or preventing phage-induced lysis. This is an example of a 
mutualistic relationship between CRISPR and the host. Whereas, viral integration is 
selfish and parasitic as the only goal is its own proliferation. 
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With the presented model from both the archaeal interference and bacterial 
adaptation, and the recent literature more fully explaining the mechanism of naïve 
spacer acquisition. The next step would be experimental design to understand the 
precise requirements of the host proteins RecG, PriA and PolA. The ideal way to set 
this investigation up would be the creation of an in vitro rolling circle replication 
assay wherein the E.coli replication machinery continuously replicates a plasmid. This 
assay has been set up by other research groups and could then be adapted and 
targeted by Cascade or Cas9 with an associated crRNA molecule to create stalled 
replication forks. The addition of RecG and PriA proteins with Cas1 and Cas2 would 
then allow analysis of the DNA to characterise the mechanism of primed spacer 
acquisition. Primed acquisition could also be further investigated in archaea by in 
vitro reconstitution of the Mth Cascade complex and blocking a replication fork. 
Similarities between the archaeal and bacterial adaptation mechanisms could 
therefore be further compared to identify the essential reactions between Cas1 and 
Cas2, host factors and Cascade proteins. Understanding of these mechanisms opens 
new possibilities of molecular tools for novel applications downstream. 
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8 Appendix 
8.1 Primer List 
All primers used in this study at listed here. Most primers were used for the 
construction of plasmids containing coding sequences for Cas genes from either E.coli 
or Methanothermobacter thermautotrphicus into vectors to add an affinity tag. 
Hexahistidine (His), Streptactin (Strep) and Maltose binding protein (MBP) tags were 
added either N- or C-terminally to the coding sequence. 
Table 19. Primers used for construction and manipulation of plasmids vectors 
Primer Name Sequence Used for 
Mth1076-A CCGGAATTCCGATAGAGTACTCTTCATG N-terminal His-Tag Mth1076 in pET-Duet-1 
Mth1076-B CCCAAGCTTTTATTATAAGCGGGGAAAG N-terminal His-Tag Mth1076 in pET-Duet-1 
Mth1077-A CGCGGATCCCAAAAAAAGGAACTCCCCTG N-terminal His-Tag Mth1077 in pET-Duet-1 
Mth1077-B CCGGAATTCCTACTATCCATTGAAGATCAC
C 
N-terminal His-Tag Mth1077 in pET-Duet-1 
Mth1078-A CCGGAATTCCCAATGCACCCTTGAGGTTAT
AAC 
N-terminal His-Tag Mth1078 in pET-Duet-1 
Mth1078-B ATAAGAATGCGGCCGCCTACTAGGGGAGT
TCCTTTTTTTC 
N-terminal His-Tag Mth1078 in pET-Duet-1 
Mth1079-A CGCGGATCCCCTCGTATACCTCAAACCC N-terminal His-Tag Mth1079 in pET-Duet-1 
Mth1079-B CCCAAGCTTTTATTAACCACCACCAATC N-terminal His-Tag Mth1079 in pET-Duet-1 
Mth1080-A CCGGAATTCCAGGTTCCAGAAAAATTAT N-terminal His-Tag Mth1080 in pET-Duet-1 
Mth1080-B CCCAAGCTTCTCATCACTCTGCAGTTGTTG
GG 
N-terminal His-Tag Mth1080 in pET-Duet-1 
Mth1081-A CGCGGATCCCGTGATATCCATGAGTGATTT
AAC 
N-terminal His-Tag Mth1081 in pET-Duet-1 
Mth1081-B CCGGAATTCTTATTAGCTTCTTGGGTTGTA
G 
N-terminal His-Tag Mth1081 in pET-Duet-1 
Mth1082-A CCGGAATTCCCCGGTGTTCTATATGAATC N-terminal His-Tag Mth1082 in pET-Duet-1 
Mth1082-B CCCAAGCTTTCATCACTCATGGATATCACC N-terminal His-Tag Mth1082 in pET-Duet-1 
Mth1083-A CGCGGATCCCTGGTGGTAACTGTGTACCTT
C 
N-terminal His-Tag Mth1083 in pET-Duet-1 
Mth1083-B CCCAAGCTTTCATCAGAGAATAACATCAAG
TG 
N-terminal His-Tag Mth1083 in pET-Duet-1 
Mth1084-A CGCGGATCCCAACTCTGCTGGGCTTGAGC N-terminal His-Tag Mth1084 in pET-Duet-1 
Mth1084-B CCGGAATTCTTATTACCACCACATCACTAA
TG 
N-terminal His-Tag Mth1084 in pET-Duet-1 
Mth1085-A CGCGGATCCCGCGGTTTTCTTGATAATCG N-terminal His-Tag Mth1085 in pET-Duet-1 
Mth1085-B CCGGAATTCTCATCAAGCCCAGCAGAGTTC N-terminal His-Tag Mth1085 in pET-Duet-1 
Mth1087-A CCGGAATTCCGAAACCCTTGCAGTGGAG N-terminal His-Tag Mth1087 in pET-Duet-1 
Mth1087-B CCCAAGCTTTCATCATAGCCACCCGAAATC N-terminal His-Tag Mth1087 in pET-Duet-1 
Mth1089-A CGCGGATCCCTATAAGAAAATGAAACTC N-terminal His-Tag Mth1089 in pET-Duet-1 
Mth1089-B CGCGGATCCCTATAAGAAAATGAAACTC N-terminal His-Tag Mth1089 in pET-Duet-1 
Mth1091-A CCCAAGCTTGAGGGATTCATCGACAGGC N-terminal His-Tag Mth1091 in pET-Duet-1 
Mth1091-B GGAATTCCATATGTCATCATGATGTAACCA
CCATACC 
N-terminal His-Tag Mth1091 in pET-Duet-1 
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Mth1624-A CGCGGATCCCAGATCCCTGAGTGGTAAG N-terminal His-Tag Mth1624 in pET-Duet-1 
Mth1624-B CCGGAATTCTCATCAACCCTCGGGGACCTC N-terminal His-Tag Mth1624 in pET-Duet-1 
Cas7pQE1-A CGGAATTCATGAAAATGTCAAGGTAC C-terminal Strep-tag Mth Cas7 in pQE-His1 
Cas7pQE1-B GGGGTACCGATCCCCTGAACCTTTCCGTAA
CTC 
C-terminal Strep-tag Mth Cas7 in pQE-His1 
S-Cas5A GGAATTCATGGAAACCCTTGCAGTGGAG C-terminal Strep-tag Mth Cas5 in pQE-His1 
S-Cas5B CCCAAGCTTTAGCCACCCGAAATCTGCAGG C-terminal Strep-tag Mth Cas5 in pQE-His1 
S-Cas6A GGAATTCATGGAGGGATTCATCGACAG C-terminal Strep-tag Mth Cas6 in pQE-His1 
S-Cas6B CCCAAGCTTTGATGTAACCACCATACC C-terminal Strep-tag Mth Cas6 in pQE-His1 
S-Cas5’A GAAGCTTCGAAACCCTTGCAGTGGAG N-terminal Strep-tag Mth Cas5 in pQE-His2 
S-Cas5’B CCCAAGCTTTAGCCACCCGAAATCTGCAGG N-terminal Strep-tag Mth Cas5 in pQE-His2 
S-Cas6’A CCCAAGCTTGAGGGATTCATCGACAGG N-terminal Strep-tag Mth Cas6 in pQE-His2 
S-Cas6’B CCGCTCGAGTGATGTAACCACCATACC N-terminal Strep-tag Mth Cas6 in pQE-His2 
MthCRISPR’-A CCCAAGCTTCGCTATCTCCAGTTTACTTC Mth CRISPR into pUC19 
MthCRISPR’-B TGCTCTAGAGATAAAATAGGAGTGGTCC Mth CRISPR into pUC19 
MthCRISPRT7 TTGTAATACGACTCACTATAGGGCGCTAT
CTCCAGTTTACTTC 
In vitro transcription of CRISPR 
MthCas-1A ACGCGTCGACATGGGCTATGATGGAATTA
ATCG 
Cas3-Cas5-Cas7-Cas8-Cas8b into pCDF-1b 
MthCas-1B ATTTGCGGCCGCTTATCTGCCTCCTAAAAA
TCC 
Cas3-Cas5-Cas7-Cas8-Cas8b into pCDF-1b 
MthCas-2A ACGCGTCGACATGGGCTATGATGGAATTA
ATCG 
Cas3-Cas5-Cas7-Cas8-Cas8b-Cas6 
In pCDF-1b 
MthCas-2B ATTTGCGGCCGCTCATGATGTAACCACCA
TACC 
Cas3-Cas5-Cas7-Cas8-Cas8b-Cas6 
In pCDF-1b 
E.Coli Cas1+2-A CATGCCATGGATGACCTGGCTTCCCC E.coli Cas1 and Cas2 into pCDF-1b 
E.Coli Cas1+2-B ATAAGAATGCGGCCGCTCATCAAACAGGT
AAAAAAGAC 
E.coli Cas1 and Cas2 into pCDF-1b 
E.Coli Cas1-A CATGCCATGGATGACCTGGCTTCCCC E.coli Cas1 into pCDF-1b 
E.Coli Cas1-B ATAAGAATGCGGCCGCTCATCAGCTACTC
CGATGGCC 
E.coli Cas1 into pCDF-1b 
E.Coli Cas2-A CATGCCATGGATGAGTATGTTGGTCG E.coli Cas2 into pCDF-1b 
E.Coli Cas2-B ATAAGAATGCGGCCGCTCATCAAACAGGT
AAAAAAGAC 
E.coli Cas2 into pCDF-1b 
Mth Cas1+2-A CATGCCATGGATGAACTCTGCTGGGCTTG Mth Cas1 and Cas2 into pCDF-1b 
Mth Cas1+2-B ATAAGAATGCGGCCGCTCATCAGAGAATA
ACATC 
Mth Cas1 and Cas2 into pCDF-1b 
Mth Cas1-A CATGCCATGGATGAACTCTGCTGGGCTTG Mth Cas1 into pCDF-1b 
Mth Cas1-B ATAAGAATGCGGCCGCTCATCACCACCAC
ATCAC 
Mth Cas1 into pCDF-1b 
Mth Cas2-A CATGCCATGGATGGTGGTAACTGTGTACC Mth Cas2 into pCDF-1b 
Mth Cas2-B ATAAGAATGCGGCCGCTCATCAGAGAATA
ACATC 
Mth Cas2 into pCDF-1b 
CRISPRamp-1 ATTTTGCGTTTCGTTCAGGT BL21AI CRISPR amplification to detect spacer 
acquisition 
CRISPRamp-2 TGGATGTGTTGTTTGTGTG BL21AI CRISPR amplification to detect spacer 
acquisition 
D151G-A CGAGAAAAATTTAATTGGTAATAATTCAG
AGGAAC 
Cas8’ QuCh of pEB389 
D151G-B GTTCCTCTGAATTATTACCAATTAAATTTTT
CTCG 
Cas8’ QuCh of pEB389 
N153A-A ATTTAATTGATAATGCTTCAGAGGAACTG
G 
Cas8’ QuCh of pEB389 
N153A-B CCAGTTCCTCTGAAGCATTATCAATTAAAT Cas8’ QuCh of pEB389 
E155A-A TTGATAATAATTCAGCTGAACTGGGAGAG
ATT 
Cas8’ QuCh of pEB389 
E155A-B AATCTCTCCCAGTTCAGCTGAATTATTATC
AA 
Cas8’ QuCh of pEB389 
N536G-A CCAGAGAGAACAACATAGGTCAGCTAATA
TCAATCC 
Cas8’ QuCh of pEB389 
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8.1.1 Cloning 
Initially all the CRISPR genes from Mth were cloned into suitable plasmid vectors, 
ORF1076-1091. This includes genes from the Type-IG and Type-IIIA CRISPR subsets. 
Each gene was cloned individually into one of the following: pET14b, pET-Duet, pET-
ACYC, pMal-C2x, pCDF-1b and pBad-A. Some plasmids were already available for ORF 
genes: 1083 (pJLH9) and 1084 (pJLH7) from Jamieson Howard and: 1085 (pEB377), 
1086 (pEB359), 1087 (pEB374), 1088 (pEB388), 1089 (pEB383) and 1090 (pEB389) 
from Edward Bolt. All cloned into vectors with N-terminal His-tags, except pEB359 
which had no tag. Some of these proteins have been expressed and purified 
previously, such as ORF1090 in Bolt et al 2004. To clone the remaining 8 genes, along 
with some previously cloned genes for expression in different plasmid vectors 
associated to the CRISPR locus of interest techniques described in Chapter 2 for all 
stages of molecular cloning. Mth aCASCADE consists of Cas5, Cas7, Cas8a2, Cas8’ and 
N536G-B GGATTGATATTAGCTGACCTATGTTGTTCT
CTCTGG 
Cas8’ QuCh of pEB389 
S540A-A ACATAAATCAGCTAATAGCAATCCTTAGG
AGGAAC 
Cas8’ QuCh of pEB389 
S540A-B GTTCCTCCTAAGGATTGCTATTAGCTGATT
TATGT 
Cas8’ QuCh of pEB389 
S540A540G CATAAATCAGCTAATAGGAATCCTTAGGA
GGAAC 
Cas8’ QuCh of pEB389 
S540A540G GTTCCTCCTAAGGATTCCTATTAGCTGATT
TATG 
Cas8’ QuCh of pEB389 
Y548F-A GGAGGAACAACAGGTTCCTCTTCGTTAAC
AA 
Cas8’ QuCh of pEB389 
Y548F-B TTGTTAACGAAGAGGAACCTGTTGTTCCT
CC 
Cas8’ QuCh of pEB389 
Y548A-A TAGGAGGAACAACAGGGGCCTCTTCGTTA
ACAACCTC 
Cas8’ QuCh of pEB389 
Y548A-B GAGGTTGTTAACGAAGAGGCCCCTGTTGT
TCCTCCTA 
Cas8’ QuCh of pEB389 
L542A-A CAGCTAATATCAATCGCTAGGAGGAACAA
CAG 
Cas8’ QuCh of pEB389 
L542A-B CTGTTGTTCCTCCTAGCGATTGATATTAGC
TG 
Cas8’ QuCh of pEB389 
Cas5MBP-A CCGGAATTCGAAACCCTTGCAGTGGAGAT
ATTC 
N-terminal MBP-tag Mth Cas5 in pMal-C2x 
Cas5MBP-B GCTCTAGATCATAGCCACCCGAAATCTGC N-terminal MBP-tag Mth Cas5 in pMal-C2x 
Cas6MBP-A GCTCTAGAGAGGGATTCATCGACAGGCC
AG 
N-terminal MBP-tag Mth Cas6 in pMal-C2x 
Cas6MBP-B GGAAGCTTTCATGATGTAACCACCATACC N-terminal MBP-tag Mth Cas6 in pMal-C2x 
Cas8bpQE-A AACTGCAGATGATCTACGAATTCAGACGC C-terminal Strep-tag Mth Cas8’ in pQE-His1 
Cas8bpQE-B TTTGCGGCCGCTCTGCCTCCTAAAAATCCA
GTTAG 
C-terminal Strep-tag Mth Cas8’ in pQE-His1 
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Cas6, encoded by ORFs 1087-1091 respectively. aCASCADE is expanded upon in 
chapter 4. 
8.1.1.1 Cas5 
Cas5 was originally cloned into pET14b (pEB374). Here Cas5 was sub-cloned into 
pMal-C2x with primers MBPCas5-1 and MBPCas5-2, introducing restriction sites 
EcoRI and XbaI. The PCR product was digested and the vector similarly. After 
restriction clean up the insert was ligated into the vector overnight and then 
transformed into DH5α and plated onto Amp. DNA was isolated from colonies and 
analytically digested, and sequenced confirming generation of pSDC25, Figure 8-1. 
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Figure 8-1 Cloning strategy for MBPCas5. Cloning procedure followed for the generation of N-terminally 
MBP tagged Cas5 from Mth (ORF1087), displaying PCR step followed by insert and vector digestion and 
the resultant construct pSDC25. 
 
 
pMal-C2x 
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8.1.1.2 Cas6 
Cas6 (ORF1091) was not available from a previously constructed vector. Plasmids 
were constructed to include N-terminal His6 and MBP tags on Cas6. These were 
generated by PCR amplification of available genomic Mth DNA (Dr. James Chong, 
University of York) with HisCas6-1+2 and MBPCas61+2 for respective tag 
introduction. This introduced NdeI/HindIII and XbaI/HindIII restriction sites 
respectfully. When amplification was optimised, DNA was excised; restriction 
digested and cleaned up, followed by ligation and transformation. Transformants 
were then analysed by DNA extraction and confirmation of cloning. Generating 
pSDC13 (His-tag, Figure 8-2) and pSDC27 (MBP-tag, Figure 8-3). 
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Figure 8-2 Cloning strategy for His6Cas6. Cloning procedure followed for the generation of N-terminally 
hexahistidine tagged Cas6 from Mth (ORF1091), displaying PCR step from genomic DNA and addition of 
restriction endonuclease sites. Followed by insert and vector digestion and the resultant construct 
pSDC13. 
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Figure 8-3 Cloning strategy for MBP Cas6. Cloning procedure followed for the generation of N-
terminally MBP tagged Cas6 from Mth (ORF1091), displaying PCR step from genomic DNA and addition 
of restriction endonuclease sites. Followed by insert and vector digestion and the resultant construct 
pSDC27. 
pMal-C2x 
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8.1.1.3 Cas7 
Cas7 was available cloned into pET14b (pEB388) Figure 8-4, but to facilitate co-
expression with Cas5 it was sub-cloned into pCDF-1b. pCDF-1b contains StrpR gene 
and CDF origin making this plasmid compatible with pET and pMal constructs for co-
expression. Cas7 Was first cloned in pQE-His1 from genomic DNA creating pSDC29, 
Figure 8-5. Then Cas7 was sub-cloned with no tag into pCDF-1b, a simple restriction 
digest of pSDC29 by NcoI and KpnI liberated the Cas7 gene. This was excised and 
ligated directly into pCDF-1b that was similarly digested. Colony DNA was purified 
and confirmed. 
 
Figure 8-4 Schematic representation of available Mth Cas7 clone. pEB388 allowed expression of 
MtCas7 (ORF 1088) on a pET14-b plasmid for generation of N-terminally hexahistidine tagged Cas7. 
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Figure 8-5 Cloning and subcloning of Cas7 to facilitate co-expression with Cas5. Mth Cas7 (ORF 1088) 
was initially cloned into pQE-His1 from genomic DNA. Generating pSDC29. pSDC29 was used as the 
precursor for the generation of pSDC31. A non-tagged Cas7 protein could be produced from this plasmid 
(pCDF-1b) that is compatible with pSDC25 (MBPCas5). 
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8.1.1.4 Cas8’ 
Cas8’ was already available (pEB389, Figure 8-6) and was used in a previous study 
where it was referred to as Nar71 (nucleic acid resolvase, molecular weight 71kDa) in 
Guy et al 2004. Cas8’ is the main focus in Chapter 4, biochemical characterisation. As 
such several site directed mutants were created. Residues of interest were targeted 
and mutagenized using the Quick Change Site directed mutagenesis procedure. In 
summary, this involves generating two overlapping primers that have a mono- or di-
nucleotide mismatch. Whole plasmid thermoclycing (akin to PCR) is the carried out 
with a high fidelity polymerase eg. Vent (NEB). Nicked plasmids are created, and 
original template DNA is removed by DpnI digestion of E.coli biosynthesised 
methylated DNA. Mutants already available from this method are K68A and K117A. 
Each of these were sub-cloned from the original pT7-7 vector into pET14b using NdeI 
and ClaI restriction digest, ligation and confirmation for N-terminal His6 tag, to allow 
purification (Figure 8-7 and Figure 8-8). Other mutants created for this study include 
D151G (Figure 8-9), N153A, E155A (Figure 8-10), N536A, S540A (Figure 8-11), L542A. 
two other mutants were attempted, Y548A and L564A but no successful 
transformations were observed after multiple attempts. In each Case primers were 
designed and used in the thermocycling reaction eg. D151G-1 and D151G-2 and 
processed as summarised in chapter 2. Clones were then sequenced and compared 
to wild-type nucleic acid sequences to identify if the mutation had been introduced. 
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Figure 8-6 The original vectors used for all subsequent Cas8’ constructs. pEB367 is the Mth Cas8’ gene 
(ORF1090) cloned into the pT7-7 vector. Cas8’ was then subcloned into pET14-b to generate a N-
terminally hexahistidine tagged Cas8’ protein from pEB389. 
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Figure 8-7 Cloning strategy for quick Change K68A mutant Cas8’. Sub cloning procedure followed for 
generation of an N-terminally hexahistidine tagged Cas8’ mutant protein, as with wild-type gene to 
create pSDC41. 
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Figure 8-8 Cloning strategy for quick Change K117A mutant Cas8’. Sub cloning procedure followed for 
generation of an N-terminally hexahistidine tagged Cas8’ mutant protein, as with wild-type gene to 
create pSDC22. 
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Figure 8-9 Cloning strategy for quick change mutants D151G and N153A of Cas8’. Primers D151G-1 and 
-2 were used to generate pSDC39, a vector that encodes N-terminally hexahistidine tagged mutant Cas8’ 
protein. Similarly to create pSDC43 primer N153A-1 and -2 were used in the generation of this construct. 
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Figure 8-10 Cloning strategy for quick change mutants E155A and N536A of Cas8’. Primers E155A-1 and 
-2 were used to generate pSDC40, a vector that encodes N-terminally hexahistidine tagged mutant Cas8’ 
protein. Similarly to create pSDC30 primer N536A-1 and -2 were used in the generation of this construct. 
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Figure 8-11 Cloning strategy for quick change mutants S540A to A540G and L542A of Cas8’. Primers 
L542A-1 and -2 were used to generate pSDC45, a vector that encodes N-terminally hexahistidine tagged 
mutant Cas8’ protein. Similarly to create pSDC38 and pSDC44 primer sets S540A-1 and -2 and A540G-1 
and -2 were used in the generation of these constructs. 
8.1.1.5 Cas8a2 
While a clone was already available (pEB383), this was excluded from this study 
because of previous work and difficulties described later. 
8.1.1.6 ORFs 1076-1082 
These ORFs form the Csm complex of type IIIA CRISPR immune system, and were 
cloned also, and pursued as far as solubility screening, but not followed up further in 
this study. A summary of the cloning can be found in appendix table X.X, detailing 
constructs and restriction enzymes used. Below is one example of the cloning 
procedure followed in all circumstances, Figure 8-12. 
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Figure 8-12 Cloning procedure used for construction of pSDC5. Mth ORf 1076, encoding Csm1 was PCR 
amplified with primers 1076-1 and 1076-2 to introduce restriction sites EcoRI and HindIII. This amplified 
product and pETDuet-1 were digested with the restriction endonucleases EcoRI and HindIII and ligated 
to produce pSDC5. 
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8.1.1.7 Cas3 
Cas3 while not being directly associated is the essential link to the interference stage 
of CRISPR immunity in the systems focused on in this study, CASCADE mediated 
immunity. This was available (pEB359, Figure 8-13) and has been characterised in 
Howard et al 2011. 
 
Figure 8-13 Construct available for Cas3. Expression vector for non-tagged Cas3 protein expression. 
8.1.1.8 Cas1 and Cas2 
Cas1 and Cas2 were no the original focus of this study, but came into use later on 
when the lab was joined by a second PhD student, Sophie Brinkmann. Then this 
happened there was a joint effort in generating Cas1 and Cas2 proteins for 
biochemical analysis in vitro of both the E.coli and Mth proteins combined with 
genetic analysis in vivo in E.coli. As such, the cloning was split between the two of us. 
Mth Cas1 and Cas2 were cloned individually and as a continuous operon. Creating 
pSDC15 (Figure 8-14), 16 (Figure 8-15) and 17 (Figure 8-16) respectively. 
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Figure 8-14 Cloning strategy for Cas1 cloning into compatible co expression vector. Cas1 was amplified 
from genomic DNA using Mth Cas1-A and –B primers, introducing NcoI and NotI restriction sites. This 
allowed restriction cloning into pCDF-1b and creation of pSDC15, N-terminally hexahistidine tagged 
Cas1. 
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Figure 8-15 Cloning strategy for Cas2 cloning into compatible co expression vector. Cas2 was amplified 
from genomic DNA using Mth Cas2-A and –B primers, introducing NcoI and NotI restriction sites. This 
allowed restriction cloning into pCDF-1b and creation of pSDC16, N-terminally hexahistidine tagged 
Cas1. 
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8.1.1.8.1  
Figure 8-16 Cloning strategy for Cas1 and Cas2 cloning for co-expression. Cas1 and Cas2 operon was 
amplified from genomic DNA using Mth Cas1-A and Cas2–B primers, introducing NcoI and NotI 
restriction sites. This allowed restriction cloning into pCDF-1b and creation of pSDC17, N-terminally 
hexahistidine tagged Cas1 and non-tagged Cas2. 
 
8.2 Oligonucleotides 
8.2.1 The following oligos were used to form substrates shown in Chapter 
4. 
ssDNA 
RGL16: 5’-ATCGATAGTCTCTAGACAGCATGTCCTAGCAAGCCAGAATTCGGCAGCGT-3’ 
dsDNA: RGL16 annealed to ELB37 
ELB37: 5’-ACGCTGCCGAATTCTGGCTTGCTAGGACATGCTGTCTAGAGACTATCGAT-3’ 
Flayed Duplex: RGL16 partially annealed to ELB20 
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ELB20: 5’-GACGCTGCCGAATTCTGGCTTGCTATGTAACTCTTTGCCCACGTTGACCC-3’ 
Partial fork DNA: RGL16 partially annealed to ELB20 and partially annealed to PM2 
PM2: 5’-GGACATGCTGTCTAGAGACTATCGAT-3’ 
Loop duplex DNA: RGL19 annealed to PM4 
RGL19: 5’-
GACGCTGCCGAATTCTACCAGTGCCTTGCTAGGACATCTTTGCCCACCTGCAGGTTCACCC-3’ 
PM4: 5’-
GGGTGAACCTGCAGGTGGGCGGCTGCTCATCGTAGGTTAGTTGGTAGAATTCGGCAGCGTC
-3’ 
D-Loop: RGL19 annealed to PM4 and PM5 
PM5: 5’-AAAGATGTCCTAGCAAGGCAC-3’ 
R-Loop1: RGL19 annealed to PM4 and ELBRNA1 
ELBRNA1: 5’-AAAGAUGUCCUAGCAAGGAC-3’ 
R-Loop2 substrates were constructed by annealing of the following strands 
-PAM (AA) R-loops: ELB103 was annealed to ELB103-B and either crRNA2 (no flap) or 
crRNA3 (5’handle) 
ELB103:  5’-
GATAAGCTTAAAATAACATCAACCACCTACAATCCAAATGTGTGGTATGGTTTTTACGGATCC
TGG-3’ 
ELB103-B:        5’-
CCAGGATCCGTAAAAAAACGCAACACACGGGTTCGGTTAGGTGGTTGATGTTATTTTAAGCTTATC-3’ 
crRNA2: 5’-CCAUACCACACAUUUGGAUUG-3’ 
crRNA3: 5’-ATTGAAATCCAUACCACACAUUUGGAUUG-3’ 
+PAM (CC) R-loops: ELB108 was annealed to ELB108-B and either crRNA2 (no flap) or 
crRNA3 (5’handle) 
ELB108: 5’-
GATAAGCTTACCCTAACATCAACCACCTACAATCCAAATGTGTGGTATGGGGGTTACGGATC
CTGG-3’ 
ELB108-B: 5’-
CCAGGATCCGTAACCCAACGCAACACACGGGTTCGGTTAGGTGGTTGATGTTAGGGTAAGCTTATC-3’ 
Other R-loops; PAM TG with ELB101 and ELB101-B, PAM TC with ELB106 and ELB106-
B, and either crRNA2 (no flap) or crRNA3 (5’handle) 
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ELB101: 5’-
GATAAGCTTACCTTAACATCAACCACCTACAATCCAAATGTGTGGTATGGCAATTACGGATC
CTGG-3’ 
ELB101-B: 5’-
CCAGGATCCGTAATTGAACGCAACACACGGGTTCGGTTAGGTGGTTGATGTTAAGGTAAGCTTATC-3’ 
ELB106: 5’-
GATAAGCTTACTCTAACATCAACCACCTACAATCCAAATGTGTGGTATGGGAGTTACGGATCCTGG-3’ 
ELB106-B: 5’-
CCAGGATCCGTAACTCAACGCAACACACGGGTTCGGTTAGGTGGTTGATGTTAGAGTAAGCTTATC-3’ 
Partial duplex structures were constructed as above with ELB10X and ELB10X-B for all 
permutations. 
Complete duplex structures constructed as follows: 
Duplex 1 (PAM TG): ELB100 annealed to ELB101: 
ELB100: 5’-
CCAGGATCCGTAATTGCCATACCACACATTTGGATTGTAGGTGGTTGATGTTAAGGTAAGCT
TATC-3’ 
Duplex 2 (PAM – AA): ELB 102 annealed to ELB103: 
ELB102: 5’-
CCAGGATCCGTAAAAACCATACCACACATTTGGATTGTAGGTGGTTGATGTTATTTTAAGCTT
ATC-3’ 
Duplex 3 (PAM TC): ELB 105 annealed to ELB106: 
ELB105: 5’-
CCAGGATCCGTAACTCCCATACCACACATTTGGATTGTAGGTGGTTGATGTTAGAGTAAGCT
TATC-3’ 
D-Loop (PAMs) substrates were created as above with the addition of crDNA2 
annealed. 
crDNA2: 5’-GTTTTACCCTAACTTTACCATACCACACATTTGGATTGTAGGTGGTTGATGTTA-
3’ 
The following oligos were used to form 3’ and 5’ flap structures for nuclease activity 
analysis: 
3’ Flaps: Either ELB104 or ELB104RNA were annealed to crRNA1 or crDNA1 for each 
flap. 
ELB104: 5’-TAACATCAACCACCTACAATCCAAATGTGTGGTATGG-3’ 
ELB104RNA: 5’-UAACAUCAACCACCUACAAUCCAAAUGUGUGGUAUGG-3’ 
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crRNA1: 5’-
CCAUACCACACAUUUGGAUUGUAGGUGGUUGAUGUUAAUUUCAAUCCCAUUUUG-3’ 
crDNA1: 5’-CATACCACACATTTGGATTGTAGGTGGTTGATGTTAATTTCAATCCCATTTTG-3’ 
5’ Flaps: Either ELB107 was annealed to crRNA1 or crDNA2 for each flap. 
ELB107: 5’-CAAAATGGGATTGAAATTAACATCAACCACCTACAAT-3’ 
8.2.2 The following oligos were used to form substrates shown in Chapter 
5. 
DNA oligonucleotides for Cas1-Cas2 assays in vitro 
Oligonucleotides annealed to generate substrates for EMSA and catalytic assays are 
given below. 
Fork-1: Nucleotides forming ssDNA from the fork branch point are underlined, and 
the branch point cytosine/guanine is in bold. The 5’ ended ssDNA is from 
oligonucleotide MW14. 
‘MW12-mod’ 5’-TCGGATCCTCTAGACAGCTCCATGATCGTTACATTAGCAGATACTGCAAC-
3’ 
‘MW14’ 5’-CAACGTCATAGACGATTACATTGCTACATGGAGCTGTCTAGAGGATCCGA-3’ 
‘PM16’ 5’-TGCCGAATTCTACCAGTGCCAGTGAT-3’ 
Fork 1a: As Fork-1 but with addition of ‘PM21’ to anneal to ‘MW14’ giving only a 4 nt 
ssDNA gap of sequence 5’-GCTA. 
‘PM21’ 5’-AATGTAATCGTCTATGACGTT-3’ 
Fork 1b: As Fork-1 but with addition of ‘ELB201’ to anneal to ‘MW14’ giving only a 2 
nt ssDNA gap 
‘ELB201’ 5’-AATGTAATCGTCTATGACGTT-3’  
Fork-2: As fork-1 for ‘MW14’, which is annealed to ‘PM17’ and the 3’ ended ssDNA is 
from oligo ‘MW12-mod’ 
‘PM17’ 5’-TAGCAATGTAATCGTCTATGACGTT-3’ 
‘MW14-mod’ 5’-TCGGATCCTCTAGACAGCTCCATGATCGTTACATTAGCAGATACTGCAAC-
3’ 
Fork-3: As fork-1 with addition of PM17 for full base pairing throughout 
Holliday junction: 
‘MW14’ and ‘MW12 annealed to; 
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‘MW13’ 5’-TGCCGAATTCTACCAGTGCCAGTGATGGACATCTTTGCCCACGTTGACCC-3’ 
‘RGL-14’ 5’-TGGGTCAACGTGGGCAAAGATGTCCTAGCAATGTAATCGTCTATGACGTT-3’ 
 
8.3 Bioinformatic analysis of Methanothermobacter 
thermautotrophicus spacer sequences 
 
To determine the PAM sequence for the substrates used in Chapter 5 each spacer 
from Mth was subjected to nBLAST analysis compared to all known nucleotide 
sequences. Each spacer was compared with 0 to 9 mismatches to any homologous 
sequences. The positions of the spacer were the correlated to the virus or plasmid 
DNA. From this positioning data the PAM sequence could be determined flanking the 
spacer that would be targeted in an interference reaction (as described in Chapters 
1,3 and 4).  These PAM sequences were then compiled (Table 20) and represented 
graphically in Chapter 4, Figure 4-2. 
Table 20. Bioinformatic analysis of Mth spacer sequences. Matched spacer and up to 9 mismatched 
sequences compared to whole known nucleotide sequence database. Genomic location of each match 
was determined to identify PAM sequence as summarised in Figure 4-2. 
Number of 
mismatches 
Spacer 
length Spacer name Virus/Plasmid S.posit E.posit 
0 36 AE000666_C1_spacer22 psiM2 3480 3515 
0 36 AE000666_C1_spacer28 psiM2 3480 3515 
0 36 AE000666_C1_spacer74 psiM100 3831 3866 
0 36 AE000666_C1_spacer8 psiM100 24022 24057 
0 37 AE000666_C1_spacer24 psiM2 22580 22616 
0 37 CP001710_C1_spacer17 psiM100 4444 4480 
0 38 AE000666_C1_spacer6 psiM100 3611 3648 
1 37 AE000666_C1_spacer110 psiM2 12197 12233 
1 38 AE000666_C1_spacer45 psiM2 3835 3872 
1 38 AE000666_C1_spacer7 psiM100 3430 3467 
2 36 AE000666_C1_spacer40 psiM2 3536 3570 
4 37 AE000666_C1_spacer122 psiM100 4025 4060 
5 29 CP000102_C3_Spacer61 pFZ1 2039 2062 
5 32 AE000666_C1_spacer100 psiM2 2616 2647 
5 37 AE000666_C1_spacer5 pME2001 330 357 
5 37 AE000666_C1_spacer5 pME2200 322 349 
5 37 AE000666_C1_spacer5 pMTBMA4 24 51 
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6 36 CP000678_C1_spacer25 pME2200 2149 2183 
6 36 CP001719_C5_spacer11 psiM2 9055 9088 
6 37 CP000102_C2_spacer10 pFZ1 7780 7815 
6 38 CP000102_C2_spacer42 pFZ1 8184 8221 
7 29 CP000102_C3_Spacer61 pFV1 4378 4402 
7 29 CP000102_C3_Spacer61 pFV1 3218 3246 
7 34 CP001719_C5_spacer2 psiM2 23907 23938 
7 35 CP001710_C1_spacer26 pFV1 8082 8114 
7 35 CP001719_C4_spacer1 pFZ1 9540 9573 
7 35 CP001719_C5_spacer20 psiM2 25364 25393 
7 35 CP002772_C2_spacer69 psiM100 30506 30538 
7 36 AE000666_C1_spacer36 psiM100 1128 1164 
7 36 CP000102_C1_spacer7 psiM2 19096 19130 
7 36 CP000102_C2_spacer33 psiM100 7063 7094 
7 36 CP000678_C1_spacer4 pFZ1 8598 8633 
7 36 CP001719_C3_spacer46 pFV1 12655 12680 
7 36 CP002772_C2_spacer9 psiM2 2509 2543 
7 37 AE000666_C1_spacer42 psiM2 25855 25888 
7 37 CP000102_C1_spacer16 psiM2 25944 25980 
7 37 CP000102_C2_spacer55 pFZ1 7788 7823 
8 25 CP001710_C2_spacer1 psiM100 1083 1106 
8 25 CP001710_C2_spacer1 pME2001 843 864 
8 25 CP001710_C2_spacer1 pME2200 835 856 
8 25 CP001710_C2_spacer1 pMTBMA4 537 558 
8 30 CP000102_C2_spacer7 pFZ1 10716 10739 
8 32 CP001719_C3_spacer13 pFV1 10037 10064 
8 34 AE000666_C1_spacer101 psiM100 2821 2852 
8 34 AE000666_C2_spacer44 pFV1 3100 3129 
8 34 CP000678_C1_spacer9 psiM2 16271 16300 
8 35 AE000666_C1_spacer98 pFV1 1559 1587 
8 35 CP000678_C1_spacer28 psiM100 20935 20967 
8 35 CP001719_C3_spacer51 psiM100 14402 14434 
8 35 CP001719_C5_spacer20 pFV1 13214 13246 
8 35 CP001719_C5_spacer20 pFZ1 10714 10746 
8 35 CP002772_C2_spacer72 pFZ1 8908 8938 
8 36 AE000666_C1_spacer34 pME2001 3736 3767 
8 36 AE000666_C1_spacer34 pME2200 4861 4892 
8 36 AE000666_C1_spacer34 pMTBMA4 3431 3462 
8 36 AE000666_C1_spacer44 psiM100 28400 28435 
8 36 CP000102_C1_spacer39 pFZ1 10441 10477 
8 36 CP000678_C1_spacer34 psiM100 29236 29268 
8 36 CP001719_C5_spacer27 psiM100 3164 3193 
8 37 AE000666_C1_spacer47 pME2001 3727 3756 
8 37 AE000666_C1_spacer47 pME2200 4852 4881 
8 37 AE000666_C1_spacer47 pMTBMA4 3422 3451 
8 37 AE000666_C2_spacer42 pME2200 4768 4804 
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8 37 CP000102_C1_spacer12 psiM100 7555 7591 
8 37 CP000102_C1_spacer37 pFV1 10838 10875 
9 25 CP001710_C2_spacer1 psiM2 12810 12831 
9 27 CP001710_C2_spacer3 psiM100 13089 13114 
9 29 CP000102_C3_Spacer61 psiM100 29225 29252 
9 32 AE000666_C1_spacer100 psiM100 19199 19231 
9 32 AE000666_C1_spacer100 pFZ1 9203 9229 
9 34 AE000666_C1_spacer101 pFZ1 9597 9628 
9 34 AE000666_C1_spacer91 pFV1 559 585 
9 34 AE000666_C1_spacer91 pFZ1 559 585 
9 34 AE000666_C2_spacer41 psiM2 12439 12470 
9 35 AE000666_C1_spacer9 psiM100 24849 24883 
9 35 AE000666_C1_spacer9 psiM2 18429 18463 
9 35 AE000666_C1_spacer98 pFZ1 2149 2177 
9 35 AE000666_C2_spacer19 psiM100 18961 18992 
9 35 CP000678_C1_spacer32 psiM2 12588 12614 
9 35 CP001719_C4_spacer10 psiM100 15477 15507 
9 35 CP001719_C4_spacer1 pFV1 4291 4323 
9 35 CP001719_C5_spacer14 pME2001 3578 3608 
9 35 CP001719_C5_spacer14 pME2200 3562 3592 
9 35 CP001719_C5_spacer14 pMTBMA4 3273 3303 
9 35 CP001719_C5_spacer14 pFV1 3111 3142 
9 36 AE000666_C1_spacer116 psiM2 234 269 
9 36 AE000666_C1_spacer93 psiM100 13020 13048 
9 36 CP000102_C1_spacer17 psiM100 2817 2852 
9 36 CP000102_C2_spacer24 psiM100 8485 8514 
9 36 CP000102_C2_spacer54 psiM100 16338 16376 
9 36 CP000678_C1_spacer13 psiM100 7822 7854 
9 36 CP000678_C1_spacer22 pFZ1 10048 10084 
9 36 CP001719_C3_spacer19 pFZ1 2022 2056 
9 36 CP001719_C3_spacer23 pFZ1 7402 7433 
9 36 CP001719_C3_spacer44 psiM100 9509 9540 
9 37 AE000666_C1_spacer103 pME2200 45 80 
9 37 AE000666_C1_spacer112 psiM100 3190 3227 
9 37 AE000666_C1_spacer114 pME2001 3736 3770 
9 37 AE000666_C1_spacer114 pME2200 4861 4895 
9 37 AE000666_C1_spacer114 pMTBMA4 3431 3465 
9 37 AE000666_C1_spacer13 pFV1 8768 8800 
9 37 AE000666_C1_spacer13 pFV1 12614 12640 
9 37 AE000666_C1_spacer56 pFZ1 9958 9990 
9 37 AE000666_C1_spacer62 pFZ1 9958 9990 
9 37 AE000666_C2_spacer21 pFV1 10862 10895 
9 37 AE000666_C2_spacer26 pFV1 10862 10895 
9 37 CP000102_C1_spacer41 psiM100 29498 29535 
9 37 CP000102_C1_spacer43 psiM100 29498 29535 
9 37 CP000102_C1_spacer9 psiM100 1495 1531 
9 37 CP000102_C2_spacer10 psiM2 23608 23641 
9 37 CP000102_C2_spacer34 pFZ1 9582 9613 
9 38 AE000666_C1_spacer18 psiM2 6326 6359 
9 38 AE000666_C2_spacer43 psiM100 3180 3217 
9 39 AE000666_C2_spacer5 pFV1 11488 11526 
 
